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Abstract 
 
γ-Aminobutyric Acid type A receptors (GABAARs) represent a diverse class of pentameric 
ligand-gated ion channels. Sixteen subunits of GABAARs (α1–6, β1–3, γ1–3, δ, ε, θ and π) 
have been identified so far, giving rise to structural heterogeneity of GABAARs which vary in 
their pharmacological properties. GABAARs that contain the α4 and δ subunits are located 
extrasynaptically, mediating tonic currents elicited by low concentrations of GABA. These 
α4βδ receptors are modulated by neurosteroids and certain anaesthetics, identifying them as 
important drug targets in research. These receptors are also implicated in numerous 
neurodegenerative and psychiatric disorders including epilepsy, sleep disorders, depression 
and stroke. This thesis discusses the pharmacological properties of α4βδ receptors expressed 
in Xenopus oocytes and how modulation of these receptors using a δ-preferred agonist, THIP, 
affects recovery in a mouse model of stroke. We also sought to identify an additional binding 
site for THIP that confers the distinct activation level of THIP at the extrasynaptic δ-containing 
receptors and the synaptic γ-containing receptors.      
Despite the growing interest in α4βδ receptors in the past decade, pharmacological studies on 
these receptors have often yielded variable results, possibly due to the expression of receptors 
in different subunit compositions (stoichiometries) or arrangements. In this study, we created 
a matrix of different mRNA injection ratios of α4, β2 and δ subunits expressed in Xenopus 
oocytes and measured the sensitivity to GABA and DS2 activation of the resulting receptor 
populations using two-electrode voltage clamp. We identified two distinct populations of 
receptors, the first with a GABA EC50 value of ~100 nM, a low Hill slope of ~0.3 and 
substantial direct activation by DS2. The second population had a GABA EC50 value of ~1 μM, 
a steeper Hill slope of 1 and little direct activation, but substantial potentiation, by DS2. The 
xviii 
 
two distinct receptor populations differ in their stoichiometry, which confers differences in their 
pharmacology and thus underlies contradictory results between different laboratories. 
Tonic currents elicited by the extrasynaptic receptors are involved in stroke. The development 
of selective compounds for stroke treatments is very promising as they target subtypes of 
GABAARs implicated in stroke and minimize the side effects. The administration of L655,708, 
a negative allosteric modulator of α5-containing receptors, 3-14 days following stroke to 
decrease tonic currents resulted in improved recovery in a mouse model of phototrombotic 
stroke. When L655,708 was given  immediately after stroke onset, a marked increase in infarct 
size was observed, suggesting that decreasing tonic inhibition too early is detrimental. As such, 
we proposed that increasing tonic currents early after stroke boosts recovery. To investigate 
this, THIP, a GABAA agonist that has preference for δ-containing receptors, was given 1 hour 
after stroke in photothrombotic mouse model. We evaluated stroke outcomes using infarct 
volume measurement and behavioral assessments. δ knock-out (KO) mice were also used to 
confirm whether THIP’s effect is mediated via δ-containing receptors. Increasing tonic currents 
1 hour post-stroke significantly decreased infarct size and promoted motor functions in wild-
type-treated THIP mice. The motor recovery effect of THIP, however, was not abolished in the 
KO mice which indicates that other receptors, possibly the binary GABAA αβ receptors, also 
contribute to THIP’s action. 
The beneficial in vivo effect of THIP has led us to interrogate potential binding site of THIP, 
apart from the canonical orthosteric binding site, that is responsible for THIP’s preference for 
δ-containing receptors over γ-containing receptors. A recent study reported that THIP potency 
was attributed to the α4 subunit and therefore we hypothesized that the α+ side harbors an 
additional binding site for THIP. GABA and THIP activity were evaluated at α4-containing 
GABAARs expressed in Xenopus oocytes. Two separate point mutations at the α4+ side were 
generated designed from a homology model and co-injected with β2, β2+δ, or β2+γ as the 
xix 
 
representation of α4-containing receptors. A double mutation on δ- side was also generated to 
investigate whether this side contributes to direct activation of THIP. There were no significant 
changes to GABA and THIP concentration-response curves in the mutants, demonstrating that 
the selected amino acids do not appear to contribute to the binding site of THIP. These results 
does not necessarily conclude that there are no additional binding sites of THIP as our 
evaluation is limited to two amino acids at the α4+ and δ- side. Alternatively, other amino acids 
on the same interface and/or other interface(s) may contribute to additional binding sites of 
THIP. 
In summary, the present thesis provides an in-depth understanding of GABAARs pharmacology 
complexity, specifically the extrasynaptic receptors that are still under-researched compare to 
the synaptic receptors. Our findings demonstrate the existence of distinct receptors populations 
of α4β2δ receptors that vary in their pharmacological properties. We also show that activation 
of these δ-containing receptors, using THIP, early in stroke is beneficial. Moreover, we exclude 
arginine at position 100 and tyrosine at position 208 of the α4 subunit and histidine at position 
92 and serine at position 155 of the δ subunit as the potential binding site of THIP. 
1 
 
Chapter 1 
Introduction 
 
γ-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian central 
nervous system (CNS) and is widely distributed throughout the brain. GABA containing 
neurons (GABAergic cells) make up ~20% of the total number of neurons and are essential in 
maintaining the overall balance of neuronal excitation and inhibition [1-4]. Disturbances to 
GABA-mediated neurotransmission are implicated in a wide range of CNS diseases, including 
anxiety, epilepsy, depression, sleep disorders, schizophrenia, stroke, and neurodevelopmental 
disorders [5-7]. Modulation of GABA receptors is therefore a relevant drug strategy for treating 
many neurological and psychiatric disorders. 
 
1. 1 GABA  
GABA is a small molecule with a chemical formula of COOH(CH2)3NH2. Free rotation from 
the single carbon-carbon bonds that form the backbone of GABA enables the molecule to exist 
in different conformations. These conformations include fully extended, partially folded, and 
fully folded conformation (Fig. 1.1). Moreover, in aqueous solution, GABA is known to be 
predominantly present in the unfolded zwitterionic conformer whereby there is a full positive 
charge on the amino group and a full negative charge on the acidic group [8, 9]. The different 
conformations of GABA are recognized by different types of GABA receptors, enzymes and 
transporters. Two distinct GABA receptor families are known and defined as the ionotropic 
GABAA receptors (GABAARs) and the metabotropic GABAB receptors (GABABRs) [10]. 
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Thus, the development of GABA analogs with restricted conformations is deemed an 
appropriate approach to produce selective ligands for the individual GABA receptor family. 
 
 
Fig. 1.1 Various conformation of GABA. GABA conformation varied from fully extended (top), 
partially folded (middle), to fully folded (bottom) (Taken from Johnston, 2000).    
 
GABA is synthesized from the precursor amino acid, glutamate through an alpha-
decarboxylation step catalyzed by glutamic acid decarboxylase (GAD) (Fig.1.2). GAD is 
present in the brain in two major isoforms, namely GAD65 and GAD67. These isoforms differ 
in sequence, molecular weight (65 and 67 kD, respectively), biological properties and levels of 
expression. Most GAD protein is in the form of GAD65, however it exists in inactive, 
apoenzyme form (apoGAD). This enzyme only operates as a small fraction of its maximal 
capacity and is responsible for synthesizing ~30% of GABA in the brain. In contrast, the bulk 
of GAD67 exists in the active (holoenzyme) form (holo-GAD) and produces ~70% of GABA. 
Consequently, changes in GAD67 activity have a bigger impact on GABA concentration 
compared to GAD65 [11-13].  
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Fig. 1.2 Synthesis, release, reuptake, and metabolism of GABA. GABA is synthesized from 
glutamate by glutamic acid decarboxylase (GAD) in the presynaptic neurons. GABA is loaded into 
vesicles by the vesicular neurotransmitter transporter (VGAT) and then released into the synaptic cleft 
through exocytosis or reverse transporter. GABA reuptake occurs via GABA transporters (GATs) of 
the surrounding neurons and glia. Thereafter, GABA is either repackaged in vesicles or metabolized by 
GABA transaminase (GABA-T) (Taken from Owen & Kriegstein, 2002).   
 
GABA produced by GAD is packed into synaptic vesicles by a vesicular neurotransmitter 
transporter (VGAT) and is released into the synaptic cleft by Ca2+-dependent exocytosis. In 
addition, non-vesicular GABA can also be released via reverse transporter action [12, 14]. 
Once released, GABA activates GABAARs allowing chloride ions to enter predominantly from 
the outside to the inside of cells, causing hyperpolarization. In contrast, GABA activation in 
immature neurons results in depolarization whereby chloride ions exit via the receptor from 
inside cells. In immature neurons, intracellular chloride ion levels are higher since the reversal 
potential for chloride is at a more depolarized level than the resting membrane potential. The 
high intracellular level of chloride ions is due to increased expression of the Na+-K+2Cl- co-
transporters (NKCCs) which transport chloride ions into neurons while expression of K+-Cl- 
co-transporters (KCCs) that transport chloride ions out of neurons is delayed [15, 16].  
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GABA in the synaptic cleft is taken up by GABA transporters (GATs) on neurons and/or 
surrounding glial cells. This can either be repackaged in vesicles or metabolized into succinic 
acid by subsequent GABA transaminase (GABA-T) and succinic semialdehyde dehydrogenase 
(SSADH). Succinic acid enters the mitochondrial tricarboxylic acid (TCA) cycle and is 
transaminated to ɑ-ketoglutarate, which can be converted back to glutamate [11, 14]. 
  
1.2 GABA Receptors 
GABA exerts its action through an array of membrane-bound receptors called GABA 
receptors. These receptors are classified as GABAARs and GABABRs. GABAARs and 
GABABRs are different in terms of their structure, physiology, and pharmacology. GABAARs 
belong to the Cys-loop ligand-gated ion channel superfamily that includes glycine (GlyR), 
serotonin (5-HT3), and nicotinic acetylcholine (nAChR) receptors [17-19]. In general, 
activation of ionotropic receptors triggers pore opening of the receptors, allowing ions to flow 
across the cell membrane and typically results in fast postsynaptic responses that only last a 
few milliseconds [17]. In contrast, GABABRs are metabotropic receptors, coupled to G-
proteins that produce slower, prolonged inhibitory signals. These receptors are known to 
activate second messenger systems and K+ and Ca2+ ion channels [4]. This thesis will primarily 
focus on GABAARs, particularly the extrasynaptic GABAARs. 
 
1. 3 GABAA Receptor Structure and Heterogeneity  
GABAARs have a similar structure to other members of Cys-loop receptor family. GABAARs 
have five subunits (pentameric) arranged around a pore that forms the channel (Fig. 1.3A). 
Each protein subunit consists of a large N-terminal extracellular domain containing the Cys-
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loop. This Cys-loop is formed by a disulfide bond between two cysteine residues separated by 
13 amino acids. Further, each protein subunit has 4 transmembrane-spanning regions (TM1-
4), a large intracellular loop between TM3 and TM4 domain, and a C-terminal extracellular 
end (Fig. 1.3). The N-terminal incorporates part of the ligand binding site for the agonist or 
certain allosteric modulators while the intracellular loop interacts with numerous proteins that 
are important in receptor trafficking and anchoring of the receptors to the cytoskeleton [2, 20].  
 
 
Fig. 1.3 GABAA Receptor Structure. Schematic presentation of pentameric GABAA receptor (A). 
Each subunit composed of a large N-terminal extracellular domain, followed by 4 transmembrane (TM) 
domain and a small C-terminal end. GABA binds at the interface of β and α subunit while 
benzodiazepines (BZs) bind at the interface of α and γ subunit (B). Each subunit also has a large 
intracellular loop connecting TM3 and TM4 that is believed to be the target for numerous protein 
interaction and post-translational modifications (Taken from Jacob, 2008).  
 
To date, molecular studies have successfully identified 19 mammalian genes that encode for 
GABAAR subunits. These include 16 subunits (α1-6, β1-3, γ1-3, δ, ε, π, and θ) that when 
combined are classified as GABAARs, followed by ρ1-3 that assemble as homomeric receptors 
that are also known as GABAA ρ receptors (previously known as GABAC receptors 
(GABACRs)) [3]. Later, evidence suggested that GABAA ρ receptors could also form as 
heteromeric receptors in combination with other ρ subunits or GABAARs subunits such as α1 
and γ subunit [21, 22]. Thus GABAA ρ receptors can also be considered a subtype of GABAARs 
that display a distinct pharmacological profile from classical GABAARs. For example, these 
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receptors are insensitive to typical modulators of GABAARs, such as benzodiazepines, 
barbiturates, neurosteroids, and are not blocked by bicuculline [4, 17]. Although there are much 
fewer GABACRs, they are widely expressed in retina and to a lesser extent in the hippocampus, 
spinal cord, superior colliculus, pons, pituitary, and gastrointestinal tract [21, 23].        
The GABAARs subunits display about 70% amino acid sequence similarity within classes, e.g. 
within α subunits, and about 30% across the different subunits [24]. Given the various subunits, 
theoretically, the total number of GABAARs subunit compositions (subtypes) could reach 
around 800. In addition, subunit variant splicing, e.g. for α6, β2, and γ2, could also contribute 
to receptor diversity [24]. Studies, however show that native GABAARs only express in a 
limited number of receptor subtypes, with the predominant form of 2α:2β:1γ [25]. In less 
abundant receptors, the γ subunit can be replaced by a δ, ε, or π subunit, while β subunit can 
be replaced by a θ subunit [16, 17]. 
 
1. 4 Distribution and Localization of GABAARs   
The variation in GABAAR composition determines the physiological and pharmacological 
properties of the receptors. Further, different GABAAR subtypes are found in different 
regional, cellular, and subcellular distributions which underlies their differences in brain 
function and behavior [3, 26, 27]. 
The predominant native GABAAR, the α1β2γ2, is found in almost all brain regions. 
Meanwhile, the less common subtypes are expressed in confined areas of the brain [1, 3]. For 
example, α2- and α3-containing receptors are highly expressed in hippocampal pyramidal 
neurons and in cholinergic neurons of the basal forebrain, respectively. A full list of regional 
and cellular localization of different GABAARs subtypes is presented in Table 1.1.  
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Table 1.1 In vivo distribution of different GABAARs subtypes (Adapted from Mohler, 2006). 
GABAARs 
subtypes 
Percent composition of 
GABAARs  
Regional and cellular localization 
α1β2γ2 Major subtype (60% of 
all GABAARs) 
Cerebral cortex (layers 1–VI, selected 
interneurons and principal cells), hippocampus 
(selected interneurons and principal cells), 
pallidum striatum (interneurons), thalamic relay 
nuclei, olfactory bulb (mitral cells and 
interneurons), cerebellum (Purkinje cells and 
granule cells), deep cerebellar, nuclei, amygdala,  
basal forebrain, substantia nigra pars reticulata, 
inferior colliculus, and brainstem 
α2β3γ2 Minor subtype (15-
20%) 
Cerebral cortex (layers I-IV), hippocampal 
formation (principal cells mainly on the axon 
initial segment), olfactory bulb (granule cells), 
striatum (spiny stellate cells), inferior olivary 
neurons (mainly on dendrites), hypothalamus, 
amygdala (principal cells), superior colliculus, and 
motor neurons 
α3βxγ2 Minor subtype (10-
15%) 
Cerebral cortex (principal cells in particular in 
layers V and VI; some axon initial segments), 
hippocampus (some hilar cells), olfactory bulb 
(tufted cells), thalamic reticular neurons, 
cerebellum (golgi type II cells), medullary 
reticular formation, inferior olivary neurons, 
amygdale, superior colliculus, brainstem, spinal 
cord, medial septum, basal forebrain cholinergic 
neurons, raphe, and locus coeruleus 
(serotoninergic and catecholaminergic neurons) 
α4βxδ Less than 5% Dentate gyrus (granule cells) and thalamus 
α5β3γ2 Less than 5% Hippocampus (pyramidal cells), olfactory bulb 
(granule cells, periplomerular cells), cerebral 
cortex, amygdala, hypothalamus, superior 
colliculus, superior olivary neurons, spinal 
trigeminal neurons, and spinal cord 
α6β2-3γ2 Less than 5% Cerebellum (granule cells) and dorsal cochlear 
nucleus 
 
Based on their subcellular location, there are two types of GABAA receptors, namely synaptic 
and extrasynaptic receptors (Fig. 1.4). GABAARs located postsynaptically, known as synaptic 
receptors, are activated after exposure to high concentrations of GABA (1-10 mM) that is 
released from presynaptic vesicles. Due to the low-affinity of synaptic receptors towards 
GABA and the rapid removal of GABA from the synaptic cleft, GABA can only occupy these 
receptors for a very short time. This transient activation generates fast inhibitory postsynaptic 
currents (IPSCs) known as ‘phasic’ inhibition.  This form of inhibition is typically mediated 
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by α1-3βγ receptors [28, 29]. These receptors exhibit rapid activation and desensitization 
kinetics, making them well suited for responding to transient GABA exposure [30].   
  
 
Fig. 1.4 Subcellular location of GABAA receptors. Schematic presentation of two types of GABAARs, 
the synaptic (show in orange) and extrasynaptic (shown in purple) receptors. The synaptic receptors, 
located in postsynaptic terminal, mainly composed of α1-3βγ, and are activated by high concentration 
of GABA (shown in blue). In contrast, the extrasynaptic receptors are found outside postsynaptic region 
and are activated by low, ambient concentration of GABA.   
 
Although most of the GABA that is released into the synapse is taken up by GABA 
transporters, some GABA diffuses out (termed spillover) to peri- or extra-synaptic sites and at 
low, ambient concentrations (micromolar GABA concentrations) is able to activate high 
affinity extrasynaptic receptors to elicit a persistent, tonic inhibition. These extrasynaptic 
receptors contain either the δ subunit or the α5 subunit [28, 29, 31].  The δ subunit preferentially 
co-expresses with α4 in the forebrain areas, such as the thalamus and dentate gyrus or with ɑ6 
subunits in cerebellar granule cells. Meanwhile tonic inhibition in the ivy/neurogliaform cells 
is mediated by a δ subunit that co-assembles with α1 and β subunits [28, 29]. Unlike the δ-
containing receptors, the α5 subunit co-assembles with the γ subunit and is expressed in 
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hippocampal pyramidal cells [28]. These extrasynaptic receptors are known to desensitize 
slowly and less extensively compared to their synaptic counterparts. Thus, they are suitable for 
generating a continuous response to sustained, low levels of GABA in peri- or extra-synaptic 
sites.  
Although most receptors contain a single α subtype, immunopurification studies and ligand 
binding studies using point-mutated subunits detected receptors containing more than one α 
subunit subtypes, such as α1α1, α1α3, and α2α3 [32, 33]. Furthermore, evidence supported that 
receptors composed of two subunits without the third subunit, such as binary αβ are able to 
form functional receptors, and are likely to be expressed at extrasynaptic sites [34-36].   
 
1. 5 GABAA Receptor Stoichiometry and Arrangement 
Although GABAARs are pentameric, the number of each subunit (stoichiometry) and 
arrangement of these subunits contributes to the complex nature of these receptors. For 
instance, the most abundant GABAAR, the α1β2γ2 subtype, has a stoichiometry of 2α:2β:1γ 
[37-40]. Variation in receptor subunit stoichiometry and/or arrangement results in the 
variability of the properties of the GABAAR. Further subunit stoichiometry and/or arrangement 
determines which interfaces are formed within the receptor. For example several arrangements 
for α1β2γ2 may exist, such as γ-α-α-β-β, γ-α-β-α-β, and γ-β-α-β-α (Fig. 1.5). To answer which 
stoichiometry is expressed, Sigel et al. (2001) developed concatenated receptors for these 
receptors that allow the expression of a receptor in a pre-defined arrangement [41]. Their 
studies suggest that α1β2γ2 is expressed in γ-β-α-β-α counterclockwise arrangement when 
viewed from extracellular side [41-43].    
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Fig. 1.5 Different arrangements of α1β2γ2 GABAAR. It is believed that α1β2γ2 receptors exist in a 
γ-β-α-β-α counterclockwise arrangement viewed from extracellular side (left). In theory, other 
arrangement may exist, such as γ-α-β-α-β (middle) and γ-α-α-β-β (right).      
 
Although the use of concatemers forces receptor expression in a fixed stoichiometry and 
arrangement, the characteristic of the concatemers is not necessarily the same as receptors 
formed by free subunits. A study with α1β3δ showed that the concatemers have different level 
of modulation by etomidate and lower sensitivity to GABA compared to receptors formed by 
free subunits [44]. In addition, the linker of the concatenated receptors could break releasing 
free subunits that can assemble with each other to form functional receptors [45].          
Unlike αβγ, the stoichiometry of δ-containing receptors remains poorly understood since the δ 
subunit exhibits promiscuous assembly properties [2]. An atomic force microscopy study on 
α4β3δ expressed in transformed human kidney 293 (HEK293) cells stably expressing the 
simian virus 40 large T-antigen (tsA) cells showed a 2α:2β:1δ stoichiometry with an anti-
clockwise arrangement α-β-α-δ-β as the most predominant [46]. This result indicates that the δ 
subunit replaces γ in the pentameric structure. Different stoichiometries could exist and 
assemble depending on the ratio of cRNA or cDNA injected into recombinant systems [47, 
48]. Further, subunit stoichiometry and arrangement may be dependent on the type of 
recombinant system being used [52]. An immunopurification study proposed that more than 
one δ subunit is incorporated following the increase of δ subunit cDNA injected into the HEK 
cells [47]. In line with this study, changes in functional and pharmacological properties were 
observed when the amount of δ subunit cRNA injected was increased [48]. In addition, 
concatemer studies suggest that the δ subunit occupies multiple positions in the receptors and 
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exists in more than one arrangement [49-51]. Differences in functional and pharmacological 
properties observed in these studies reflect changes in subunit stoichiometry and/or 
arrangement. This phenomenon is also observed in other ligand-gated ion channels such as 
nAChRs [53].  
In contrast, a recent study demonstrated that altering the transfection ratio of cDNA in HEK 
cells had no effect on the stoichiometry of α4β3δ GABAARs [54]. Additionally, no significant 
changes were observed in both EC50 and Hill slopes of α4β3δ expressed in Xenopus oocytes 
when the amount of δ cRNA was increased [55]. These conflicting studies on the subunit 
stoichiometry of α4βδ demonstrate that further studies are required to gain a deeper 
understanding of the properties of α4βδ and this is one of the aims of this thesis (Chapter 3). 
 
1. 6 Pharmacology of GABAA Receptors: GABA-Binding Site 
Information about the structure of the GABAARs has mainly come from studies from other 
Cys-loop receptors, bacterial homologs, and the acetylcholine binding protein. The 
acetylcholine binding protein (AChBP) from the snail Lymnaea stagnalis provided the first 
high-resolution crystal structure for the extracellular domain [56]. Subsequent crystal 
structures of a heteromeric nAChR from the Torpedo marmorata electric organ, bacterial 
Erwinia chrysanthemi LGIC (ELIC) and Gloeobacter violaceus LGIC (GLIC), and the 
Caenorhabditis elegans glutamate-gated chloride channel α homopentamer (GluClα) were 
reported [57-60]. Despite providing structural insight for potential interaction of orthosteric 
and allosteric ligands, these models have limited applications due to low sequence identity to 
GABAARs [61].   
In 2014, the crystal structure of human β3 homomeric GABAAR was reported for the first time 
[61]. When viewed from the side, the GABAAR has a height of approximately 110 Ȧ with a 65 
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Ȧ extracellular domain (ECD) (Fig. 1.6A). The receptor has a toroidal (dougnout-like) shape 
when viewed from the top with each subunit surrounded by 3 N-linked glycans (Fig. 1.6B Top). 
The ECD is composed of an amino-terminal α-helix (α1), 10 β-strands folded to form a curled 
β-sandwich and a second α-helix (α2) that lies between β-strands 3 and 4, just below α1. The 
transmembrane domain (TMD) consists of four membrane-spanning helices (M1-M4), the M2 
helices from each of the subunits come together to form an ionotropic transmembrane pore 
(Fig. 1.6B Bottom). The outermost M4 helix links to the extracellular C-minus end. Water and 
solute from the extracellular side go through the pore from a vestibule lined by ECDs and from 
lateral tunnels located between the ECDs. These tunnels are surrounded by negatively charged 
groups. Halfway down the vestibule, there is a positively charged ring that has been proposed 
as an ion selectivity filter (Fig. 1.6C). The intracellular domain is comprised of a small M1-M2 
loop, followed by bigger M3-M4 loop [61]. 
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Fig. 1.6 Crystal structure of human β3 homomeric GABAAR. Lateral view of the receptor (A). (α-
helices are in red, except for the pore-lining M2 shown in teal; β-strands are in blue; loops are in grey). 
Orange ball-and-stick representation was used to depict N-linked glycans. Top, View of the receptor 
from extracellular space showing five subunit, with single subunit shown in grey (B). Bottom, 
Transmembrane domain arrangement of GABAAR (B). Two subunits colored in rainbow (from blue N 
terminal to red C terminal). Water-filled of ECD vestibule and TMD pore shown in light green (C). 
Diameter (Φ) indicated systematically (Taken from Miller & Aricescu, 2014).     
 
According to convention, each subunit has a principal site, known as (+) side, and a 
complementary side known as a (-) side. The GABA binding site is located at the extracellular 
interface of a β+α- [62]. Each side harbors several discontinuous segments containing the 
ligand-recognition site. The principal side of the GABA binding site governs loop A-C that 
comprises of the β4 strand and neighboring residues (Asp95-Lei 99), part of the β7-8 loop (Glu 
155-Tyr 159) and the β9-10 loop (Phe 200-Tyr205) respectively. Meanwhile the 
complementary side hosts loop D and E that consist of a segment from the β2 strand (Tyr 62-
Gln 64) and the β6 (Leu 125-Arg 129) strand [61]. Since the predominant GABAARs are 
composed of 2α:2β:1γ with an arrangement of β-α-β-α-γ, there are two β+α- interfaces that 
bind GABA. These two binding sites exhibit slightly distinct properties from each other. 
Binding at one site results in channel opening characterized by brief open times and 
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noncomplex burst while binding at both sites significantly increases the channel open 
probability. Concatenated and mutational studies on α1β2γ2 indicate that the distinct properties 
arise from the different flanking subunits, i.e. γ and β, α and γ [63]. 
 
1. 6. 1 GABAARs Modulators 
In general, GABAARs are competitively blocked by the alkaloid, bicuculline and modulated 
by neurosteroids, anaesthetics, and barbiturates [4, 7, 62].  The synaptic and extrasynaptic 
receptors display distinct pharmacological properties towards different ligands and the distinct 
properties are utilized to differentiate these two receptor subtypes.  
Benzodiazepines are positive allosteric modulators (PAMs) of synaptic GABAARs. This class 
of drugs is used clinically to treat anxiety, seizures, epilepsy, insomnia and muscle spasms [64, 
65]. Benzodiazepines mediate their actions by binding to the extracellular domain of α+γ- 
interface, which is homologous to the GABA binding site [66, 67], to increase the apparent 
affinity of GABA without affecting GABA efficacy. It is also thought that benzodiazepines 
shift the channel equilibrium to the open state [68]. More specifically, a recent kinetic study 
revealed that benzodiazepines displace the equilibrium between resting and pre-activated states 
of GABAARs, thereby inducing conformational rearrangement of the receptors such that the 
transitions into the open state become more likely [69]. 
Histidine at position 101 (H101) for α1 and α2, at the position 126 (H126) for α3, and at the 
position of 105 (H105) for α5 is crucial for allosteric modulation of the receptors by 
benzodiazepines. Meanwhile at α4 and α6 subunit, the corresponding position is replaced by 
arginine, and hence these subunits are insensitive to benzodiazepines. Point mutation from 
histidine to arginine abolished diazepam activity at α1H101Rβ2γ2, α2H101β2γ2, 
α3H126Rβ2γ2, and α5H105β2γ2 whereas the reverse mutation resulted in diazepam-sensitive 
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α4R100Hβ2γ2 and α6R100Hβ2γ2 [70, 71]. This functional switch has been applied in 
transgenic mice and unravelled distinct functional roles for individual α subunits [5,72,73]. 
These studies showed that sedation is primarily mediated by α1-containing receptors, 
anxiolysis by α2-containing receptors, myorelaxant by both α2- and α3-containing receptors, 
and amnesia by α5-containing receptors.   
General anaesthetics encompass structurally diverse compounds, including barbiturates and 
intravenous anaesthetics such as etomidate and propofol [74]. These compounds produce their 
anaesthetics effect, mainly by enhancing GABA-mediated currents.   
Barbiturates have also been used as antiepileptic, sedative and hypnotic agents [75], however 
due to safety concerns they have been replaced by benzodiazepines [75]. Barbiturates 
potentiate GABA-evoked currents by increasing channel opening time [76, 77]. In addition to 
their modulatory action, barbiturates can directly activate GABAARs or block GABA-evoked 
currents, depending on their concentrations [78, 79]. Unlike benzodiazepines, barbiturates do 
not require the γ subunit to potentiate GABA action [80] as they bind to the α+β- and γ+β- 
interface of the transmembrane domain [81].   
The general anaesthetics, propofol and etomidate, also potentiate GABA-elicited currents. 
Similar to barbiturates, their actions are concentration dependent. At low micromolar 
concentrations, these anaesthetics enhance submaximal GABA-elicited currents; at higher 
concentrations, they directly activate GABAARs in the absence of GABA. At millimolar 
concentrations, they can also block GABA-elicited currents [82]. Propofol and etomidate bind 
at the interface of the transmembrane domain of the α and β subunit [82-84]. Indeed, in vitro 
electrophysiology studies showed that propofol and etomidate also increase GABA efficacy on 
δ-containing receptors [85, 86]. It is unlikely that these effects are δ-selective since similar 
increases are also observed at αβ receptors.  
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1. 6. 2 δ-selective Ligands 
δ-containing receptors play a substantial role in physiological and pathophysiological 
processes. Thus, it is important to understand the properties of these receptors using compounds 
that exhibit selectivity for δ-containing receptors. Neurosteroids enhance the expression of δ-
containing receptors and are able to increase the efficacy of GABA at these receptors. 
Meanwhile, the “δ-selective compound 2”, known as DS2, has been proposed as δ-selective 
ligand as it is an efficacious PAM at ɑ4/6βδ. AA29504 is another PAM that has preference for 
δ-containing receptors although the evidence for its selectivity is limited. The hypnotic drug 
THIP directly activates δ-containing receptors with higher efficacy and potency than at γ-
containing receptors. These compounds are described below in more detail.  
 
1. 6. 2. 1 Neurosteroids  
Steroid hormones are endocrine messengers that modify mood and behavior through genomic 
mechanisms by regulating gene expression [87]. Interestingly, certain steroids can also act in a 
paracrine manner where they generate immediate responses through membrane bound 
receptors, including GABAARs, to influence neuronal excitability [87, 88]. These endogenous 
neurosteroids and their synthetic analogues have analgesic, anxiolytic, anticonvulsant, and 
anaesthetics properties [88].  
Neurosteroids that are synthesized from cholesterol in neurons and glia at low nanomolar 
concentrations enhance GABA responses while at sub- to micromolar concentrations, they 
directly activate GABAARs [89]. These two distinct effects result from different binding sites. 
Neurosteroid activation is mediated by αT236 (M1) and βY284 (M3) residues at the β-α 
interface; whilst neurosteroid potentiation comes from αQ241 (M1)-αN407 (M4)/αY410 (M4) 
within the α subunit [89].   
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Certain endogenous neurosteroids, for example, pregnenolone sulfate (PS) and 
dehydroepiandrosterone sulfate (DHEAS) inhibit GABAARs [87]. The binding site of 
neurosteroid inhibition is believed to be different from the activation or potentiation binding 
site. A single mutation study indicated that residue of α1V256 of the 2’ position in the lining 
of the M2 pore is involved in the inhibitory action of PS [90]. However, more studies are 
needed to corroborate this result.    
In brain slice recordings neurosteroids enhance synaptic inhibition by prolonging the decay of 
miniature inhibitory postsynaptic currents (mIPSCs). It was thought that extrasynaptic δ-
containing receptors exhibit a higher degree of modulation from neurosteroids compared to γ-
containing receptors. This is not necessarily the case because a recent study showed that the 
exaggerated enhancement of δ-containing receptors by neurosteroids is related to the functional 
intrinsic properties of these receptors in which GABA acts as a partial agonist [88]. Because 
GABA exhibits such low open probability at these receptors, the likelihood for other ligands 
to fully activate or modulate the receptors is substantial (Chapter 5). Further, the modulation 
amplitude is generally normalized against GABA thus the modulation is deemed to be highly 
significant. A study on genetically modified mice that are lacking the δ subunit revealed 
diminished pharmacological effects of neurosteroids in these mice, indicating that 
neurosteroids mediate their action via δ-containing receptors. It is not entirely clear whether 
these changes result from indirect alteration in δ knock-out (δ-/- or δ KO) mice [91]. Moreover, 
Shu et al. (2012) found that the structure-activity relationship of neurosteroids at δ-containing 
receptors is similar to the synaptic α1β2γ2L.     
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1. 6. 2. 2 δ-Selective Compound 2  
4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridine-3-yl benzamide, known as “δ-selective 
compound 2” (DS2), is a PAM that has been widely use to differentiate between δ- and γ-
containing receptors [51, 52, 92, 93]. At α4β3δ, low concentrations of DS2 increase the potency 
and efficacy of GABA while at ɑ4β3 and α4β3γ2, no apparent modulation is observed, 
indicating selectivity for δ-containing receptors [94]. In contrast, a recent study showed that 
DS2 also worked at α4β2γ2 with similar potency (~3-fold) and only ~6-fold less efficacious 
compared to α4β2δ. However, the modulatory action of DS2 at α4β2γ2 did not exceed the 
GABA maximum current, demonstrating limited modulatory effect at these receptors [95].   
Aside from having a modulatory action, Jensen et al. (2013) showed that DS2 directly activated 
α4β3δ expressed in Xenopus oocytes and proposed that this activation results from spontaneous 
channel activity of α4β3δ [94].  However the direct activation by DS2 was also observed in 
concatemers of α4β2δ that have very little spontaneous channel activity [51], and thus, the 
direct activation by DS2 is unlikely ascribed from the degree of spontaneous channel activation 
but from direct action on the receptor in the absence of GABA.  
Whole-cell electrophysiology supports the notion of DS2 selectivity for δ-containing receptors. 
DS2 enhances tonic currents in ventrobasal thalamic neurons and cerebellar granule cells that 
express high levels of δ-containing receptors [96]. Moreover, DS2 enhanced tonic currents in 
thalamic relay neurons and layer 2/3 neurocortical neurons without affecting IPSCs [97]. In 
line with these results, DS2-enhanced tonic inhibition was diminished in brain slices of δ KO 
mice [94].  
Despite having preference for δ-containing receptors, DS2 cannot be used in in vivo 
experiments since DS2 has a very limited brain penetration [94]. DS2 does however, play an 
important role in the characterization of extrasynaptic receptors in vitro. Mutational and 
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binding studies demonstrate that DS2 does not bind at the orthosteric, benzodiazepine, 
etomidate, or neurosteroid sites, suggesting that DS2 mediates its action via a novel binding 
site. To identify where the DS2 binding site might lie on the GABAARs, chimeras between δ 
and γ subunit were made [95]. The region from the extracellular domain to the first 
transmembrane domain of the δ subunit was identified as a potential DS2 binding site [95].  
However, further studies are needed to determine which residues are responsible for DS2 
binding. 
 
1. 6. 2. 3 AA29504  
AA29504 ([2-Amino-4-(2,4,6-trimethylbenzylamino)-phenyl]-carbamic acid ethyl ester) is a 
derivative of retigabatine, a potassium channel opener. Although AA29504 is a weak activator 
of voltage-gated K+ channel (KCNQ), this compound causes a leftward shift of the GABA 
concentration-response curve accompanied by an increase in the efficacy of GABA at the 
α4β3δ receptor, as well as acting as a direct agonist. At a concentration of 3 μM, AA29504 
started to activate α4β3δ receptors and this response could not be completely blocked by 
bicuculline [98]. Direct activation by AA29504 has also been shown in brain slice recordings 
where it was observed that AA29504 evoked a small tonic current per se in the dentate gyrus 
granule cells and was further confirmed using primary cortical cultures [99]. Application of 
AA29504 on layer 2/3 pyramidal neurons did not affect spontaneous IPSCs. In the dentate 
gyrus granule cells, AA29504 possibly recruits δ-containing receptors to contribute to the 
synaptic response thereby prolonging the mIPSCs decay time [99]. Interestingly, AA29504 
positively modulates THIP-evoked tonic currents, demonstrating AA29504 selectivity for 
extrasynaptic receptors [98].  In addition to modulation and direct activation of AA29504 at 
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α4β3δ receptors, this compound also modulates GABA at α1β3γ2S in a benzodiazepine-like 
manner [98].  
AA29504 readily crosses the blood brain barrier where subcutaneous injection of 2 mg/kg in 
mice results in a brain concentration of 1 μM [99]. AA29504 alleviates memory deficits in an 
animal model of schizophrenia and displays anti-anxiety properties [98-100].  
 
1. 6. 2. 4 THIP 
THIP (4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridin-3(-ol))  also known as Gaboxadol, was first 
developed by the Povl Krogsgaard-Larsen group. This compound is a derivative of the GABAA 
agonist muscimol, a physchoactive isoxazole isolated from Amanita muscaria [101]. THIP 
enhances the quality of sleep and was tested in clinical trials for sleep disorders [102-104]. 
THIP failed in clinical trial phase 3 due to a lack of efficacy and considerable side effects [105].      
Although THIP has a lower potency than GABA at α4βδ, THIP elicits a higher response than 
GABA and as such THIP has superagonism at the extrasynaptic δ-containing receptors. The 
superagonistic effect of THIP is the result of THIP’s ability to prolong the channel opening 
time and thus producing longer bursting time [106]. THIP is considered to be selective for δ-
containing receptors since THIP displays high efficacy and high potency at δ-containing 
receptors compared to γ-containing receptors in electrophysiology recordings [95, 107]. Brown 
et al. (2002) showed that at binary α4β3 receptor, THIP also acts as a superagonist indicating 
that THIP cannot be used to distinguish αβ receptors from αβδ receptors. 
Even though THIP is unable to discriminate between αβ and αβδ receptors, brain slice recording 
and animal behavioural studies demonstrate that the δ-containing receptor is essential in 
mediating THIP’s effects. Whole cell recording in neocortical layer 2/3 pyramidal cells and 
cerebellar granule cells, known to express δ-containing receptors, showed that the application 
21 
 
of THIP induced tonic currents [108-110]. Tonic currents generated by low concentrations of 
THIP was abolished in brain slices of δ KO mice, indicating that THIP evoked tonic currents 
via δ-containing receptors [110]. In line with these results, behavioral studies revealed that the 
ataxic and hypnotic properties of THIP were attenuated in δ KO mice, confirming the 
importance of δ-containing receptors in mediating the effect of THIP [111,112].  
THIP binds to the same site as GABA i.e. at β+α- as shown by radioligand binding studies 
[113, 114]. Meanwhile a docking study showed that THIP has a similar interaction with GABA 
(Fig. 1.7). The 3-hydroxy-isoxazole moiety of THIP interacts with α1R66, β2T202, and 
α1T129. There is a salt bridge interaction with β2E155 and π-cation interaction with β2Y205 
derived from the protonated amine of THIP. Compared to GABA, THIP has an additional 
interaction with β2F200 [115]. The selectivity of THIP for δ-containing receptors over γ-
containing receptors remains elusive. Further studies are required to determine whether the 
selectivity involves an additional binding site at δ-containing receptors. Thus, one of our aims 
is to interrogate additional binding site(s) of THIP that is responsible for superagonism activity 
at δ-containing receptors using site-directed mutagenesis (Chapter 5).    
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Fig. 1.7 THIP binding mode on β+ɑ- interface determined by induced fit docking. THIP (shown 
in pink) is docked on the orthosteric binding site at the interface of β2 subunit (shown in teal) and the 
α1 subunit (shown in smudge) (Taken from Bergman et al., 2013).     
 
1.7 Role of Extrasynaptic Receptors in Disease 
δ-containing receptors are important in maintaining neuronal excitability by generating tonic 
currents. These receptors regulate behavioral functions such as memory, sleep and nociception. 
Furthermore, the expression of δ-containing receptors undergoes changes under different 
physiological and pathological conditions. For example, during acute stress, the expression of 
δ-containing receptors is increased as a result of exposure to neurosteroids that are indirectly 
released by the hypothalamic-pituary-adrenal (HPA) axis. The activated HPA axis produces 
steroid hormones that can be metabolized into neurosteroids which in turn increase the 
expression of δ-containing receptors [116, 117].   
One of the causes of sleeping disorders is alterations of the thalamo-striatal-cortical network 
dynamics and this alteration is associated with changes in extrasynaptic receptor function [29]. 
THIP improves the quality of sleep by increasing slow-wave or non-rapid eye movement 
(NREM) sleep. This action is thought to be mediated through the thalamic nuclei where a high 
level of expression of δ-containing receptors is present [102, 104, 109, 118].  
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GABAAR subunit mutations, including mutations in the δ-subunit are linked to idiopathic 
generalized epilepsies [119, 120]. Idiopathic generalized epilepsies encompass one third of all 
epilepsies. Although this type of epilepsy is polygenic, mutations on the gene encoding the δ 
subunit cause abnormal expression, reduced current amplitudes and a change in the channel 
gating of δ-containing receptors that lead to hyperexcitability. Typically, there is a reduction 
in the δ subunit protein and mRNA levels, as well as reduced tonic inhibition in animal models 
of epilepsy [121, 122]. It is thought that decreased receptor activity results in epilepsy and 
contributes to the pathogenesis of epilepsy [123]. On the other hand, others proposed that 
increased excitability and epilepsy cause a decrease in receptor expression [31]. However 
increasing tonic current is not necessarily beneficial for all types of epilepsy. For instance, an 
animal model of absence epilepsy is associated with increased tonic inhibition in 
thalamocortical neurons [29].  
Downregulation of δ-containing receptors is also reported in psychiatric disorders, such as 
depression and schizophrenia [31]. Antidepressant activity of THIP has been demonstrated in 
male rodents [124]. Furthermore, female mice lacking the δ subunit exhibited depression-like 
symptoms post-partum. These symptoms were alleviated when THIP was given to 
heterozygous mice, confirming that the δ subunit is involved in depression [125]. In line with 
this result, a decrease of α4 and δ mRNA was observed in depressed suicide victims [126].  
Studies on patients with schizophrenia revealed that the expression of α4 and δ subunit is 
decreased in dorsolateral prefrontal cortex, a brain region that is involved in working memory 
impairment observed in schizophrenia patients [127]. In addition, increasing the activity of 
extrasynaptic receptors using THIP or AA29504 reverses the memory impairment in an animal 
model of schizophrenia [100].      
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1.8 GABAA Receptors and Stroke 
Stroke occurs when there is a focal disruption of cerebral blood flow (CBF) as a result of 
ischaemia or hemorrhage, leading to a sudden loss of neurological function [128, 129]. It is the 
second most common cause of death worldwide [130]. Stroke often results in weakness, 
paralysis and impairment of cognitive functions in the patients and therefore stroke is the 
leading cause of disability worldwide [128].    
The most common type of stroke is ischaemic stroke and it accounts for 80% of stroke cases 
[131]. Ischaemic stroke results from occlusion of blood vessel, either by an embolus or 
thrombosis that leads to CBF reduction. The occlusion induces a series of molecular and 
cellular cascades that occur rapidly [132]. These cascades involve energy failure, 
excitotoxicity, elevation of Ca2+, generation of free radicals, peri-infarct depolarization and 
inflammation (Fig. 1.8) [132-135]. 
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Fig. 1.8 Diagram showing major cascades involved in pathophysiology of ischaemic stroke.   
Energy failure causes neurons depolarization. Glutamate (glu) and K+ diffusion result in wave of 
depolarization (peri-infarct depolarization). Water enters cells due to osmotic gradient and cell swell, 
leading to necrosis. Glutamate receptors that are activated result in surge of intracellular Ca2+ thus 
activating numerous enzyme systems. Generated free radicals attack membranes, mitochondria, DNA, 
and protein which in turn inducing apoptosis. Free radicals also trigger the release of pro-inflammatory 
mediators that activate microglia and promote leukocytes infiltration via upregulation of adhesion 
molecules (Adapted from Dirnagl et al., 1999).   
 
The ischaemic centre (core) experiences severe damage that is irreversible within minutes or 
hours, causing necrosis and death of neuronal glial and vascular cells (ischaemic infarction). 
The area that surrounds the ischaemic core is called the penumbra (also referred to as peri-
infarct tissue). The penumbra is functionally impaired but still maintains structural integrity 
[134]. The damage in penumbra is potentially reversible with therapeutic intervention but is 
time restricted [136]. If the ischaemic insult persists, the penumbra will develop into ischaemic 
core (Fig. 1.9) [132].  
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Fig. 1.9 Development of ischaemic core to penumbra over time. Right after stroke, the ischaemic 
core (depicted in black) experience irreversible damage.  Over time, without any treatment, the peri-
infarct tissue (shown in grey) surrounding the core will change into ischaemic core (Taken from Dirnagl 
et al., 1999).  
 
GABAARs are implicated in stroke [6, 31]. Ischaemia causes the accumulation of extracellular 
GABA that may occur due to Ca2+-dependent vesicular release, reversal of GABA transporters 
or leakage from injured neurons [137, 138]. Although there is accumulation of extracellular 
GABA, it is not accompanied with an increase in GABAergic function. Interestingly, there is 
a reduction in GABA synthesis and release, down-regulation and desensitization of the 
receptors, possibly as a consequence of GABA accumulation [137-139]. Clinical studies also 
detected a decrease in GABA concentration in stroke patients [140, 141]. Taken together, the 
GABAergic function is decreased following ischaemia.  
GABAARs expression is affected by cortical infarct. An autoradiography study showed a 
reduction of [3H]-muscimol binding in focal ischaemic rodents, suggesting down-regulation of 
GABAARs [142]. This down-regulation further translates as a reduction in GABA 
functionshown by the decrease of paired pulse inhibition in brain slice recordings [142]. In 
addition, immunohistochemistry studies demonstrated decreased expression of α1, α2, α5 and 
γ2 subunit on day 1 and day 7 after photothrombosis infarct [143, 144]. In contrast, there is an 
increase of α1 and α2 subunit mRNA ipsilateral to the lesion [145]. This mRNA up-regulation 
may not reflect an increase of protein expression since protein synthesis is inhibited in cerebral 
ischaemia [146].   
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Accumulating evidence demonstrates that increasing GABAergic neurotransmission using 
GABA uptake inhibitors and various GABAA ligands result in neuroprotection in a variety of 
animal stroke models [147-151]. Out of all the compounds tested, only two reached clinical 
trials, namely diazepam and clomethiazole [134, 138]. These two compounds did not show any 
benefit in clinical trials, despite showing promising result in pre-clinical studies. The failed 
translation from bench to bedside is mostly due to the validity of animal models of stroke in 
rodents and the design of clinical trials [152, 153]. Another plausible explanation is that these 
drugs are not selective enough to target the specific GABAAR subtypes involved in stroke 
recovery and timing of intervention may also play a critical role. 
Although animal studies demonstrated the protective effect of GABAergic compounds, the 
underlying mechanism by which these compounds afford neuroprotection remains poorly 
understood. Early theories speculated that the protective effect results from opposing the effect 
of the excitatory action of glutamate, which plays a major role in pathophysiology of stroke 
[137, 138]. In vitro and in vivo studies suggested that exogenous GABA or GABA agonists 
inhibit glutamate release [154, 155]. Others proposed that the GABAergic system mediates the 
protective effect through other pathways, such as stimulating recovery of ATP, inhibiting the 
increase of cytochrome c that is responsible for promoting apoptotic pathways, blockade of 
Ca2+ into nerve cells and interfering the inflammatory pathways [156-159]. Moreover, 
hypothermia produced by GABAergic drugs may contribute to neuroprotection [138]. 
As mentioned before, the peri-infarct tissue is functionally impaired but still salvageable within 
a certain amount of time after stroke [132, 136]. This peri-infarct zone is thus the target for 
stroke treatment. Within this region, brain plasticity is higher, allowing the remapping of 
sensory and motor functions which in turn results in functional recovery [160-162]. The 
remapping process is dependent on neuronal excitability and thus, GABAergic-mediated 
inhibition plays an important role in stroke recovery as shown in recent studies [163, 164].  
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In recent years, scientists have been trying to differentiate the role of synaptic and extrasynaptic 
GABAARs in stroke recovery using subtype selective compounds. Increasing phasic inhibition 
using zolpidem, a positive allosteric modulator which has high affinity for ɑ1-containing 
receptors, starting from 3 days post-stroke promotes behavioral recovery without affecting 
infarct size [163]. In line with this, the spontaneous IPSCs were increased in brain slice 
recording in layer 5 pyramidal neurons of peri-infarct cortex; which was also accompanied by 
an elevation of α1 subunit expression [163]. Moreover, clinical findings reported transient 
improvement of aphasia in stroke patients when given zolpidem [165]. Overall, these results 
demonstrate that enhancing the synaptic inhibition using zolpidem results in functional 
recovery after stroke (Fig. 1.10). In contrast, a recent study proposed a novel receptor target 
for zolpidem [166]. Zolpidem has been shown to modulate GABA at binary α1β3 receptors, 
indicating that zolpidem may also acts by enhancing tonic currents via these receptors.  
 
 
Fig. 1.10 Proposed GABAergic neurotransmission effects in stroke. Both the synaptic and 
extrasynaptic GABAARs play a role in stroke recovery. Elevating phasic inhibition via the synaptic 
receptors at late phase results in neuroprotection. Meanwhile, the protection provided by the 
extrasynaptic receptors is time-dependent. Increasing the activity of these receptors early in stroke is 
proposed to be protective and detrimental at the late phase.     
 
Similarly, targeting the extrasynaptic receptors also provides neuroprotection. High 
concentrations of GABA that are released into the synaptic cleft following stroke are thought 
to cause GABA spillover to peri- and extra-synaptics GABAARs and subsequent increase of 
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tonic currents [164]. Treatment using an inverse agonist of α5-containing receptors, L655,708, 
from 3 days post-stroke resulted in functional recovery without any change in infarct size in 
mice with photothrombotic stroke. Moreover, mice lacking the α5 subunit displayed marked 
motor function improvement, indicating that decreasing tonic current in stroke is beneficial 
[164]. In contrast, when L655,708 was given early in stroke, there was no functional 
improvement and the infarct size was significantly increased, showing that decreasing tonic 
current early in stroke is detrimental. These results demonstrate that modulation of tonic 
inhibition at different time points have distinct effects in stroke (Fig. 1.10). Since decreasing 
tonic currents early exacerbate stroke injury, we propose that increasing tonic current early in 
stroke promotes recovery in stroke. We aim to test this hypothesis by giving THIP, a 
superagonist at δ-containing receptors, 1 hour post-stroke in photothrombotic mouse model 
(Chapter 4).  
To date, there are various animal stroke models, however, there is no model that can mimic 
human stroke entirely. The selection of which animal model to use depends on the purpose of 
the research and specific questions that need to be addressed. There are two major models of 
cerebral ischaemia, global and focal ischaemia [167, 168]. Description about animal stroke 
models is shown in Table 1.2.  
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Table 1.2 Overview of animal models of stroke. 
Models Principle Comments Reference 
Global ischaemia Blockade of major blood 
vessel results in 
substantial reduction of 
CBF to the whole brain 
- Causes damage to large 
proportion of the brain 
- Commonly used in 
large mammals 
- Mimic damage occurs 
in cardiac arrest  
Green et al. 
(2003)  
Traystman (2003) 
 
Focal Ischaemia 
 
 
 
 
A.Middle Cerebral 
Artery Occlusion 
(MCAO)  
 
 
 
 
 
 
 
 
B. Thromboembolism 
 
 
 
 
 
 
C. Photothrombotic 
 
 
 
 
 
 
 
D. Endothelin-1 
CBF is reduced in a 
specific brain region 
following mechanical or 
cerebral 
thromboembolism 
occlusion 
- MCA is occluded; 
similar to human stroke 
- Occlusion can be 
transient or permanent 
- Proximal MCAO is 
induced by intraluminal 
sutures without 
craniotomy 
- Distal MCAO is 
produced by vascular clip 
or electrocoagulation 
Induced by different 
methods, including the 
injection of synthetic 
macrospheres or 
microspheres, autologous 
blood clots, and purified 
thrombin 
Photoactive dye, usually 
rose bengal, is used to 
trigger thrombus 
formation following 
activation by light source 
illumination through 
intact scull  
 
 
Involve the injection of a 
potent vasoconstrictor, 
endothelin-1 
 
 
 
 
 
- Proximal MCAO 
produces damage to 
cortex and deep brain 
structures  
- Distal MCAO results in 
damage that is restricted 
to cortex; require 
craniotomy 
 
 
 
 
 
- Limited use in research 
due to high variability in 
infarct size and location 
 
 
 
 
- Reproducible infarct 
size and location 
- Exhibits similar cellular 
responses to MCAO 
model 
- Limited penumbra  
- Unable to produce 
infarct on deeper brain 
structures 
- Induction of infarct in 
any desired region 
- Limited control of 
inschemia intensity and 
duration 
Bacigaluppi et al. 
(2010) 
Woodruff et al. 
(2011) 
 
Longa et al. 
(1989) 
Tamura et al. 
(1981) 
Prinz & Endres 
(2010) 
Bacigaluppi et al. 
(2010) 
 
 
 
Gerriets et al. 
(2003) 
Bacigaluppi et al. 
(2010) 
Killic, Hermann, 
& Hossmann 
(1998) 
Watson et al. 
(1985) 
Labatgest & 
Tomasi (2013) 
Schroeter, Jander, 
& Stoll (2002) 
Durukan & 
Tatlisumak 
(2007) 
Sharkey (1993) 
Prinz & Endres 
(2010) 
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1.9 Aims 
The extrasynaptic GABAARs play a pivotal role in the overall balance of neuronal excitability 
by mediating tonic inhibition elicited by low concentrations of GABA. These receptors are 
implicated in numerous neurodegenerative and psychiatric disorders including epilepsy, sleep 
disorders, depression, schizophrenia, and stroke making them attractive therapeutic targets for 
CNS drug development. This project has 3 distinct aims relating to δ-containing receptors: 
1. Pharmacological studies of α4βδ receptors have often yielded contradictory results. We 
hypothesize that the expression of receptors in different stoichiometries or arrangements is one 
possible explanation for this observation. The first aim of the thesis is to investigate variability 
of α4β2δ receptors by generating a matrix of different ratios of α4, β2, and δ cRNA and express 
them in Xenopus laevis oocytes. The resulting receptors were tested with GABA and DS2 using 
two-electrode voltage clamp to investigate the functional changes of the receptors expressed in 
different injection ratios. 
2. Extrasynaptic receptors are involved in stroke recovery. Decreasing tonic inhibition using the 
negative allosteric modulator of α5-containing receptors, L655,708, 3-days post-stroke results 
in motor recovery in a mouse model of phototrombotic ischaemia. However, giving L655,708 
early after stroke exacerbated the infarct size, indicating inflection time point of tonic GABA 
modulation in stroke recovery. We hypothesize that increasing tonic current soon after stroke 
promotes recovery. As such, the second aim of the thesis is to address the effect of increasing 
tonic inhibition early in stroke by giving THIP to mice induced photothrombotic ischaemia 1 
hour after stroke. Neuroprotection of THIP was evaluated using sensorimotor function tests and 
infarct size was also measured. In addition, to further investigate whether neuroprotective effect 
of THIP is specifically mediated through δ-containing receptors, δ-/- mice was used. The results 
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of this study establish the extrasynaptic receptors, in particular the δ-containing receptors, as a 
potential novel drug target for stroke recovery. 
3. THIP is an important pharmacological tool for understanding the pharmacological and 
functional significance of δ-containing receptors, and most of its physiological effects are 
mediated by these receptors. Binding studies demonstrated that THIP binds to the same site as 
GABA, namely at the β+α- interface. However, there may be distinct level of direct activation 
of THIP mediated at other interfaces. Therefore, the last aim of the thesis is to unravel whether 
or not additional binding site(s) of THIP confer superagonism at δ-containing receptors. 
Homology modeling of GABAARs with THIP predicted amino acid residues on the α+ side that 
interact with THIP. Mutations on those residues were generated and evaluated on α4-containing 
receptors in Xenopus ooytes. Furthermore, δ- side was also studied to determine whether THIP 
bind to this side by performing a double mutation to alter δ- to resemble γ-. 
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Chapter 2 
Materials and Methods 
 
2. 1 Materials 
2. 1. 1  GABAARs Subunits DNA 
The cDNA encoding human α4 and δ GABAARs subunits subcloned in pcDNA1/Amp and γ2L 
and β1 GABAARs subunit subcloned in pCDM8 were provided by Prof. Bjarke Ebert (H. 
Lundbeck A/S, Valby, Denmark). The human β3 cDNA subcloned in pGEMHE was also 
provided by Prof. Bjarke Ebert. The human β2 cDNA GABAAR subunit subcloned in pcDM8 
were a gift from Dr. Paul Whiting (Merck Sharpe and Dohme Research Labs, Harlow, UK). 
 
2. 1. 2 Chemicals 
GABA, dimethyl sulfoxide (DMSO), zinc chloride, ampicillin, gentamycin, tetracycline 
hydrochloride, theophylline, sodium pyruvate, sodium chloride, potassium chloride, 
magnesium chloride, calcium chloride, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) hemisodium, sodium bicarbonate, ethanol, xylene, acetic acid, cresyl violet, 
parafolmaldehyde, and rose bengal were purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia) while DS2 and AA29504 was purchased from Tocris Bioscience (Bristol, UK). 
THIP was generously provided by Dr. Bjarke Ebert (H. Lundbeck A/S,Valby, Denmark). 
Pentobarbital was purchased from Virbac (Milperra, NSW, Australia) and tricaine was 
purchased from Western Chemical (Ferndale, WA, USA). 
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2. 2 Methods 
2. 2. 1 Homology Modeling 
The following protocol was performed by Michael Zhang from the Faculty of Pharmacy, The 
University of Sydney. Homology models for the ɑ4β2 and ɑ4β2δ GABAARs were produced 
using Schrodinger’s Maestro version 10.5 (Schrödinger, New York, N.Y, USA) [1]. Protein 
amino acid sequences obtained were from the uniport database (www.uniprot.org). The protein 
sequences used were p43681, p17787 and o14764 for ɑ4, β2 and δ respectively. These 
sequences were imported into Prime Homology Modelling and produced using Protein Data 
Bank (PDB) of human GABAAR β3 homopentamer X-ray crystal structure as the template. 
The M4 intracellular loop was manually removed from the amino acid sequence after studying 
the alignment and the most energy stable model was selected as the best homology model. The 
THIP molecule was docked using both Maestro’s standard and induced fit docking using a grid 
generated in Glide (Schrödinger, New York, N.Y, USA) [1]. Images were then produced and 
captured using PyMOL (Schrödinger, New York, N.Y, USA). 
 
2. 2. 2 Molecular Biology 
2. 2. 2. 1 Site-directed Mutagenesis  
Arginine at position 100 and tyrosine at 208 of α4 were point mutated into histidine (α4R100H) 
and cysteine (α4Y208C), respectively using QuickChange II Site-directed Mutagenesis Kit 
(Agilent Technologies, Mulgrave, VIC, Australia). QuickChange II Site-directed Mutagenesis 
Kit was also used to generate double mutation of δ subunit at histidine 92 and serine 155 into 
alanine and threonine (δH92AS155T) respectively. Sense and antisense oligonucleotide 
primers were designed to contain the desired mutation in the middle region with total length 
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around 25-40 bases (Table 2.1). These primers were synthesized by Thermo Fischer Scientific 
(Scoresby, VIC, Australia). 
 
Table 2.1 Primers used to generate the α4R100H, α4Y208C and δH92AS155T mutations.    
Mutations Primers 
α4R100H Sense        ACCCCTGATACTTTCTTCCACAATGGAAAGAAATCTGTC 
                 282                                                                                              320 
Antisense GACAGATTTCTTTCCATTGTGGAAGAAAGTATCAGGGGT 
                 320                                                                                              282 
α4Y208C Sense       ACGGGTGAATGTATTGTTATGACGGTTTACTTCCACCTCAG 
                615                                                                                                   655 
Antisense CTGAGGTGGAAGTAAACCGTCATAACAATATATTCACCCGT 
                 655                                                                                                    615 
δH92A Sense        TGACGGTGTTCCTGGCGCAGAGCTGGCGGGA 
                  262                                                                         292 
Antisense  TCCCGCCAGCTCTGCGCCAGGAACACCGTCA 
                  292                                                                         262 
S155T Sense        ACGGCGTGATCCTGTATACCATCCGAATCACCTC 
                 449                                                                                 482 
Antisense  GAGGTGATTCGGATGGTATACAGGATCACGCCGT 
                  482                                                                                 449 
 
The mutagenesis reaction was prepared as previously described (Table 2.1) [2]. 1 µL of 
PfuUltra HF DNA polymerase (2.5 U/µL) was added to the reaction setup and polymerase 
chain reaction was then performed using T100™ thermal cycler (Bio-Rad Laboratories Pty., 
Ltd., Gladesville, NSW, Australia) as shown in Table 2.2. Once the cycle was completed, 1 µL 
of Dpn I restriction enzyme (10 U/µL) was added and incubated at 37°C for 1 hour to digest 
the parental (nonmutated) DNA. The mutant DNA was then transformed into E.coli (section 
2.2.2.2) and the extracted DNA (section 2.2.2.3-2.2.2.4) was sequenced at Australian Genome 
Research Facility Ltd. (Westmead, NSW, Australia).    
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Table 2.2 Site-directed mutagenesis reaction setup. 
Component Amount 
10x reaction buffer 5 µL 
DNA template (5-50 ng) X µL  
Sense oligonucleotide primer (125 ng) X µL 
Antisense oligonucleotide primer (125 ng) X µL 
dNTP mix 1 µL 
Nuclease free water Add to a final volume of 50 µL   
 
 
Table 2.3 Cycling parameters for site-directed mutagenesis reaction. 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
2 16 95°C 30 seconds 
  55°C 1 minute 
  68°C 1 minute/kb of plasmid 
length 
3 1 4°C ∞ 
 
 
2. 2. 2. 2 Bacterial Transformation 
Plasmid cDNAs were transformed into suitable competent E. coli cell lines. TOP10/P3 
Competent Cells (Thermo Fischer Scientific, Scoresby, VIC, Australia) were used for 
GABAARs subunits subcloned in pCDM8 (β1, β2 and γ2L) while NEB 10-beta cells were used 
for subunits subcloned in pGEMHE and pcDNA1/Amp (β3, ɑ4 and δ). 1-5 µL of plasmid was 
added to 25 µL of competent cells and incubated on ice for 30 minutes. Cells were heat shocked 
for 30 seconds in a 42°C water bath (LabMaster, Sydney, NSW, Australia) allowing the 
plasmids to enter the cells and they were then placed back on ice. 250 µL of Super Optimal 
broth with Catabolite repression (SOC) outgrowth medium (New England Biolabs, Ipswich, 
MA, US) was added to the transformed cells and incubated for 1 hour at 37°C in a shaking 
incubator at 240 rpm (Labec Laboratory Equipment, Marrickville, NSW, Australia). The cells 
were evenly spread on Luria Bertani (LB) (13.72 g/L agar, 9.14g/L tryptone, 4.57 g/L yeast 
extract, 4.57 g/L NaCl; Sigma-Aldrich, Castle Hill, NSW, Australia) agar plates containing the 
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appropriate antibiotic. α4, β3 and δ cDNA expressing plasmids were selected using 0.1 mg/ml 
ampicillin LB agar plates; β1, β2 and γ2L cDNA expressing plasmids were selected using 0.1 
mg/ml ampicillin and tetracycline 0.01 mg/ml LB agar plates and incubated overnight at 37°C.        
 
2. 2. 2. 3 Bacterial Culture for Plasmids DNA 
Single-isolated colonies were picked from LB agar plates and transferred into 5 ml Terrific 
broth (11.8 g/L select peptone 140, 23.6 g/L yeast extract, 9.4 g/L dipotassium hydrogen 
phosphate, 2.2 g/L potassium dihydrogen phosphate; Thermo Fischer Scientific, Scoresby, 
VIC, Australia) containing the appropriate antibiotic for selections. The liquid cultures were 
then incubated for at least 16 hours at 37°C in a shaking incubator at 240 rpm. 
 
2. 2. 2. 4 DNA Extraction  
Plasmid DNAs were isolated using QIAprep® Spin Miniprep Kit (Qiagen, Chadstone, VIC, 
Australia). Bacterial cells were pelleted from overnight culture by centrifugation at 13,000 rpm 
for 3 minutes at room temperature (Eppendorf Centrifuge 5417R, North Ryde, NSW, 
Australia). The pelleted cells were resuspended in 250 µL resuspension buffer P1 (50 mM Tris-
HCl pH 8.0, 10 mM EDTA, 100 μg/ml RNaseA) and lysed with the addition of 250 µL lysis 
buffer P2 (200 mM NaOH, 1% SDS, 1:1000 LyseBlue). The solution turned into blue, 
indicating a complete lysis reaction. 350 µL of buffer N3 (4.2 M Gu-HCl, 0.9 M potassium 
acetate, pH 4.8) was added to neutralize the solution and changed the solution into colorless. 
This step caused chromosomal bacterial and cellular debris to precipitate. Plasmids were 
separated from cellular debris by centrifuging the solution for 15 minutes at 13,000 rpm in 
room temperature. The clear supernatant containing the plasmids were transferred into 
QIAprep spin miniprep column for purification. Spin columns were centrifuged for 1 minute 
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at 13,000 rpm, allowing the plasmids to bind to the column. The columns were subsequently 
washed with 750 µL buffer PE (10 mM Tris-HCl pH 7.5, 80% ethanol) and centrifuged twice 
for 1 minute at 13,000 rpm to remove any residual solvents. The DNAs were then eluted with 
50 µL of buffer EB (10 mM Tris-HCl pH 8.5) into 1.5 ml eppendorf tubes by centrifugation at 
13,000 rpm for 1 minute. 
 
2. 2. 2. 5 Determination of DNA Purity and Concentration 
The quality and quantity of the DNA was determined using agarose (Thermo Fischer Scientific, 
Scoresby, VIC, Australia) gel electrophoresis and Nanodrop® ND-1000-UV-Vis 
spectrophotometer (Thermo Fisher Scientific, Scoresby, VIC, Australia) respectively [3]. 1% 
agarose gel (w/v) was prepared by weighing 500 mg agarose and adding 50 ml of TAE buffer 
(40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 7.6). The mixture was then heated in a 
microwave until all of the agarose completely dissolved. After the agarose solution cooled 
down, 5 µL of SYBR® Safe DNA Gel Stain (Thermo Fischer Scientific, Scoresby, VIC, 
Australia) was added and the gel solution was cast. DNA was mixed with gel loading buffer II 
(95% formamide, 18 mM EDTA and 0.025% each of SDS, xylene cyanol and bromophenol 
blue; Thermo Fischer Scientific, Scoresby, VIC, Australia) in 1:1 ratio and were ran against 1 
kb DNA ladder (Thermo Fischer Scientific, Scoresby, VIC, Australia) in PowerPac™ Basic 
Power Supply (Bio-Rad Laboratories, Pty., Ltd., Gladesville, NSW, Australia) at 100 V and 
400 mA for 30 minutes. The agarose gel was visualized using GelDOC™ 1000 and Imagelab 
software (Bio-Rad Laboratories, Pty., Ltd., Gladesville, NSW, Australia). High quality of DNA 
was shown as clear and defined bands.  
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Quantity of the DNAs was assessed at 260 nM using Nanodrop® ND-1000-UV-Vis 
spectrophotometer (Thermo Fischer Scientific, Scoresby, VIC, Australia) based on the 
following modified Beer-Lambert equation: 
c = (A * e)/b 
Where c is nucleic acid concentration (ng/µL), A is absorbance (AU), e is wavelength-
dependent extinction coefficient (ng-cm/ µL) and b is path length (cm).   
Purity of DNA was assessed through ratio of sample absorbance at 260/280 nm. Absorbance 
value of   ̴1.8 is generally accepted as pure. Meanwhile nucleic acid purity was determined 
using ratio of sample absorbance at 260/230 nm. A range of 1.8-2.2 is considered acceptable. 
Values of 260/280 nm and 260/230 nm that were considerably lower than the aforementioned 
values may indicate the presence of contaminants.     
  
2. 2. 2. 6 DNA Lineriazation and Purification 
The plasmids containing the α4, β1, δ and γ2L subunits were linearized with the restriction 
enzymes HpaI (Genesearch Pty. Ltd., Arundel, QLD, Australia), β2 containing plasmids were 
linearized with NotI (Genesearch Pty. Ltd., Arundel, QLD, Australia), β3 containing plasmids 
were linearized with NheI (Genesearch Pty. Ltd., Arundel, QLD, Australia) [4,5]. 15 µL of 
plasmids, 5 µL of 10x buffer (NEBuffer 3.1 and CutSmart® Buffer for NotI and HpaI 
respectively), 29 µL of nuclease free water (Thermo Fischer Scientific, Scoresby, VIC, 
Australia) and 1µL of restriction enzyme were added to 1.5 ml tubes to form a 50 µL reaction 
mixture. The mixture was incubated for 2 hours in SBH 200D block heater (Bibby Scientific, 
Staffordshire, OSA, UK) at 37°C.   
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Once the reaction was complete, the linearized DNA was purified using QIAquick Nucleotide 
Removal Kit (Qiagen, Chadstone, VIC, Australia). 500 µL of PN1 was added to tube 
containing 50 µL from previous reaction. This mixture was then transferred to a quick spin 
column and centrifuged for 1 minute at 6000 rpm. The linearized DNA bound to matrix column 
was washed with 750 µL of buffer PE and centrifuged twice for 1 minute at 13,000 rpm to 
eliminate residual solvents. The DNA was eluted by centrifugation for 1 minute at 13,000 rpm 
following the addition of 50 µL of EB buffer. 
 
2. 2. 2. 7 Synthesis of mRNA 
cRNAs were transcribed from the linear cDNA templates using the mMESSAGE 
mMACHINE® T7 Transcription Kit (Thermo Fischer Scientific, Scoresby, VIC, Australia) 
[6]. A 20 µL reaction mixture was assembled at room temperature by adding 10 µL 2X 
NTP/CAP, 2 µL of 10x reaction buffer, 6 µL of DNA and 2 µL of RNA Polymerase Enzyme 
Mix into a PCR tube. The mixture was then incubated for 2 hours in a thermal cycler at 37°C. 
To remove the DNA template, 1 µL TURBO DNAse was added and the mixture was further 
incubated at 37°C for 15 minutes.  
To increase the stability, the resulting mRNAs were polyadenylated using the Poly-A-tailing 
kit (Thermo Fischer Scientific, Scoresby, VIC, Australia) [5]. 20 µL of DNAse treated mixture 
was transferred to 1.5 ml RNAse free tube. 36 µL of nuclease-free water, 20 µL of 5x E. coli 
Poly(A) Polymerase (E-PAP) buffer, 10 µL of 25 mM MnCl2 and 10 µL of 10 mM ATP were 
subsequently added. Lastly, 4 µL of E-PAP was added then the mixture was incubated at 37°C 
for 1 hour in heating block.  
The polyA-tailed RNA was purified by the addition of 30 µL lithium chloride and was left 
overnight in -20°C freezer. The next day, the RNA was pelleted by centrifugation at 14,000 
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rpm for 15 minutes at 4°C and the supernatant was removed. RNA pellets were washed with 
500 µL of pre-chilled 70% (v/v) ethanol and subjected to centrifugation at 14,000 rpm for 15 
minutes at 4°C. The ethanol was then carefully removed. The ethanol wash step was repeated 
to maximize the removal of unincorporated nucleotides. RNA pellets were air-dried and 
dissolved in 20 µL of nuclease-free water.  
 
2. 2. 2. 8 Determination of mRNA Purity and Concentration 
The presence of mRNA was determined using 1% agarose gel electrophoresis as described in 
section 2.2.2.5. Sample was prepared by mixing 2 µL of DNAse-treated mRNA that was taken 
earlier (section 2.2.2.7) with 3 µL of gel loading buffer II and then heated at 90°C for 1 minute. 
High quality of mRNA appeared as clear and defined bands, without a smear.  
The concentration of mRNA was measured using Nanodrop® ND-1000-UV-Vis (section 
2.2.2.5). Purity of mRNA is indicated with absorbance ratio at 260/280 nm and 260/230 nm of  
 ̴ 2 and 1.8-2, respectively.  
 
2. 2. 3 Electrophysiology 
2. 2. 3. 1 Harvesting and Digestion of Oocytes 
Quarantine Approved Premise (QAP) was obtained from Australian Quarantine and Inspection 
Service (AQIS) to maintain Xenopus laevis (African Clawed Frogs) in-house. Surgery 
procedures on Xenopus laevis were approved by Animal Ethics Committee of the University 
of Sydney (reference number: 2013/5915). Female X. laevis was anaesthetized by submerging 
the X. laevis in 0.17% tricaine supplemented with 0.06% NaCO2 for 10-15 minutes. After the 
loss of righting reflex, the frog was transferred to a container filled with ice where surgery was 
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performed. A small incision through the skin and muscle layer on the abdomen was made to 
obtain several ovarian lobes. The ovarian lobes were stored in oocyte releasing buffer 2 (OR2) 
(82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES hemisodium salt; pH 7.4). The 
muscle and skin layer was sutured separately and the frog was allowed to recover for 5 days in 
a separate tank before being placed back into her original tank.  
The lobes were cut into smaller pieces and then treated with collagenase A (Boehringer 
Mannheim, Indianapolis, IN, USA) dissolved in OR2 solution for 1-2 hours at 18⁰C to separate 
oocytes from follicle cell layer and connective tissues. After the digestion was complete, the 
oocytes were rinsed thoroughly with OR2 and ND96 storage solution (96 mM NaCl, 2 mM 
KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.4; supplemented with 2.5 mM sodium 
pyruvate and 0.5 mM theophylline). Oocytes that have a diameter of 1000-1200 µM (stage V) 
or diameters larger than 1200 µM (stage VI) were collected and stored in ND96 storage solution 
augmented with 50 µg/ml gentamycin and tetracycline in the refrigerator until the injection 
[3,4].   
 
2. 2. 3. 2 cRNA Injection 
Needles for injection were made from Drummond Scientific borosilicate glass capillaries 
(Thermo Fisher Scientific, Scoresby, VIC, Australia) using a microprocessor-controlled 
vertical pipette puller (Pull-100, Coherent Scientific, Hilton, SA, Australia). The glass needles 
were filled with mineral oil and installed on the microinjector (Nanoject, Drummond Scientific 
Co., Broomall, PA, USA). RNA mixtures were made accordingly and filled into the needle. 
Each oocyte was injected with 5-8 ng of mRNA in a final volume of 50.6 μL. The injected 
oocytes were incubated in ND96 augmented with 50 µg/ml gentamycin and tetracycline in 
incubator (Labec Laboratory Equipment Pty. Ltd., Marrickville, NSW, Australia) at 18⁰C with 
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shaking (mini orbital shaker SO5, Bibby Scientific, Staffordshire, OSA, UK) for 3-7 days prior 
to recording. ND96 antibiotic buffer was changed the next day and the oocytes were observed 
under a light microscope (Olympus, Nothing Hill, VIC, Australia). Unhealthy and dead oocytes 
were removed [4,6]. 
 
2. 2. 3. 3 Two-Electrode Voltage Clamp  
Whole-cell currents were recorded using the two-electrode voltage clamp technique with a 
Geneclamp 500B amplifier (Axon Instruments, Sunnyvale, CA, USA) and digitized with a 
Powerlab/200 (ADInstruments, Bellavista, NSW, Australia) analogue to digital conversion 
with Chart software (ADInstruments, Bellavista, NSW, Australia) version 3.5 [4]. The 
recording microelectrodes were made from Harvard Apparatus glass capillaries using single 
stage microelectrode puller (PP-830, Narishige, Tokyo, Japan). The microelectrodes were 
filled with 3 M KCl and had resistance between 0.2 and 1.2 MΩ. Oocytes were impaled and 
clamped at −60 mV and superfused with ND96 recording solution. DS2 stock solution was 
made using DMSO while GABA, THIP and ZnCl2 were dissolved in ND96 recording solution. 
Electrophysiology recording of GABA and THIP concentration-response curves at β1- and β3-
containing receptors were carried out by Nathan Luke Absalom from the Faculty of Pharmacy, 
The University of Sydney. 
 
2. 2. 3. 4 Data Analysis  
The currents evoked by GABA (I) were normalized to the fitted maximum currents evoked by 
GABA (IGABA_max_fit) and the currents evoked directly by DS2, THIP or AA29504 were 
normalized to the maximum GABA-evoked currents (IGABA_max) [4].  
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Meanwhile, the modulation of DS2 was measured in the presence of increasing concentration 
of GABA on a fixed concentration of DS2. The modulation was calculated as follows: 
% Modulation = (IGABA + DS2)/ IGABA_max) x 100% 
Normalized concentration-response curves were generated and analyzed using GraphPad 
Prism® version 6.04 according to the following equation: 
I = Imax ([A]n
H/([A]nH + EC50n
H)) 
Where [A] is the agonist concentration, nH is Hill slope, and the EC50 value is the concentration 
of agonist that produces a response that is 50% of the maximum current. Mean parameters of 
each curve were obtained from at least four oocytes. EC50 values are expressed as mean with 
95% confidence interval while nH, maximum efficacy (Emax), percentage of activation by DS2 
and AA29504 are expressed as mean ± S.E. Alternatively, the data were fitted to sum of two 
Hills equation where the nH values were constrained to 1: 
I = I1max ([A]n
H1/([A]nH1 + EC50
1nH1)) + I2max ([A]n
H2/([A]nH2 + EC50
2nH2))   
The estimated logEC50 values, Hill slopes, DS2 activation, Emax on different ratios or different 
GABAARs subtypes were compared using the non-parametric Kruskal-Wallis test followed by 
a Dunn’s post hoc test. Meanwhile, the estimated logEC50 values and Hill slopes between two 
different ratios were compared with a Student’s t-test. An F test was used to determine which 
fit is the preferred model.  
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2. 2. 4 Photothrombotic-induced Stroke  
2. 2. 4. 1 Animals 
All animal experiments followed the guidelines of the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes (National Health and Medical Research Council, 
Australia, 8th Edition) and were approved by the University of Sydney Animal Ethics 
Committee (reference number: 2013/6005 and 2013/6038). 
Two pairs of heterozygous genotype of B6.129-Gabrdtm1Geh/J were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA). The pairs were bred to obtain the desired homozygous 
genotype, δ knock-out (KO) and wild-type (WT) mice [7,8]. Mice aged 3-4 months were used 
for the experiments.  
Mice were housed in same-sex groups, no more than five per cage, and were maintained on 12 
hours light/dark cycle (lights off at 7 PM) with free access of water and food, except during 
experiments. All experiments were carried out during the light phase of the light/dark cycle. 
All mice were kept in individually ventilated cage (IVC) systems at The University of Sydney 
Bosch Rodent Facility. 
 
2. 2. 4. 2 Mouse Genotyping 
Deletion of DNA encoding the δ subunit was confirmed using PCR using three primers 
purchased from Thermo Fischer Scientific.  
Primers 1: GCA   GGC   TGT   CCT   ACA   ACC   AT  
     ATG    GT T   GTA  GGA  CAG   CCT   GC  
Primers 2: ATG   CCA   CTC   CTG   ATG   CCT   AC  
     GTA   GGC   ATC   AGG   AGT   GGC  AT  
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Primers 3: GGG   GTT   TGC   TCG   ACA   TTG  
     CAA   TGT   CGA   GCA   AAC   CCC 
Mice were anaesthetized with isoflurane and were ear-punched for identification. Their tails 
were snipped and kept separately in eppendorf tubes for genotyping. Tubes containing the 
sample were quick-spun to ensure that the sample was at the bottom of the tubes. 300 µL 
DirectPCR Lysis Reagent (Tail) (Australian Biosearch, Wangarra, WA, Australia) and 15 µL 
of proteinase K (Promega, Alexandria, NSW, Australia) were added to the tubes and were 
placed in 55°C water bath overnight to allow sample lysis. The next morning, the lysate were 
vortexed (Ratec, Boronia, VIC, Australia) and incubated at 85°C for 45 minutes to inactivate 
the proteinase K. 50 µL of PCR mixtures were prepared with the addition of 0.5 µL of each of 
the primers, 25 µL AmpliTaq Gold® (Thermo Fischer Scientific, Scoresby, VIC, Australia), 
18.5 µL of nuclease-free water and 5 µL of lysate. The mixture was carefully mixed and PCR 
was performed using thermal cyler as shown in Table 2.3. Once the PCR was finished, 15 µL 
of the mixture was taken and added to 5 µL of gel loading buffer II and was then analyzed 
using electrophoresis on 3% agarose gel containing 0.1% SYBR® Safe DNA Gel Stain at 100 
V and 400 mA for 30 minutes. The gel was visualized and the sample that had one band at the 
bottom was δ-/- mouse. In contrast, sample that had one band at the top showed genotype of 
WT, whilst sample with two bands indicated heterozygous genotype (Fig. 2.1).  
 
Table 2.4 Cycling Parameters for mouse genotyping. 
Segment Cycles Temperature Time 
1 1 94°C 3 minutes 
2 35 94°C 30 seconds 
  60°C 1 minute 
  72°C 1 minute 
3 1 72°C 2 minutes 
4 1 10°C ∞ 
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Fig. 2.1 Mouse Genotyping. An example of agarose gel electrophoresis for genotyping. Left lane 
showing one band at the bottom is of the knock-out genotype. Two bands on the middle lane indicate 
heterozygous while one band at the bottom on the right lane shows wild-type genotype. 
 
 
2. 2.4. 3 Phototrombotic Model of Focal Ischaemia 
Photothrombotic mouse model of stroke was used to evaluate how tonic inhibition affects 
cortical excitability that will later influence functional recovery. This model was suitable for 
the thesis aim since the damage induced was limited to the motor cortex area. Furthermore, this 
method is minimally invasive and applicable to transgenic mice.  
Mice were anaestesized using isoflurane and secured to stereotaxic frame (Harvard Apparatus, 
Holliston, MA, USA). Vaseline was applied to prevent the eyes from drying. Rectal probe was 
inserted to monitor body temperature and the temperature was maintained at 37°C with a 
heating pad (Harvard apparatus, Holliston, MA, USA) throughout the surgical procedure. The 
head of the mouse was shaved and cleaned with betadine to disinfect the skin.  A midline 
incision of around 1.5 cm was made after loss of reflex was confirmed. Periost was gently 
removed using a cotton swab and bregma was identified. The cold light source (Schott KL 
1600, Coherent Scientific Pty. Ltd., Hilton, SA, Australia) with green filter (Coherent Scientific 
Pty. Ltd., Hilton, SA, Australia) attached to 40x objective (Olympus, Nothing Hill, VIC, 
Australia) was positioned 1.5 mm to the left of bregma. 0.2 ml of rose bengal solution (10 
mg/ml in normal saline) was injected intraperitoneally (i.p) 5 minutes before illumination. 
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Following illumination for 15 minutes, the incision was closed using surgical glue and the mice 
were kept in a recovery cage placed on a heating pad until they were fully awake (around 1 
hour) [9,10,11].       
THIP (1 mg/kg/10 ml) was dissolved in 0.9% saline. THIP or saline (10 ml/kg) was given i.p 
1 hour after stroke to the WT and δ KO mice.  
 
2. 2. 4. 4 Behavioral Assessment 
Behavioral assessment was performed 1 day before surgery to establish baseline performance 
levels. Animals were tested again 7 days following the surgery to evaluate functional outcomes. 
The experimenter was blinded to the animal treatment group.   
 
2. 2. 4. 4. 1 Grid-Walking Task 
A box (30 cm x 20 cm x 15 cm) with grid wire (12 mm x 12 mm) as the base was used. The 
box was placed at height of 28 cm. Each mouse was placed in the box and allowed to explore 
freely for 5 minutes. A mirror was placed under the apparatus to allow video footage (Legria 
HF R706 camera, Canon, Macquarie Park, NSW, Australia). The number of foot faults and 
non-foot-fault steps for forelimb and hindlimb was counted. A foot fault was defined as the 
whole limb going through the grid hole. If the mouse only used its wrist or one toe to support 
the step, this was also considered as a foot fault [12,13].  
Percentage of forelimb or hindlimb faults was calculated according to the following equation: 
Number of foot faults/(number of foot faults + non-foot-faults) x 100 % 
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2. 2. 4. 4. 2 Cylinder Test 
The cylinder test, also referred as spontaneous forelimb (SFL) task, monitors the asymmetrical 
use of forelimbs activity during vertical exploration in a cylinder. A mouse was placed in a 
plexiglass cylinder (diameter of 10 cm and height of 19 cm) and the activity was recorded for 
5 minutes. A mirror was placed beside the cylinder to allow footage when the mouse turned 
away from the camera. Forelimb contacts to the wall were counted until 20 movements were 
achieved. One full rear was counted as one movement. The first forelimb to touch the cylinder 
wall during a full rear was recorded as an independent placement for that limb. When the 
second forelimb contacted the wall and the first limb was still in place, the first limb was 
recorded as independent placement, whilst the second limb was considered as both placements. 
If both limbs were used simultaneously on the wall or if the animal explores the wall by 
alternating between both limbs, then it was scored as both movements. The time during each 
rear of left forelimb, right forelimb, or both forelimbs were scored. The percentage time on 
each limb was calculated and utilized to derive SFL asymmetry index ((% ipsilateral use)) – 
((% contralateral use)) [14,15].      
 
2. 2. 4. 5 Transcardial Perfusion 
Following behavioral tests, transcardial perfusion was performed to chemically fix the brains 
of mice [16]. Perfusion allows the brain to be cleared from blood cells that interfere with 
histological examination. A lethal dose of 0.2 ml pentobarbital was administered i.p to the 
mice. Once the mice were unresponsive to toe pinches, they were placed on a surgical table in 
supine position. Lateral incision beneath the rib cage was made followed by incision along the 
rig cage to expose the heart. 26G x 0.5 inch needle (Terumo, Macquarie Park, NSW, Australia) 
connected to Minipuls3 gilson pump (John Morris Scientific, Chatswood, NSW, Australia) was 
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carefully inserted to the apex of left ventricle and secured by hemostat. The right atrium was 
clipped and the pump was turned on to perfuse the mice with phosphate buffered saline (PBS) 
(3.4 g/L sodium phosphate monobasic, 10.9 g/L Sodium Phosphate dibasic, 9 g/L NaCl) [16]. 
After the fluid exiting the atrium was entirely clear, mice were then perfused with 4% 
parafolmaldehyde (PFA) (in PBS) until the mice were fixated (approximately 25 ml).               
 
2. 2. 4. 6 Histology and Infarct Size Measurement 
Following perfusion, the mice were decapitated and the brains were extracted. Brains were kept 
in 4% PFA for a minimum period of 48 hours to ensure the brain was fixed throughout. The 
brains were transferred to 15% sucrose (w/v; in 0.1 M phosphate buffer) and then 30% sucrose 
to extract the water and cyroprotect the brains. Brains were embedded with Tissue-Tek® 
(ProSciTech, Thuringowa, QLD, Australia) and were coronally sliced at 30 µM on a cryostat 
(Leica Microsystem, Mt. Waverley, VIC, Australia).  
Brain sections were mounted on gelatin-coated glass microscope slides. The sections were 
dehydrated with increasing concentrations of ethanol (50, 70 and 100%) and then rehydrated 
prior to incubation in 0.1% cresyl violet for 8 minutes. The sections were rinsed in 0.07% acetic 
acid and diffentiated by dipping the slides in increasing concentration of ethanol. The sections 
were cleared in xylene for 5 minutes and were coverslipped using Eukitt® (Sigma-Aldrich, 
Castle Hill, NSW, Australia) [9].  
Once the slides were dry, images were acquired using 10x objective using Axioscan Z.1 (Carl 
Zeiss, Dublin, CA, USA). The infarct areas of each section were delineated and measured using 
imageJ software (National Institute of Health, Bethesda, MD, USA). Infarct size was calculated 
by summing the infarct areas of all sections and multiplying by the slice thickness.  
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2. 2. 4. 7 Statistical Analysis 
All data are expressed as mean ± S.E. Behavioral and histology data were compared using the 
non-parametric Kruskal-Wallis test followed by a Dunn’s post hoc test. 
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Chapter 3 
High and Low GABA Sensitivity α4β2δ GABAA Receptors are 
Expressed in Xenopus laevis Oocytes with Divergent 
Stoichiometries 
 
3. 1. Introduction  
Activation of GABAARs in the brain generally leads to cellular inhibition by allowing influx 
of Cl- ions. These receptors can be located at both the synapse, where they contribute to phasic 
inhibition controlled by presynaptic GABA release, and at extrasynaptic and perisynaptic sites 
where they generate tonic inhibition in response to low concentrations of GABA to fine-tune 
the inhibitory response of neurons (reviewed in [1]). To perform these different cellular roles, 
different GABAARs subtypes are formed from the large number of distinct receptor subunits. 
In recent years there has been a growing interest in understanding how GABAAR subtypes, 
especially receptors containing α4, β and δ subunits, are activated at low GABA concentrations 
to mediate tonic inhibition [2].  The pharmacology of α4βδ receptors has also been of 
considerable interest in research, with these receptors identified as important targets for 
neurosteroids, alcohol, and certain anaesthetics [1, 3-5]. A deeper understanding of the 
pharmacology of these receptors is required to fulfill their potential as drug targets for various 
neurological and psychiatric disorders, including pain, epilepsy, sleep disorders, depression, 
and schizophrenia [2, 6, 7].  
Despite considerable research efforts in the field, it is striking how the functional and 
pharmacological studies of δ-containing receptors have yielded variable results. The sensitivity 
of α4βδ receptors to ethanol is a classic example whereby some researchers report that low 
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concentrations of ethanol potentiate GABA on δ-containing receptors [8-11], while others do 
not observe this potentiation [12]. Additionally, there are a number of reports that describe 
α4β3δ receptors forming two distinct receptor populations: one receptor population that is 
sensitive to nanomolar concentrations of GABA and THIP and another population that is 
sensitive to micromolar concentrations of both compounds. A similar difference in GABA 
potency was also observed at α4β2δ receptors in one study [13]. Whilst most reports describe 
micromolar effects of GABA at α4β2δ receptors [14-17], Eaton et al. (2014) report that GABA 
acts at nanomolar concentrations using concatenated constructs [13].  
The subunit composition of GABAARs and their pentameric arrangement around a central, ion-
conducting pore are crucial determinants of the pharmacological properties of the receptor, 
determining the putative ligand-binding interfaces and intrinsic activation properties [18]. To 
date, the exact stoichiometry of α4βδ receptors expressed both natively, and in heterologous 
systems, remains equivocal. While a number of studies attempt to address this question [19-
22], firm conclusions have been difficult to draw over what stoichiometrie(s) or arrangement(s) 
are formed, and under what conditions these occur. In the abundant α1β2γ2 receptor, the γ2 
subunit take the position as a fifth “auxiliary” subunit that does not participate in GABA 
binding, and it is generally assumed that the δ subunit substitutes for the γ2 subunit in α4βδ 
receptors receptors. This has been questioned by reports that the level of δ subunit 
incorporation varies by varying the ratio of cRNA or cDNA in recombinant systems [20], while 
the expression of concatenated constructs suggest that the δ subunit can occupy various 
positions within the receptor complex [18, 21]. Differences in functional and pharmacological 
properties of these receptors are thought to accompany these differences in both subunit 
stoichiometry and arrangement [10, 22]. However, a caveat of some of these studies is that 
while measuring the responses of concatenated constructs can potentially yield information 
about a specific arrangement and stoichiometry of a single receptor, the technique itself may 
 65 
alter intrinsic receptor properties and force the assembly of receptors that would not occur 
otherwise. Along this, the use of concatenated constructs was recently shown to significantly 
alter the sensitivity to GABA and etomidate [23].  
DS2 has proven useful at identifying δ-containing GABAAR in native systems where it 
enhances tonic currents. At the molecular level, DS2 can either positively modulate GABA-
elicited currents, or directly activate α4β3δ receptors. Similarly, there are reports of various 
levels of direct activation of α4β2δ receptors by DS2 but it is not well understood what 
conditions favour direct activation as opposed to positive modulation [13-15, 24]. 
We hypothesized that variations in the pharmacology of α4β2δ receptors arise from the 
expression of receptors with either different stoichiometries or different subunit arrangements.  
In this study, we tested this hypothesis by injecting a matrix of different cRNA injection ratios 
that varied the subunit ratio of α4, β2, and δ cRNA in Xenopus laevis oocytes. The 
pharmacology of the receptors expressed was evaluated with GABA and DS2 to determine 
functional changes between the receptors expressed under different injection ratios. Our results 
demonstrate that GABA and DS2 activity were markedly changed depending on the subunit 
ratio of α4:β2, clearly indicating that receptors with different stoichiometries are expressed. 
There are at least two discrete receptor populations: one containing high GABA sensitivity and 
high efficacious DS2 direct activation and another with lower GABA sensitivity and relatively 
low-efficacy DS2 activation. At the latter receptors, DS2 positively modulated the GABA-
elicited current. These data suggest that variability of the pharmacological properties of α4β2δ 
receptors are likely to be the result of the expression of receptors with different stoichiometries. 
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3. 2 Results 
There has been considerable variation in the reports describing the pharmacological properties 
of δ-containing GABAA receptors. We hypothesized that these variations in the pharmacology 
of α4β2δ receptors arise from the expression of receptors with either different stoichiometries 
or different subunit arrangements in heterologous systems. To investigate whether the 
expression of different receptor populations can be manipulated to preferentially express one 
receptor population in preference to another, we varied the molar ratios of α4, β2, and δ cRNA 
injected in Xenopus laevis oocytes. This method has previously been shown to give a 
reasonable degree of control over subunit assembly of resulting receptors [22, 25-27]. All 
cRNA was derived from a single RNA stock of each subunit to allow for a comparison between 
relative RNA ratios. We then created a matrix of injection ratios allowing us to alter the relative 
ratio of one subunit while keeping the ratio of the other two constant.  
 
3. 2. 1 α4β2δ Receptors Expressed from the Injection of a 1:1:1 cRNA Ratio in Oocytes 
Equimolar or close to equimolar (e.g. 1:1:2) cRNA ratios have commonly been used to express 
GABAA α4β2δ receptors in oocytes [14]. α4β2δ receptors were therefore initially expressed by 
injecting a cRNA mixture with a 1:1:1 ratio of the three subunits. As expected, receptors 
responded to applications of GABA in a concentration-dependent manner (Fig. 3.1A top 
panel). When stimulated with a maximally efficacious GABA concentration (100 µM, 
henceforth termed GABA100µM), the average evoked peak current amplitude from n = 11 
oocytes were 160 nA (Table 3.1), a finding that was in good agreement with previous reports 
of δ-containing receptors [14, 15]. Plotting average GABA-evoked peak current amplitudes as 
a function of the concentration of GABA revealed a concentration-response curve that when 
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fitted with a one-site Hill equation had an EC50 value (half maximal efficacious GABA 
concentration) of 140 nM and a Hill slope of 0.3 (Fig. 3.1B, Table 3.1).  
 
Fig. 3.1 Electrophysiological recordings of GABA- and DS2-evoked α4β2δ currents using X. laevis 
oocytes injected with cRNA containing a 1:1:1 subunit ratio. (A) Example of traces from single 
experiments showing GABA (top panel) or DS2 activation (bottom panel). Bars above each trace 
represent application period and the specific GABA or DS2 concentration. Applied bulk washout 
periods are omitted. (B) Peak current amplitudes for GABA activation were normalized to the 
maximum current fitted from individual experiments fitted to the Hill equation (IGABA_max_fit). 
Normalized responses were plotted as mean ± S.E. from n = 11 oocytes and fitting data to the Hill 
equation yielded an EC50 value of 0.14 µM (95% confidence intervals: 0.072-0.26 µM) with a Hill slope 
of 0.3 ± 0.03. (C) Peak current amplitudes for DS2 activation were normalized to that of a maximal 
efficacious GABA (100 µM) concentration (IGABA_100µM) in the same oocytes and plotted as mean ± S.E. 
from n = 15 oocytes. Data points were fitted to the Hill equation, which yielded an EC50 value of 0.97 
µM (95% confidence intervals: 0.47-2.0 µM) with a Hill slope of 0.99 ± 0.15. 
 
Table 3.1 GABA concentration-response curve from α4β2δ receptors using X. laevis oocyte 
electrophysiology. 
α4+β2+δ  
ratio 
EC50 (95% CI) 
(µM) 
nH Imax (nA) n 
1:1:1 0.14 (0.072 - 0.26) 0.3 ± 0.03 160 ± 10 11 
5:1:1 1.6 (1.3 - 2.0)* 0.9 ± 0.1** 60 ± 8 6 
1:5:5 0.46 (0.1 - 2.0) 0.3 ± 0.1  70 ± 14 9 
1:5:1 0.57 (0.16 - 2.03) 0.3 ± 0.04  75 ± 9  5 
5:1:5 1.6 (1.3 - 1.9)* 0.9 ± 0.1** 55 ± 7 7 
1:1:5 0.72 (0.18 - 2.8) 0.4 ± 0.1 70 ± 10 8 
5:5:1 0.23 (0.12 - 0.42) 0.4 ± 0.03 85 ± 11 8 
* p < 0.05 and ** p < 0.01 Dunn’s multiple comparison post hoc test compared to α4+β2+δ (1:1:1) 
 
This low Hill slope is atypical for a GABAA receptor and may instead be the result of two 
receptor populations with distinct GABA potencies. However, fitting the concentration-
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response curve to a higher-order equation was not statistically different to fitting the data with 
a one-site Hill equation (t-test, P = 0.24), suggesting this was not a biphasic curve. When 
GABA concentration-response curves were plotted and fitted for each oocyte, the EC50 values 
had a wide range from 6.4 to 610 nM and the Hill slopes ranged from 0.28 to 0.42. This suggests 
that the low Hill slope is likely to be an inherent feature of the receptor population(s) expressed 
in all oocytes (Fig. 3.1B), as opposed to be a result of averaging data from oocytes expressing 
receptors with either high or low affinity for GABA.  
A defining feature of δ containing receptors has been their sensitivity to high modulatory 
efficacy of DS2. This potentiation of GABA-elicited currents has been described by several 
groups and, although results vary between studies, it is widely accepted that δ incorporation 
into a GABAA receptor increases the modulatory efficacy of GABA by DS2 [28]. Therefore, 
we attempted to describe the DS2 modulation by performing a full GABA concentration-
response curve in presence of DS2. However, this proved difficult to perform as applications 
of DS2 (1 µM) alone elicited current amplitudes that were approximately 4-fold larger than 
that of GABA100µM (Fig. 3.1A Bottom). This effect where DS2 directly activated the receptor 
confounded the measurement of the efficacy of modulation.  
To determine the potency and efficacy of DS2 agonism relative to GABA, we performed 
concentration-response curves of DS2 and α4β2δ receptors responded to DS2 application in a 
concentration-dependent manner. The average DS2-evoked peak current amplitudes plotted as 
a function of the DS2 concentration were well approximated by the Hill equation (Fig. 3.1C), 
with derived fitting parameters of an EC50 value of 0.97 µM and a Hill slope of 0.98, indicating 
the presence of a saturable DS2 binding site(s).  
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Table 3.2 Properties of α4β2/3δ from selected publications. 
Receptor 
(ratio) 
GABA DS2 activity Reference 
EC50 (µM) nH Modulation Activation 
α4+β2+δ  
(high sensitivity) 
0.14-0.72 0.3-0.4 NA ✓ current study 
α4+β2+δ  
(low sensitivity) 
1.6 0.9 ± 0.1 ✓ ✗ current study 
α4+β2+δ 
(1:1:2) 
α4+β3+δ 
(1:1:2) 
1.5 ± 0.1 
 
NA 
NA 
 
NA 
✓ 
 
✓ 
✓ 
 
✓ 
[14] 
α4+β2+δ 
(1:1:5) 
α4+β3+δ 
(5:1:5) 
1 
 
(1)b = 0.012 
(2)b = 1.3 
1.3 ± 0.2 
 
(1)b = 1.2 ± 0.5 
(2)b = 1.1 ± 0.3 
NA 
 
NA 
NA 
 
NA 
[30] 
α4+β2+δ 
(5:1:5) 
δ-β2-α4+β2-α4c 
0.8 ± 0.1 
 
1.4 ± 0.3 
0.8 ± 0.1 
 
1.2 ± 0.1 
✓ 
 
✓ 
✗ 
 
✗ 
[15] 
α4+β2+δ 
(5:1:5) 
β2- δ + α4c 
0.010 ± 0.001 
 
0.17 ± 0.02 
0.8 ± 0.1 
 
1 ± 0.1 
✓ 
 
NA 
✗ 
 
NA 
[13] 
NA: Not available, b: fitted to biphasic curve, c: concatenated receptor 
 
Although these features of α4β2δ receptors, including the current amplitude levels and 
sensitivity to DS2, are in good agreement with previous data, the EC50 value of GABA and the 
Hill slope value appear to be different (Table 3.2) [14, 29]. GABA was approximately 10-fold 
more potent than the bulk of previous descriptions, and this was accompanied with a low Hill 
slope of the concentration-response curve. High GABA-sensitivity receptors have been 
described for the α4β3δ subtype and this has been accompanied with biphasic fitting of the 
concentration-response curve [29]. Further, while there is consensus in the literature that DS2 
is a modulator with some selectivity for δ-containing receptors, there remains controversy 
regarding the direct activating effects of the compound. Jensen et al. (2013) reported strong 
activation by DS2 on human recombinant α4β3δ receptors expressed in Xenopus oocytes 
whereas other studies using either concatenated constructs or free subunits of α4β2δ in oocytes 
or HEK 239 cells did not reveal any direct DS2 activation [13, 15, 24] (Table 3.2). It is 
generally accepted that GABAA receptors can form promiscuously when expressed in 
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heterologous expression systems such as oocytes [30]. Accordingly, injection of α4+β2+δ 
subunits using a 1:1:1 cRNA ratio could potentially form more than one receptor population 
that varies either in composition, stoichiometry and/or subunit arrangement.  
 
3. 2. 2 α4δ, β2δ and α4β2 Binary Receptors 
The formation of binary receptors constitutes one possible reason for receptor populations with 
distinct pharmacological properties to be formed. For example, binary α1β2 receptors express 
well in a variety of expression systems [25, 31]. Therefore, to determine the functional 
properties of potential binary receptors, cRNA mixtures of α4+δ, β2+δ or α4+β2 were injected 
into oocytes using subunit ratios of 5:1 or 1:5 (e.g. α4+δ (5:1) or α4+δ (1:5)). 
Oocytes injected with α4+δ (5:1), α4+δ (1:5) or β2+δ (5:1) ratio did not elicit any response to 
GABA or GABA+DS2 applications. β2+δ (1:5) injection resulted in minute GABA-evoked 
currents in 8 out of 17 oocytes with a mean peak current amplitude of 6.5 ± 1.5 nA from the n 
= 8 expressing oocytes (Fig. 3.2A). These currents were not modulated by DS2 (0.3 µM). 
Somewhat larger currents were observed from injecting α4+β2 (5:1), where GABA100µM 
evoked currents with a mean peak amplitude of 25 ± 7 nA from n = 6 oocytes (Fig. 3.2B). This 
is significantly less than that observed with α4+β2+δ (1:1:1) above (t-test, P < 0.001). Further, 
a low concentration of GABA (1 µM) barely evoked any current and co-applications of DS2 
(1 µM) had no effect. Finally, injecting α4+β2 (1:5) resulted in GABA100µM-evoked currents 
with a mean peak amplitude of 95 ± 10 nA for n = 7 oocytes. Upon visual inspection, currents 
from these α4β2 receptors appeared to have a faster current decay in presence of GABA 
compared with the α4β2δ receptors above (Fig. 3.2C and 3.2D, compare with 3.1A), but 
otherwise had similar properties. A full GABA concentration-response curve fitted to a one-
site Hill equation revealed an EC50 value of 1.9 µM and a low Hill slope of 0.5 (Fig. 3.2E), 
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while a higher order biphasic fit was not significantly better (P = 0.68, F-test). The application 
of DS2 (0.3-1 µM) did not modulate an EC20 concentration of GABA nor give direct activation 
at these α4β2 receptors (Fig. 3.2C). 
 
 
Fig. 3.2 GABA activation and DS2 modulation of binary β2δ or α4β2 receptors recorded using X. 
laevis oocytes electrophysiology. Representative current traces evoked by applications of GABA, 
GABA+DS2 or DS2 alone for (A) β2+δ (1:5), (B) α4+β2 (5:1) and (C) α4+β2 (1:5). (D) Representative 
GABA-evoked current traces in an oocyte injected with α4+β2 (1:5). (E) Peak current amplitudes from 
GABA concentration-response curves at α4+β2 (1:5) injected oocytes were fitted as described in the 
Fig. 3.1 legend and plotted as averaged values ± S.E. from n = 7 oocytes. Data points were fitted to the 
Hill equation, which resulted in an EC50 value of 1.9 (0.9-4.2) µM and a Hill slope of 0.5 ± 0.1. 
 
Out of the three possible types of binary receptors (α4δ, β2δ and α4β2), only α4β2 receptors 
gave robust GABA-evoked currents. Since binary receptors themselves can potentially express 
in different stoichiometries, e.g. (α4)3(β2)2 or (α4)2(β2)3, expression of the binary receptor 
combinations were attempted with two different cRNA ratios (5:1 and 1:5). Interestingly, 
injection of α4β2 (1:5) cRNA gave rise to substantially higher current levels than α4β2 (5:1) 
cRNA. This indicates that an (α4)2(β2)3 stoichiometry either yield higher surface expression 
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levels or give higher degree of activation upon GABA applications. This is consistent with 
previous studies showing that α1β2 GABAA receptors yield best current levels in the 2α:3β 
arrangement [32]. Several studies have suggested that αβ receptors are fully functional and 
often constitute a contaminant when expressing ternary receptors [4, 31]. However, in the 
context of the current study, α4β2 receptors were insensitive to modulation and direct activation 
by DS2. This is in sharp contrast to observations with the α4+β2+δ (1:1:1) ratio above and this 
limits the likelihood that α4β2 binary receptors constitute a major fraction of the receptor pool 
in these experiments. 
 
3. 2. 3 α4β2δ Ternary Receptors from Variant cRNA Ratios 
As binary receptors do not appear to constitute a major receptor population expressed from 
injecting α4+β2+δ (1:1:1), we next determined how altering the molar subunit ratio of α4+β2+δ 
in the cRNA mixture might influence ternary receptor formation. The receptors formed by 
different injection ratios were compared by performing full GABA concentration-response 
curves and evaluating the direct activation properties of DS2 (300 nM) (DS2300nM). The 300 
nM concentration was chosen as it elicited large currents at receptors with high sensitivity to 
DS2, without compromising the potential selectivity by activating receptors with lower 
sensitivity to DS2. 
 
3. 2. 3. 1 Varying the α4 cRNA Ratio 
Initially, the effects of increasing the ratio of the α4 subunit, while maintaining a constant β2:δ 
ratio were evaluated. Oocytes injected with α4+β2+δ (5:1:1) responded to GABA100µM 
applications with an average peak current amplitude of 60 nA (Table 3.1). The full GABA 
concentration-response curve was well approximated with a one-site Hill equation giving an 
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EC50 value of 1.6 µM and Hill slope of 0.9 (Fig. 3.3A, Table 3.1). Further, the direct DS2300nM 
activation level was low (Fig. 3.3C) and the DS2300nM activation, EC50 value and Hill slope to 
GABA were all significantly different from that of the α4+β2+δ (1:1:1) ratio (P < 0.05 DS2 
and EC50, P < 0.01 Hill slope) (Fig. 3.3B).  
 
 
Fig. 3.3 Electrophysiological recordings of GABA- and DS2-evoked α4β2δ receptor currents 
using cRNA with variant relative amounts of α4. Observations for the α4+β2+δ (1:1:1) ratio from 
Fig. 3.1 are depicted in gray to allow comparison. (A) α4β2δ (5:1:1) and α4β2δ (1:5:5) GABA 
concentration-response curves plotted as averaged values ± S.E. from n = 6-9 oocytes. Regression 
results are presented in Table 3.1. (B) Peak current activation by DS2 (300 nM) (IDS2_300nM) was 
normalized to maximal efficacious GABA (100 µM) control applications (IGABA_100µM) in the same 
oocytes and depicted as mean ± S.E. from n = 7-10 oocytes for the indicated cRNA ratios. (C, D) 
Representative current traces evoked by applications of a maximally efficacious GABA concentration 
(GABA100µM) or DS2 (300 nM) for (C) α 4+ β 2 + δ (5:1:1) and (D) α 4 + β 2 + δ (1:5:5). * Indicate 
statistical significant difference (P < 0.05, Kruskal-Wallis, Dunn’s post hoc). 
 
Decreasing the relative amount of α4 by injecting α4+β2+δ (1:5:5) resulted in an average 
GABA100µM-elicited peak current amplitude of 70 nA (Table 3.1). When fitted to a one-site 
Hill equation, the full GABA concentration-response curve had an EC50 value of 720 nM and 
a low Hill slope of 0.4 (Fig. 3A, Table 3.1). Similarly to oocytes injected with α4+β2+δ (1:1:1), 
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oocytes injected with α4+β2+δ (1:5:5) were efficiently activated by DS2300nM (Fig. 3.3B and 
3.3D). The EC50 value, Hill slope, and DS2 activation were not significantly different to that 
obtained with the α4+β2+δ (1:1:1) (P > 0.05). 
 
3. 2. 3. 2 Varying the β2 cRNA Ratio 
Next, we altered the relative amounts of β2, initially increasing the amount of β2 and injecting 
a ratio of α4+β2+δ (1:5:1). Oocytes injected with this ratio responded to GABA100µM 
applications with an average peak current amplitude of 75 nA (Table 3.1). The fitted GABA 
concentration-response curve displayed an EC50 value of 570 nM and a Hill slope of 0.3 (Fig. 
3.4A, Table 3.1). DS2300nM evoked currents with amplitudes similar that of GABA100µM (Fig. 
3.4C), with no significant differences between the α4+β2+δ (1:5:1) and (1:1:1) ratios for the 
GABA EC50 value, Hill slope or DS2300nM activation (P > 0.05). Hence, the data obtained from 
increasing the relative amount of the β2 subunit resembled those obtained with the α4+β2+δ 
(1:1:1) ratio (Fig. 3.4B).  
Decreasing the amount of β2 by injecting α4+β2+δ (5:1:5) resulted in an average GABA100µM-
evoked peak current amplitude of 55 nA (Table 3.1). The GABA concentration-response curve 
was well approximated by a one-site Hill equation with an EC50 value of 1.6 µM and Hill slope 
of 0.9 (Fig. 3.4A, Table 3.1). There was limited direct activation with DS2300nM (Fig. 3.4D) and 
the DS2300nM activation, EC50 value, and Hill slope to GABA were all significantly different 
from that of the α4+β2+δ (1:1:1) ratio (P < 0.05 DS2 and EC50, P < 0.01 Hill slope) (Fig. 3.4B). 
However, the EC50 value, Hill slope, and DS2300nM were not significantly different to the 
α4+β2+δ (5:1:1) ratio (compare Fig. 3.4A with 3.3A).  Hence, the data obtained from 
decreasing the relative amount of the β2 subunit resembled those obtained with the α4+β2+δ 
(5:1:1) ratio (Fig. 3.4A and 3.3A).  
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Fig. 3.4 Electrophysiological recordings of GABA- and DS2-evoked α4β2δ receptor currents 
using cRNA with variant relative amounts of β2. (A) α4β2δ (1:5:1) and α4β2δ (5:1:5) GABA 
concentration-response curves plotted as averaged values ± S.E. from n = 5-7 oocytes. Regression 
results are presented in Table 3.1. (B) Peak current activation by DS2 (300 nM) (IDS2_300nM) was 
normalized to maximal efficacious GABA (100 µM) control applications (IGABA_100µM) in the same 
oocytes and depicted as mean ± S.E. from n = 5-7 oocytes for the indicated cRNA ratios. (C, D) 
Representative current traces evoked by applications of a maximally efficacious GABA concentration 
(GABA100µM) or DS2 (300 nM) for (C) α 4 + β 2 + δ (1:5:1) and (D) α 4 + β 2 + δ (5:1:5). * Indicate 
statistical significant difference (P < 0.05, Kruskal-Wallis, Dunn’s post hoc). 
 
3. 2. 3. 3 Varying the δ cRNA Ratio 
We then altered the relative amount of the δ subunit that was injected, initially increasing the 
amount of δ subunit by injecting α4+β2+δ (1:1:5). Oocytes responded to GABA100µM 
applications with an average peak current amplitude of 70 nA, and the GABA concentration-
response curve was well approximated by a one-site Hill equation with an EC50 value of 720 
nM and a Hill slope of 0.4 (Fig. 3.5A, Table 3.1). Robust direct activation was observed with 
DS2300nM (Fig. 3.5C), similar to the EC50 value, Hill slope, and DS2300nM activation obtained 
by the α4+β2+δ (1:1:1) ratio. 
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Fig. 3.5 Electrophysiological recordings of GABA- and DS2-evoked α4β2δ receptor currents 
obtained by injecting various amount of δ cRNA subunit in X. laevis oocytes. (A) α4β2δ (1:1:5) 
and α4β2δ (5:5:1) GABA concentration-response curves plotted as averaged values ± S.E. of n = 8 
oocytes. Regression results are presented in Table 3.1. (B) Peak current activation by DS2 (300 nM) 
(IDS2_300nM) was normalized to maximal efficacious GABA (100 µM) control applications (IGABA_100µM) 
in the same oocytes and depicted as mean ± S.E. from n = 6-7 oocytes for the indicated cRNA ratios. 
(C, D) Representative current traces evoked by applications of a maximally efficacious GABA 
concentration (GABA100µM) or DS2 (300 nM) for (C) α4+β2+δ (1:1:5) and (D) α4+β2+δ (5:5:1). 
 
Decreasing the relative amount of the δ subunit by injecting α4+β2+δ (5:5:1) gave an average 
GABA100µM-evoked peak current amplitude of 85 nA and the GABA concentration-response 
curve was well approximated by a one-site Hill equation, with an EC50 value of 230 nM and a 
Hill slope of 0.4 (Fig. 3.5A, Table 3.1). DS2300nM-evoked current amplitudes were on par with 
those of GABA100µM (Fig. 3.5D). There were no significant differences in any the GABA 
concentration-response curves or DS2300nM-activation measured between the three ratios where 
only the ratio of the δ subunit was altered (Fig. 3.5A, 3.5B).  
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3. 2. 3. 4 Overall Observations from the Variant cRNA Ratios 
All α4+β2+δ cRNA ratios yielded GABA100µM-evoked peak current amplitudes that were of 
similar magnitude, indicating that none of the ratios used were approaching a limit hindering 
receptor expression levels. Further, the results from the variant α4+β2+δ cRNA ratios show 
that expressed receptors fall into two classes. Two cRNA ratios, 5:1:1 and 5:1:5, yielded 
receptors, which had single-digit micromolar GABA sensitivity, Hill slopes close to 1, and 
limited direct DS2 activation. The remaining ratios yielded receptors that had sub-micromolar 
GABA sensitivities with accompanying low concentration-response curve Hill slopes and 
efficacious direct activation by DS2 applications, features that resemble those obtained with 
the 1:1:1 ratio. While data for 5:1:1 and 5:1:5 ratios were significantly different from all other 
ratios, no further significant differences were noted even for α4+β2 (1:5). This indicates that a 
high α4 to β2 ratio favours the formation of a receptor population with low GABA sensitivity 
and little DS2 activation, whereas the reverse lead to receptors with higher sensitivity to GABA 
and much greater levels of direct DS2 activation. Interestingly, the pharmacological properties 
of the low-sensitivity α4β2δ receptors appear to correspond to previously published data [14, 
29]. 
 
3. 2. 4 DS2 Potentiated the GABA-elicited Currents at α4β2δ Receptors Injected with 
5:1:1 and 5:1:5 cRNA Ratios 
As α4β2δ receptors from the 5:1:1 or 5:1:5 cRNA ratios only displayed limited activation upon 
DS2300nM application it was necessary to both verify that the δ subunit was still incorporated in 
the receptor complexes, and determine the pharmacology of DS2 at these receptors. To do this, 
full concentration-response curves of GABA were obtained in absence and presence of DS2. 
DS2 (1 µM) increased the GABA sensitivity approximately 2-fold with EC50 values of 0.8 µM 
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and 0.7 µM, respectively (Fig. 3.6A and Fig. 3.6B). However, more pronounced effects were 
observed for the average maximum current amplitudes, which were increased at all 
concentrations. At the maximum GABA concentrations, the mean peak current amplitudes 
were increased by 2-3 fold. These data are in good agreement with previous observations [14]. 
 
 
Fig. 3.6 Electrophysiological recordings of DS2 modulated GABA-evoked currents from α4β2δ 
receptors using X. laevis oocytes. (A) α4β2δ (5:1:1) GABA concentration-response curves plotted as 
averaged values ± S.E. of n = 6 oocytes. In the absence of DS2 the fitted EC50 value was 1.47 (1.01-
1.98) µM and the Hill slope 0.95 ± 0.1 whereas presence of DS2 (1 µM) resulted in a fitted EC50 value 
of 0.76 (0.60-0.96) µM and Hill slope of 0.96 ± 0.1. (B) α4β2δ (5:1:5) GABA concentration-response 
curves plotted as averaged values ± S.E. of n = 8 oocytes. In the absence of DS2 the fitted EC50 value 
was 1.6 (1.29-2.03) µM and the Hill slope 0.88 ± 0.1 whereas presence of DS2 (1 µM) resulted in a 
fitted EC50 value of 0.69 (0.52-0.91) µM and Hill slope of 1.16 ± 0.2. 
 
3. 2. 5 THIP and AA29504 Activity on Different Receptor Populations 
To further verify that distinct receptor populations are expressed, two compounds, THIP and 
AA29504, that have preference on δ-containing receptors were used on ratios that represented 
the two distinct receptor populations [33, 34].  
THIP is a widely used pharmacological tool that activates δ-containing receptors with high 
sensitivity [33]. We injected two ratios that represented the two distinct receptor populations; 
an α4+β2+δ (1:1:1) ratio for high sensitivity receptors and an α4+β2+δ (5:1:1) ratio for low 
sensitivity receptors populations. The application of 1 mM THIP evoked peak current 
amplitudes approximately 1.8-fold greater than GABA100µM at both ratios. When fitted to a 
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one-site Hill equation, the THIP concentration-response curve at the 1:1:1 ratio had an EC50 
value of 1.69 µM, which was approximately 6-fold lower than at the 5:1:1 ratio. Further, the 
Hill slope of the THIP concentration-response curve was significantly lower at 1:1:1 compare 
to 5:1:1 ratio (t-test, P < 0.0005) (Fig. 3.7). Differences in the EC50 values and Hill slopes 
indicate that the injection of α4β2δ in 1:1:1 and 5:1:1 ratios resulted in the expression of 
different receptor populations that had different THIP-activation properties.  
 
 
Fig. 3.7 Electrophysiological recordings of THIP-evoked current from α4β2δ receptors using X. 
laevis oocytes. Peak current amplitudes were normalized to maximal efficacious GABA (100 µM) 
applications (IGABA_100µM) and fitted to a one-site Hill equation by non-linear regression. THIP 
concentration-response curves plotted as averaged value ± S.E. of n = 5-6 oocytes. The fitted EC50 value 
was 3.15 (0.59-16.72) µM and the Hill slope was 0.3 ± 0.04 for 1:1:1 ratio. While at 5:1:1 ratio, the 
fitted EC50 value was 14.5 (11.66-20.32) µM and the Hill slope was 0.87 ± 0.1.  
 
Next, different injection ratios were used whereby α4+β2+δ (5:1:5) represented the low 
sensitivity receptor population and α4+β2+δ (1:1:5) represented the high sensitivity receptor 
population. AA29504 acts both as a positive modulator and agonist at α4β3δ receptors [34]. 
When a low concentration of AA29504 (100 nM) was applied in the absence of GABA, 
AA29504 elicited current amplitudes at both the 5:1:5 and 1:1:5 ratios where larger currents 
(relative to GABA) were observed at 1:1:5 ratio compared to 5:1:5 (Fig. 3.8A). Considering 
the large current amplitudes evoked by such low concentration of AA29504, the modulatory 
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efficacy of AA29504 was not evaluated. Instead, we performed concentration-response curves 
of AA29504 at the low and high sensitivity receptor populations. When fitted to one-site Hill 
equation, the AA29504 concentration-response curve at 5:1:5 ratio revealed an EC50 value of 
5.59 µM and a Hill slope of 1.4. (Fig. 3.8B). AA29504 activated 1:1:5 ratio with much higher 
potency of 1089 µM and low Hill slope of 0.43, however, the application of 100 µM AA29504 
did not reach saturable concentration (Fig. 3.8B). Higher concentrations of AA29504 were not 
applied as these concentrations need a longer washout period (> 30 minutes) that was 
impractical for the study. Differences in AA29504 concentration response curves at 5:1:5 and 
1:1:5 support the notion that indeed different receptor populations are expressed in recombinant 
system.   
   
 
Fig. 3.8 Electrophysiological recordings of AA29504-evoked current from α4β2δ receptors using 
X. laevis oocytes. (A) Representative current traces evoked by applications of a maximally efficacious 
GABA concentration (GABA100µM) or AA29504 (100 nM) for α4β2δ (5:1:5) and α4+β2+δ (1:1:5). Peak 
current amplitudes were normalized to maximal efficacious GABA (100 µM) applications (IGABA_100µM) 
and fitted to a one-site Hill equation by non-linear regression. AA29504 concentration-response curves 
plotted as averaged value ± S.E. of n = 9-11 oocytes. The fitted EC50 value was 5.59 (3.45-9.25) µM 
and the Hill slope was 1.4 ± 0.35 for 5:1:5 ratio. While at 1:1:5 ratio, the fitted EC50 value was 1089 
(9.41-∞) µM and the Hill slope was 0.43 ± 0.16.     
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3. 3 Discussion 
δ-containing GABAARs have, in general, been challenging to study due their inherently low 
GABA-evoked current responses and the limited range of available selective compounds [10, 
15]. To further complicate matters, there is considerable variability in the functional and 
pharmacological properties of α4β(x)δ GABAA receptors, most likely due to the expression of 
receptor populations with different subunit stoichiometries. To investigate this, we evaluated 
the effect of varying the cRNA ratio of α4+β2+δ receptor subunits on resulting receptor 
populations using Xenopus laevis oocyte electrophysiology and discovered that cRNA ratios 
indeed have large effects on the pharmacological characteristics of the resultant receptor 
populations.  
 
3. 3. 1 The “Reference” α4β2δ Receptor 
Mixed receptor populations are a common phenomenon when expressing GABAARs in 
recombinant expression systems [29, 35]. Further, studies with nicotinic acetylcholine 
receptors have shown that differences in receptor stoichiometry of the same two subunits can 
have a significant impact on receptor properties, including the sensitivity to the endogenous 
ligand (acetylcholine) and the pharmacological modulation by exogenous compounds [26, 36]. 
Hence, different receptor populations need not necessarily be the result of receptors formed by 
different subunits, but may be the result of an alternative subunit stoichiometry or arrangement 
of the same subunits in case of ternary receptors.  
To investigate whether different stoichiometries or arrangements influenced receptor function, 
this study evaluated the influence of varying cRNA ratios on fundamental α4β2δ receptor 
characteristics including the GABA-evoked current levels, GABA concentration-response 
curves, and DS2 sensitivity. These characteristics were initially defined for a “reference” α4β2δ 
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receptor population, formed by the injection of α4+β2+δ cRNA in a 1:1:1 ratio, which other 
receptor populations could be compared to. Notably, these receptors had high sensitivity to 
GABA with an EC50 value of 140 nM, a very low fitted Hill slope of 0.3, and were directly 
activated by DS2.  
The pharmacological properties of this “reference” receptor is different to most previous 
reports of α4β2δ receptors,  where a typical EC50 value of 1-2 µM, a Hill slope in the vicinity 
of 1, and no DS2 direct activation has been observed [14, 28]. Where the existence of δ-
containing receptors with GABA sensitivity in the nM range that were directly activated by 
DS2 has been found, this has usually been reported for α4β3δ receptors [14, 28]. It is possible 
that our “reference” receptor population contained a mixture of different stoichiometries or 
arrangements, which would be consistent with the low Hill slope that we observe. 
Alternatively, as the low Hill slope is observed within all individual oocytes, this could suggest 
that a uniform receptor population with “unusual” properties is also plausible. 
 
3. 3. 2 Ternary Receptors Formed when Varying the cRNA Ratios  
In addition to the “reference” ratio, a matrix of six different cRNA ratios of ternary receptors 
were expressed where each subunit in turn constituted of a high (~70) or low (~10) percentage 
of the total cRNA mixture. Across all the variations of these ratios that were tested, the overall 
current amplitude levels remained similar. This indicates that altering the ratio of subunit 
cRNA is not having a large effect on the overall expression levels of α4β2δ receptors. 
Four out of the six cRNA ratios that were analyzed resulted in receptors with characteristics 
resembling the “reference” receptor, including high GABA sensitivity, shallow Hill slopes, and 
direct activation by applications of a low concentration of DS2. A common denominator of 
these ratios was that they contained either equimolar or 5-times surplus of β2 subunits 
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compared with α4 subunits. Only two ratios yielded receptors with different characteristics. 
These had lower GABA sensitivity, Hill slopes close to 1, and displayed no direct activation 
by DS2 applications; however, they were still efficiently modulated by DS2, which 
demonstrates the incorporation of the δ subunit. A 5-fold surplus of α4 compared with β2 
subunits represented the common denominator for these two ratios. Therefore, the receptor 
populations could reasonably be grouped into two categories: a population with higher 
sensitivity to GABA and efficacious DS2 activation and a population with lower sensitivity to 
GABA and minimal DS2 activation. As mentioned, it is the latter of these two receptor 
categories that resembles the pharmacological properties of the bulk of previous studies on 
α4β2δ receptors expressed in oocytes [14, 16].  
Given the substantial influence of the δ subunit on the intrinsic characteristics of α4β2δ 
receptors, it might be anticipated that large differences would result when changing the molar 
ratios of the δ subunit vs. α4 and β2 subunits. Instead, a δ subunit component in the range of 
10 to 70% of the total cRNA mixtures ensured incorporation into all assembled receptors. This 
finding is in contrast to a study in HEK293 cells showing that increasing the δ subunit cDNA 
component in transfected HEK293 cells increased incorporation of δ in surface expressed 
receptors on behalf of β2 subunits [20, 22]. However, these data are consistent with a recent 
report, concluding that the stoichiometry of α4β3δ receptors in HEK293 cells remains 
(α4)2(β3)2(δ)1 despite variations in the transfected δ subunit cDNA [10, 17]. Hence, it appears 
plausible that the δ subunit incorporates consistently into α4βδ receptors provided the relative 
molar ratios in the cRNA or cDNA are not too extreme. 
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3. 3. 3 DS2 Pharmacology at α4β2δ Receptors 
The pharmacology of DS2 is considerably more complicated than a selective positive 
modulator at δ-containing GABAARs. While it has significantly higher efficacies at α4β2δ than 
α4β2γ receptors, this is strongly influenced by the intrinsic properties of the α4β2δ receptors. 
Here, we report that at certain populations of α4β2δ receptors, DS2 is an efficient agonist. This 
has also been reported at α4β3δ receptors [14]. 
An important consideration is how DS2 can have such different pharmacological properties at 
receptors with different stoichiometries or arrangements. The positive modulator of α4β2 
nAChRs, NS9283, becomes an agonist at receptors when additional binding sites are 
introduced [37]. It is possible that when we shift subunit ratios, we are increasing the number 
of DS2 binding sites and thus converting a positive modulator into an agonist. Alternatively, 
we may have altered the intrinsic properties of the receptor such that it is far more likely to 
open when DS2 is bound, regardless of whether a GABA molecule is also bound. This question 
is likely to require future sophisticated electrophysiological experiments to answer. 
 
3. 3. 4   Ternary Receptor Stoichiometries and Subunit Assembly Order 
The different categories that we identify raise the question of what receptor populations can be 
expressed in oocytes. One receptor population arises from a high α4:β2 ratio, and our data is 
consistent with a receptor that most likely consists of (α4)2(β2)2(δ)1 stoichiometry. This 
conclusion is fully consistent with a receptor having two β2-α4 interface GABA-activation 
sites with equal binding affinity, which would result in a Hill slope close to 1, and the 
incorporation of the δ subunit is demonstrated by the DS2 potentiation of GABA-elicited 
currents. From the large body of literature data, including those for the archetypical γ-
containing receptors [19, 32], the subunit arrangement of such a receptor would likely be β2-
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α4-β2-α4-δ with a counterclockwise rotation when viewed from the extracellular side (Fig. 
3.9A).  
For the low α4:β2 ratio ternary receptors, the situation is more complex. There must be at least 
one α4 subunit present, since minimal currents are recorded from the injection of β2 and δ 
alone. It is thus likely that a low α4:β2 ratio would result in receptors with only one α4 subunit 
present. Further, we can infer that the receptor complex must have at least one δ subunit present 
given the high sensitivity to DS2 applications, however since altering the ratio of the δ subunit 
gives identical results, it is more likely that only one δ subunit is incorporated. This leaves three 
β2 subunits to take up the remaining positions and a likely stoichiometry of (α4)1(β2)3(δ)1, a 
hypothesis consistent with data for binary (α4)2(β2)3 receptor (α4β2 (1:5) injection) where the 
presence of three β2 subunits yield a similar low Hill slope. 
 
 
Fig. 3.9 Proposed stoichiometries of α4β2δ receptors arising from high or low α4:β2 ratios. 
Receptors are viewed from the extracellular side. Given that changing the total cRNA mixture content 
of the δ subunit from approximately 10-70% made no difference, all proposed stoichiometries are 
assumed to have one δ subunit. (A) a high α4:β2 ratio likely results in a “classical” (α4)2(β2)2(δ)1 
stoichiometry arrangement where the receptor has two β2-α4 interface GABA binding sites (arrows). 
(B-E) a low α4:β2 ratio likely results in receptors with one α4 and three β2 subunits. Four potential 
stoichiometry arrangements are possible in this scenario. These receptor combinations can additionally 
harbor β2-β2 and β2-δ interface GABA binding sites (arrows). While GABA binding has so far not 
been demonstrated in β2-β2 interfaces, β3 homomeric receptors can be activated by GABA. That the 
β2-δ interface can bind GABA is supported by the (low) activity at β2δ binary receptors in Fig. 3.2. 
Since it has been shown that optimal additive effects on activation requires three non-consecutive 
interfaces, some of the potential β2-β2 GABA binding interfaces are less likely to be involved in 
receptor activation (open arrows). 
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To further complicate matters, a receptor stoichiometry composed of (α4)1(β2)3(δ)1 could 
potentially have four different subunit arrangements: β2-α4-β2-β2-δ,  β2-β2-α4-β2-δ, β2-β2-
β2-α4-δ, and α4-β2-β2-β2-δ (Fig. 3.9B-E). As it was previously shown that the additive effects 
of activation via three sites in the nicotinic acetylcholine receptor α7 require binding in non-
consecutive sites [38], the four possible arrangements can then be separated into those that have 
consecutive sites (Fig. 3.9D-E) and those that do not (Fig. 3.9B-C). Furthermore, the coupling 
of ligand binding to channel gating may also be altered by different arrangements of subunits. 
This would lead to different intrinsic activation properties, and possibly different rates of 
channel opening in the presence of none, or one, molecule of GABA bound, that would alter 
GABA potency, efficacy, and the Hill slope. At this point, it cannot be concluded which of 
these combinations arise from expressing receptors with a low α4:β2 ratio and in fact it is likely 
that some, or all of them express simultaneously to some degree, at a given injection ratio.  
Translating these results of the receptor populations that are expressed in oocytes to the 
receptors found in the mammalian brain is not straightforward. The concentrations of THIP 
that activate extrasynaptic GABAARs in the brain are too low for the low sensitivity receptor, 
suggesting that more β2 subunits may be incorporated into the native receptor [39]. It is also 
possible that the regulation of subunit order and stoichiometry is not as strict in native brain 
tissue, or that it is more variable under certain conditions and during development. This may 
be resolved by compounds that selectively enhance, modulate or inhibit one of the receptor 
populations. 
 
3. 4 Conclusion 
This study demonstrates that given sufficient amounts of α4, β2, and δ subunits in a cRNA 
mixture, the molar ratio of α4:β2 determines whether resulting receptor populations display 
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low or high sensitivity for GABA. Whereas the receptor with low sensitivity to GABA most 
likely has a stoichiometry of (α4)2(β2)2(δ)1, the receptor with a high sensitivity to GABA 
appears to have an additional β2 subunit and hence a stoichiometry of (α4)1(β2)3(δ)1. An 
important point in this regard, is that the subunit ratios in cRNA mixtures is not an exact science 
and the outcome of any given mixture will vary depending on the quality of the individual 
cRNA batches. Consequently, despite using similar conditions different researchers can 
perform experiments on different receptor populations and report seemingly contradictory 
pharmacological properties. Interestingly, most literature data on α4β2δ receptors expressed in 
mammalian cell lines such as HEK293 appear to observe only receptors with a low sensitivity 
to GABA. This raises the thought-provoking question for future studies of whether receptors 
with high sensitivity to GABA exist in native brain tissue and under which conditions. 
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Chapter 4 
Increasing Tonic Current Early After Stroke Enhances Recovery 
in Photothrombotic Mice 
 
4. 1 Introduction 
Stroke is the leading cause of severe long-term disability world wide [1, 2]. Stroke survivors 
suffer from muscle weakness, paralysis and impaired cognitive function. To date, tissue-
plasminogen activator (t-PA) is the only pharmacological agent approved for stroke and must 
be given within the first 4.5 hours after stroke onset to be effective [3, 4]. Because of the limited 
time window for administration and the risk of haemorrhage, less than 5% patients received t-
PA in stroke centres [5, 6], highlighting the need for new and effective pharmacological 
treatments.  
Following ischaemic stroke, there is an increase in extracellular GABA caused by leakage from 
injured neurons, Ca2+-dependent vesicular release and reversal of GABA transport [7, 8]. The 
accumulation of GABA results in a decrease in GABA synthesis and release and a down-
regulation and desensitization of the receptors, thereby reducing GABAergic function [7-9]. In 
accordance with reduced GABAergic function, there is a loss of GABAergic interneurons after 
photothrombotic stroke in mice [10].     
Despite the large number of studies carried out to evaluate GABAergic compounds, including 
GABA uptake inhibitors, GABAA agonists and GABAA modulators, in numerous animal 
models of stroke [11-15], there is little translation of treatment from animal models to the clinic. 
One possible explanation is the compounds tested are not selective for the GABAAR subtypes 
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involved in stroke. The use of selective compounds avoids off-target effects, hence minimizing 
the side effects that are often problematic.  
In the past decade, inhibition mediated by specific GABAARs has emerged as a target to 
improve functional recovery. Increasing phasic inhibition using zolpidem, a positive allosteric 
modulator which has high affinity for α1-containing GABAARs, starting from 3-days post-
stroke promotes behavioural recovery without affecting infarct size [16]. In line with this, the 
spontaneous inhibitory postsynaptic currents were increased in brain slice recording from layer 
5 pyramidal neurons of the peri-infarct cortex; which was also accompanied by an elevation of 
α1 receptor subunit expression [16].  Meanwhile, Clarkson et al. (2010) showed that tonic 
inhibition of peri-infarct cortex was increased several days after stroke, which was proposed to 
inhibit the underlying plasticity to promote functional recovery. Moreover, Clarkson et al. 
(2010) demonstrated that decreasing tonic inhibition using the negative allosteric modulator of 
α5-containing receptors, L655,708, 3-days post-stroke resulted in motor recovery in a mouse 
model of phototrombotic ischaemia [17].  
Little is known about the effect of GABAergic-mediated tonic inhibition within 24 hours after 
stroke. The application of L655,708 from stroke onset significantly increased infarct size, 
indicating that decreasing tonic inhibition too early exacerbates stroke (Fig. 5.1) [17]. This 
result shows that timing of intervention plays a crucial role. Although infarct size and 
functional recovery of δ knock-out (KO) and wild-type (WT) mice were similar following 
stroke [17], the role of δ-containing receptors as targets for stroke is not well-characterized 
despite these receptors also mediating tonic currents.     
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Fig. 4.1 The effect of L655,708 treatment on infarct size at different time points. Infarct size of 
vehicle-treated group, L655,708-early treated group and L655,708-late treated group. Columns 
represent mean ± S.E.M from n = 4 mice; * P < 0.05, one way ANOVA, post hoc Newman-Keuls’ pair 
wise comparisons test (Taken from Clarkson et al., 2010). 
 
If reducing tonic currents early leads to increased infarct volume, then increasing tonic currents 
early after stroke is hypothesized to reduce infarct volume and promote recovery. To 
investigate this, THIP, an agonist that has preference for δ-containing receptors (as no a5-
selective agonist is reported to date), was given 1 hour post-stroke in photothrombotic mouse 
model. Stroke outcomes were evaluated using sensorimotor function tests and infarct size 
measurement. To establish whether THIP’s effect is mediated via the δ-containing receptors, δ 
KO mice were used. Our results suggest that increasing tonic currents 1 hour after stroke boosts 
recovery and decreases infarct size. Together with the results from Clarkson et al. (2010), this 
indicates that modulation of tonic inhibition at different time points has distinct effects in 
stroke. We also demonstrate that the protective effect of THIP is not exclusively dependent on 
the presence of δ subunit.  
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4. 2 Result 
4. 2. 1 THIP Reduced Infarct Size in Photothrombotic Mice and This Effect was 
Abolished in δ KO Mice   
To investigate whether increasing tonic currents boosts stroke recovery in the early phase of 
stroke, THIP was administered 1 hour after inducing photothrombotic stroke in mice. THIP 
readily crosses the blood brain barrier and has preference for δ-containing receptors as THIP 
exhibits high efficacy and potency at δ-containing receptor compared to γ-containing receptors 
[18-20]. 1 mg/kg dose of THIP was chosen as this dose selectively activates δ-containing 
receptors and is devoid from activity at synaptic γ-containing receptors [20-22].  
The average damage to the motor cortex in vehicle-treated WT animals was 2.8 ± 0.7 mm3 
(Fig. 4.2A Top and Fig. 4.2B). The administration of THIP 1 hour following stroke 
significantly reduced the infarct volume of WT group to 0.83 ± 0.2 mm3 (Fig. 4.2A Middle and 
Fig. 4.2B, P = 0.03). THIP was also given to the δ KO mice to assess whether the infarct-
reducing effect of THIP is mediated by δ-containing receptors. In the KO group, the 
administration of THIP early after stroke did not affect the infarct volume compared to the WT 
vehicle group (2.6 ± 0.8 mm3; Fig. 4.2A Bottom and Fig. 4.2B). This result might indicate that 
the δ subunits are required to elicit the neuroprotective effect of THIP.  
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Fig. 4.2 Infarct volume of wild-type (WT) and δ knock-out (KO) mice after photothrombotic 
stroke. (A) Representative cresyl violet sections of vehicle-treated WT (top), THIP-treated WT 
(middle) and THIP-treated δ KO (bottom) showing the lesion in the motor cortex area (highlighted by 
red circle). (B) Bar graph showing the infarct volume quantification, data represent mean ± S.E.M from 
n = 6-8 mice; * P < 0.05, one-way ANOVA, post hoc Dunn’s multiple comparison test compared to 
vehicle-treated WT. 
 
4. 2. 2 THIP Enhanced Functional Recovery in Grid-walking Task 
Grid-walking and cylinder tasks were used to evaluate functional outcomes after stroke. 
Photothrombotic stroke increased the number of forelimb faults 7-days post-stroke in vehicle-
treated WT mice (Fig. 4.3). Similar to the infarct volume measurement results, treatment with 
1 mg/kg THIP improved motor recovery as demonstrated by a decrease in the number of 
forelimb faults in WT mice, although this did not reach statistical significance (Fig. 4.3, P = 
0.6). Interestingly, when THIP was given to δ KO mice, a decrease in the number of forelimb 
faults was also observed. This suggests that THIP’s recovery effect is not exclusively mediated 
by δ-containing receptors. Meanwhile, there were no differences in the number of hindlimb 
faults before and after stroke induction on all of the groups (data not shown). Given the larger 
size of the hindlimb compared to forelimb, the likelihood of hindlimb faults is smaller, thus 
having similar number of hindlimb faults before and after stroke. 
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Fig. 4.3 Behavioral assessment using grid-walking task. Motor recovery was evaluated in vehicle-
treated WT, THIP-treated WT, and THIP-treated δ KO group one day before stroke surgery and 7 days 
post-surgery. Columns represent mean ± S.E.M from n = 6-8 mice.     
 
The cylinder task was not as robust as the grid-walking task in detecting motor deficits 
following stroke as the cylinder task showed high variability within each group (Fig. 4.4). 
Moreover, the cylinder task displayed similar pattern at pre-test and post-stroke whereby the 
WT vehicle and KO THIP group had lower usage of left forelimb and WT THIP group had 
higher usage of left forelimb. 
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Fig. 4.4 Behavioral assessment using cylinder task. Motor recovery was evaluated in vehicle-treated 
WT, THIP-treated WT, and THIP-treated δ KO group one day before stroke surgery and 7 days post-
surgery. Columns represent mean ± S.E.M from n = 6-8 mice.     
 
4. 3 Discussion  
There is surmounting evidence for systemic pharmacological treatments altering GABA-
mediated inhibition resulting in neuroprotection in animal models of stroke [10, 14, 15], 
however this does not necessarily translate into clinical trials. The failed translation from bench 
to bedside is, in part, due to timing of intervention and lack of drug selectivity. Decreasing 
tonic inhibition from day 3-14 after stroke in photothrombotic mice is beneficial [17]. 
Conversely, reducing tonic currents immediately after photothrombotic stroke worsened stroke 
as demonstrated by a marked increase in infarct size. As such, we proposed that increasing 
tonic currents early after stroke enhances recovery in a photothrombotic mouse model. Our 
results demonstrated that increasing tonic current using THIP in the early phase of stroke 
resulted in neuroprotection and improved functional recovery. Despite being considered as a 
δ-preferring agonist, THIP’s effects were not entirely dependent on the δ-containing 
GABAARs. Furthermore, the present study highlights that the outcome of modulating tonic 
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inhibition in stroke is dependent on intervention timing and this can be used to determine the 
treatment window of α5 or δ-selective ligands to promote functional recovery in stroke patients. 
THIP was used in this study since it elicits tonic currents via δ-containing receptors. THIP is 
much more potent and efficacious at δ-containing receptors compared to γ-containing receptors 
[18, 19]. THIP at 1 mg/kg was used as this dose is sufficient to directly activate δ-containing 
receptors while having no activity on γ-containing receptors, resulting in an increase of only 
the tonic currents [20-22]. THIP exhibited a neuroprotective effect and improved functional 
recovery when given 1 hour post-stroke. The protective effect of THIP has also been reported 
in hippocampal slice cultures against NMDA-induced excitotoxicity [23]. Interestingly, 
decreasing tonic current at later stage (3-14 post-stroke) promoted motor recovery albeit no 
change was observed on the infarct size [17]. This strongly suggests that intervention timing is 
critical when selective ligands for α5 or δ-containing receptors are used as pharmacological 
interventions.  
The neuroprotective effect of THIP was abolished in the KO group as the infarct size in the 
THIP-treated KO group was similar to vehicle-treated WT group, indicating that δ-containing 
receptors mediate this effect. However, the motor recovery effect of THIP was still evident in 
the KO group. This indicates that the δ-containing receptors are unlikely to be the sole target 
but other receptors may also be involved in mediating THIP’s action. Previous study showed 
that genetic deletion of δ subunits does not cause significant changes on the infarct size nor the 
behavioural assessment after stroke, suggesting that δ KO mice have similar stroke outcome 
compared to the WT mice [17].  
The residual action of THIP in δ KO mice strongly suggests that THIP mediates some of its 
action through other receptors. Deletion of a single GABAARs subunit in mice leads to 
compensatory overall changes in GABAARs subunits expression [24-26]. The residual effects 
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of THIP are most likely mediated by the binary α4β receptors [21]. In support of this notion, 
we (Chapter 5) show that THIP acts as a superagonist (relative to GABA) both at α4β2 and 
α4β2δ receptors with similar potency. The α4β receptors are expressed in in vivo systems and 
evoked tonic currents [27-29]. 
GABAergic-mediated inhibition plays an important role in increasing cortical plasticity to 
mediate recovery following stroke [10, 16, 17]. Neuronal plasticity however, occurs several 
days after stroke onset [30] and thus THIP does not appear to affect brain plasticity. It is most 
likely that THIP’s recovery promoting-effect is derived from increased tonic inhibition. This 
counteracts glutamate-mediated excitotoxicity which plays a major role in pathophysiology of 
stroke [7, 8]. Others proposed that the GABAergic ligands mediate the protective effect through 
other pathways. In oxygen glucose deprived hippocampal slices, diazepam treatment resulted 
in the recovery of ATP and inhibition release of cytochrome c from mitochondria that is 
responsible for promoting apoptosis [31]. Additionally, GABAAR agonists such as 
clomethiazole, protected mitochondrial energetics and attenuated the release of pro-
inflammatory cytokines while at the same time triggered the release of anti-inflammatory 
cytokines in rats-induced hypoxia-ischaemia [32]. Further studies are required to corroborate 
whether THIP acts via these pathways.  
 
4.4 Conclusion 
This study demonstrates that increasing tonic currents early after stroke is beneficial. Our 
results underline the importance of developing subtype selective GABAARs compounds, 
specifically targeting the α5 or δ-containing receptors as these receptors mediate tonic 
inhibition that is involved in stroke recovery. Timing of intervention is also a key factor that 
determine the success use of these compounds. Data from this study is promising but we need 
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to increase the number of animals in our groups. Overall, our results further establish the 
extrasynaptic GABAARs as a potential novel drug target for the treatment of stroke. 
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Chapter 5 
Elucidating Whether an Additional Binding Site for THIP Exists 
on α4-containing GABAA Receptors 
 
5. 1 Introduction 
A growing body of evidence has shown the importance of the extrasynaptic δ-containing 
GABAA receptors in neuronal processes. Despite generating smaller amplitude currents 
compared to synaptic receptors, the continuous activity of the δ-containing receptors plays a 
crucial role in controlling neuronal excitability [1]. Moreover, alteration in tonic inhibition is 
considered as one of the underlying pathophysiology mechanisms of various diseases, 
including sleep disorders [2, 3], seizures [4, 5], depression [6, 7] and stroke [8, 9]. In order to 
unravel the physiological and pharmacological role of δ-containing receptors, the need for δ-
selective compounds for understanding these conditions of utmost importance. 
The δ-containing receptors are pharmacologically distinct from γ-containing receptors, most 
obviously through the insensitivity of δ-containing receptors to classical benzodiazepines. 
Previously, positive allosteric modulators, such as neurosteroids and DS2, were shown to 
significantly enhance the response to GABA at δ-containing receptors [10-12]. However, a 
comparison of various positive allosteric modulators at δ- and γ-containing receptors conducted 
by Ahring et al. (2016) revealed similar modulatory potency at between these receptors, 
indicating limited selectivity of the compounds. Instead, the higher level of GABA modulation 
observed at δ-containing receptors was found to be due to intrinsic properties of the receptors 
and differences were the result of δ-containing receptors displaying low open-state probability 
when activated by GABA.  
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Owing to the low efficacy of GABA, the GABAA agonist, 4,5,6,7-tetrahydroisoxazolo (5,4-
c)pyridine-3(-ol) (THIP or gaboxadol), is a superagonist at δ-containing receptors [11, 14, 15]. 
THIP has been widely used in animal studies as a pharmacological tool that activates δ-
containing receptors. THIP is considered to be selective for δ-containing receptors as THIP 
displays higher efficacy and potency at δ-containing receptors compared to γ-containing 
receptors [11, 13]. Further, THIP-evoked tonic currents are believed to be mediated by α4βδ 
receptors, as these currents are markedly decreased in brain slice recordings of the thalamic 
ventrobasal complex in α4 and δ knock-out (KO) mice [15-17]. In line with this, the ataxic 
effects of THIP were abolished and attenuated on α4 and δ KO mice respectively [16, 18].  
THIP binds at the orthosteric site of the extracellular interface of the β principal (+) and the α 
complementary (-) side [14, 19, 20]. However, the distinct efficacy at the δ-containing 
receptors compared to γ-containing receptors may be caused by THIP binding at an additional 
site. Although THIP superagonism can result from the inherent properties of the receptors, 
studies have been unable to rule out the likelihood that THIP binds to other site(s) [20, 21]. 
The possibility of THIP binding to another interface has also been suggested in a recent study 
where the potency of THIP was attributed to the α4 subunit [22]. Since the α- side contributes 
to the orthosteric site, we hypothesized that an additional binding site for THIP resides on the 
α+ side and that this site is responsible for superagonist activity of THIP.   
To test our hypothesis, α4-containing receptors, including binary α4β, ternary α4βδ and α4βγ 
receptors were expressed in Xenopus oocytes and their pharmacology were assessed using 
GABA and THIP. A homology model was generated to predict which amino acids that are 
associated with THIP binding, and then point-mutations were created and evaluated on β2-
containing receptors. In addition, a double mutation on δ-side was also generated to evaluate 
the potential contribution of this side to THIP’s superagonism. Our result showed the amino 
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acids tested in this study only resulted in minute change to THIP activation, indicating that 
these amino acids are not responsible for THIP potency.  
     
5. 2 Results 
The prototypical GABAA agonist, THIP is more efficacious than GABA at the extrasynaptic 
δ-containing receptors, binding at the extracellular β+α- interface. Despite binding to the same 
site as GABA, it remains unclear why THIP exhibits distinct activation levels at receptors with 
different levels of affinity to GABA, i.e. δ- and γ-containing receptors. We hypothesized that 
the increased efficacy at δ-containing receptors is conferred by an additional binding site that 
lies on the α4+ side. Initially, we tested GABA and THIP at α4-containing GABAARs 
expressed in Xenopus oocytes. To test our hypothesis, two separate point mutations at the α4+ 
side were generated that were designed from a homology model (Fig. 5.1) and co-injected with 
β2, β2+δ, or β2+γ as the representation of α4-containing receptors. Further, the δ- side was 
mutated to resemble the γ- side by performing double mutations to assess changes in direct 
agonism of THIP.     
 
 
Fig. 5.1 THIP binding mode at α4+β2- interface. THIP (shown in green) is docked at the interface of 
α4 subunit (shown in yellow) and the β2 subunit (shown in blue). A tyrosine at position 208 and arginine 
at position 100 is proposed to interact with THIP.     
ɑ+ β- 
Y208 
R100 
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5. 2. 1   THIP Displays Superagonism at Binary α4β and Ternary α4βδ Receptors 
GABA and THIP activity were evaluated at binary α4β1-3 and ternary α4β1-3δ GABAARs 
expressed in Xenopus oocytes using two-electrode voltage clamp electrophysiology. GABA 
potently activated α4β1 and α4β1δ receptors with an EC50 of 80 nM and 30 nM, respectively, 
while at α4β2-3 and α4β2δ, the GABA potency is at low micromolar range, ranging from 1.59 
to 2.24 µM (Table 5.1). In agreement with previous studies [14, 23], GABA concentration-
response curves at α4β3δ displayed a biphasic curve when fitted to the two-site Hill equation, 
suggesting the presence of a mixture of receptors being expressed with distinct GABA 
potencies (P = 0.0001; F test = 7.34 (3,150)). The high-sensitivity component that was 
estimated to comprise 45.5 % of the total populations had an EC50 of 42 nM while the low-
sensitivity component had an EC50 of 9.31 µM. The GABA EC50 at the ternary receptors is 
similar to their binary counterparts, demonstrating that incorporation of δ subunit did not 
necessarily lead to increased sensitivity to GABA. 
 
Table 5.1 GABA and THIP-elicited concentration-response curves at α4β1-3, α4β1-3δ and 
α4β2γ2l expressed in Xenopus oocytes. 
Receptor 
subtypes 
(ratio) 
GABA THIP 
EC50 (95% CI) 
(µM) 
nH ± s.e.m n EC50 (95% CI) 
(µM) 
nH ± s.e.m Emax± s.e.m n 
Binary   
α4β1 (1:10) 0.08(0.04-0.15) 0.52±0.06 5 12.66 (2.78-57.63) 0.64±0.22 114±22 4 
α4β2 (5:1) 2.24 (1.64-3.07) 0.92 ± 0.11 4 20.61 (15.73-27.0) 0.88 ± 0.1 149 ± 5 6 
α4β3 (10:1) 1.93(1.41-2.66) 0.82±0.09 4 33.47(24.98-44.85) 0.74±0.05 131±5 5 
Ternary     
α4β1δ 
(1:1:5) 
0.03(0.02-0.05) 0.97±0.19 5 0.24(0.08-0.7) 0.55±0.14 134.5±10.2 4 
α4β2δ 
(5:1:5) 
1.59 (1.33-1.92) 0.89 ± 0.06 8 16.53 (11.31-
24.15) 
0.85 ± 0.1 202 ± 8.9 5 
α4β3δ 
(5:1:5) 
(1)a = 0.42 (0.002-
1.82) 
(2)a = 9.31(2.4-
177.83) 
1a 
 
1a 
13 (1)a = 0.08 (0.006-
0.78) 
(2)a = 24.04 
(11.53-62) 
1a 
 
1a 
219.5±48.4 5 
α4β2γ2l 
(5:1:5) 
41.45 (36.11-47.58) 0.94±0.05 6 417.5 (138.1-1262) 1.20±0.34 46.05±11.92 5 
a Fitted to two-site Hill equation, with the Hill slope value constrained to 1 
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THIP acted as a superagonist at α4β2-3 and α4β1-3δ receptors, eliciting maximum currents 
that were larger than a maximal GABA concentration (GABAmax) (Table 5.1). This result 
indicates that the endogenous ligand, GABA, is inefficient in opening α4β and α4βδ receptors 
and hence only acts as a partial agonist at these receptors [24, 25]. However, at α4β1 receptors, 
THIP is equally as efficacious as GABA. Interestingly, THIP potencies at α4β1-3 and α4β2δ 
were similar, while THIP was most potent at α4β1δ. At α4β3δ receptors, two sites for THIP 
were identified from the concentration-response curve when the curve was fitted to two-site 
Hill equation (Table 5.1) (P < 0.0001; F test = 10.14 (3,44)). Although previous studies have 
shown higher sensitivities for THIP at δ-containing receptors compared to their αβ counterparts 
[14, 22], others did not [24]. This discrepancy may be because of different experimental 
conditions, such as RNA quality and ratio of RNA injected into Xenopus oocytes that have 
been shown to affect the types of receptor populations formed.  
   
5. 2. 2   The Effects of the Mutants α4R100H and α4Y208C on GABA Concentration-
response Curves at α4β2 and α4β2δ Receptors    
Since THIP displays similar activity among the α4β1-3 and α4β1-3δ receptors, the β2-
containing receptors were chosen for the next experiments. Further, these receptors have been 
previously optimized to produce homogeneous receptor populations with a stoichiometry of 
2α4:2β2:1δ [26]. To assess whether THIP has an additional binding site at the α4+ side, two 
mutations were chosen based on our homology model (Fig. 5.1). The arginine residue at 
position 100 and tyrosine at position 208 of the α4 subunit were point mutated to histidine 
(α4R100H) and cysteine (α4Y208C), respectively, to maximize the possibility of abolishing 
the potential interaction between THIP and the amino acids. The α4R100 and α4Y208 are also 
homologous to the residues of α1H101 and α1Y209 that were previously identified to 
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contribute to benzodiazepine and non-benzodiazepine binding [27-30]. Moreover, THIP and 
non-benzodiazepine compounds share similar core structure, albeit THIP has an acidic moiety. 
This further suggests that these amino acids maybe implicated in additional binding site for 
THIP. 
  
Table 5.2 GABA and THIP-elicited concentration-response curves at mutants of α4Y208C, 
α4R100H and δH92A/S155T expressed in Xenopus oocytes.   
Receptor 
subtypes 
GABA THIP 
EC50 (95% CI) 
(µM) 
nH ± s.e.m n EC50 (95% CI) 
(µM) 
nH ± s.e.m Emax± s.e.m n 
Binary   
α4Y208Cβ2 1.06 (0.89-1.26)* 0.88 ± 0.06  6 12.49 (9.38-16.65) 0.97 ± 0.11 108 ± 4* 4 
α4R100Hβ2 1.70 (1.28-2.26) 0.77 ± 0.07* 4 13.07 (8.41-20.31) 0.89 ± 0.14  117 ± 6 4 
Ternary     
α4Y208Cβ2δ 2.02 (1.66-2.44) 0.81 ± 0.05 6 17.15 (12.97-22.68)  0.85 ± 0.08 137 ± 4.4* 6 
α4R100Hβ2δ 2.57 (1.92-3.44) 0.76 ± 0.07* 4 22.26 (16.38-30.25) 0.85 ± 0.08 159 ± 5.6 3 
α4Y208Cβ2γ2l 42.80(29.69-61.69) 0.75±0.08 5 247.2(154.7-395)* 1.20±0.18 50.2±4.8 6 
α4R100Hβ2γ2l 
α4β2δγ- 
69.49(43.26-111.6) 
2.54(1.88-3.21) 
0.74±0.01* 
0.84±0.07 
4 
5 
633.4(81.39-4930) 
24.42(10.38-57.48) 
0.95±0.27 
0.64±0.11* 
57.85±24.57 
139±9.3* 
5 
5 
* P < 0.05, one-way ANOVA, post hoc Dunn’s multiple comparison test compared to wild-type counterparts 
 
α4Y208C and α4R100H were co-injected with β2 or β2+δ subunit to express the desired 
receptors and the mutation’s effect on GABA-evoked currents was evaluated. To ensure that 
δ-containing receptors were expressed, DS2, a potentiator that is relatively selective for δ-
containing receptors, was used [10, 26]. As expected, DS2 at 300 nM did not modulate low 
concentration of GABA at α4β2 receptors, whilst DS2 enhanced currents evoked by 300 nM 
GABA at the α4β2δ receptors (Fig. 5.2A and 2B).    
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Fig. 5.2 Representative current traces of α4β2 and α4β2δ GABAARs. Example of traces from single 
experiments demonstrating current responses to GABA, GABA + DS2 and THIP for (A) α4β2 and (B) 
α4β2δ receptors. Bars above each trace represent application period and the specific compounds 
concentration. 
 
GABA had an EC50 value of 2.3 µM at α4β2 receptors. Similarly, at α4Y208Cβ2 and 
α4R100Hβ2 receptors GABA had EC50 values of 1.06 and 1.7 µM respectively (Fig. 5.3A, 
Table 5.2). There was a significant shift of GABA potency at α4Y208Cβ2 (P < 0.05) compared 
to the wild-type, albeit the difference was only 2-fold. In addition, the Hill slope value at 
α4R100Hβ2 was statistically lower than the wild-type (P < 0.05).   
At the wild-type α4β2δ receptors, GABA had an EC50 value of 1.59 µM, while at α4Y208Cβ2δ 
and α4R100Hβ2δ receptors GABA had a similar potency of 2.02 and 2.57 µM, respectively. 
The Hill slope value at α4β2δ was 0.89, whilst the Hill slope at α4R100Hβ2δ was 0.76, which 
was significantly different to the wild-type (P < 0.05). Very small changes of GABA activation 
observed here is as expected because the mutations were located on the principal site of the α4 
subunit while GABA is known to bind at the β+ and α- interface [31]. Taken together, although 
there were significant changes in the Hill slope and EC50 caused by the mutations, the small 
magnitude of these changes suggest that these mutations caused little change to GABA 
activation of α4β2 and α4β2δ receptors. 
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Fig. 5.3 GABA concentration-response curve for α4β2 and α4β2δ wild-type and mutants of 
α4Y208C, α4R100H and δH92A/S155T expressed in Xenopus oocytes. Peak current amplitudes for 
GABA activation were normalized to the maximum current fitted from individual experiments 
(IGABA_max_fit) and fitted to a one-site Hill equation by non-linear regression. Regression results are 
presented in Table 5.2 (A) α4β2, α4Y208Cβ2 and α4R100Hβ2 GABA concentration-response curve 
plotted as averaged value ± S.E. of n = 4-6 oocytes. (B) α4β2δ, α4Y208Cβ2δ, α4R100Hβ2δ and α4β2δγ- 
GABA concentration-response curve plotted as averaged value ± S.E. of n = 4-8 oocytes. 
 
5. 2. 3   Mutation of α4Y208C Reduced the Efficacy of THIP at α4β2 and α4β2δ Recep-
tors  
To investigate whether the mutations resulted in any changes on THIP activity, THIP-evoked 
currents were determined on these mutant receptors. The application of 1 mM THIP elicited 
peak current amplitudes approximately 1.5-fold greater than GABAmax for α4β2, demonstrating 
superagonism at α4β2 receptors (Fig. 5.4A, Table 5.2). THIP superagonism on binary receptors 
has also been reported by others [22, 24]. Interestingly, the α4Y208C mutation caused a 
significant reduction of THIP efficacy to similar level of GABAmax (Fig.5.4A, Table 5.2) (P < 
0.05). THIP efficacy at α4R100Hβ2 was also reduced to 117% of GABAmax, however this was 
not statistically different than at the wild-type α4β2 receptors (Fig.5.4A, Table 5.2). 
Meanwhile, the potency of THIP at both of the mutants was similar compared to the wild-type 
receptors (Fig. 5.4A, Table 5.2).  
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Fig. 5.4 THIP concentration-response curve for α4β2 and α4β2δ wild-type and mutants of 
α4Y208C, α4R100H, and δH92A/S155T expressed in Xenopus oocytes. Peak current amplitudes for 
THIP activation were normalized to the maximum current of GABA (IGABA_max) and fitted to a one-site 
Hill equation by non-linear regression. Regression results are presented in Table 5.2 (A) α4β2, 
α4Y208Cβ2 and α4R100Hβ2 THIP concentration-response curve plotted as averaged value ± S.E. of n 
= 4-6 oocytes. (B) α4β2δ, α4Y208Cβ2δ, α4R100Hβ2δ and α4β2δγ THIP concentration-response curve 
plotted as averaged value ± S.E. of n = 3-6 oocytes. 
 
At α4β2δ receptors, THIP also acted as a superagonist where the application of 1 mM THIP 
evoked maximum currents approximately 2-fold greater than GABAmax (Fig. 5.4B). α4Y208C 
mutation resulted in a significant decrease of THIP efficacy to 137% (Fig. 5.4B, Table 5.2) (P 
< 0.05). THIP efficacy at α4R100Hβ2δ was also reduced but this was not statistically different. 
The decrease in THIP efficacy at mutant receptors was not accompanied by a shift on THIP 
potency (Fig. 5.4B, Table 5.2). The decrease in THIP efficacy at α4Y208C expressed in α4β2 
and α4β2δ suggests that although α4Y208 is not involved in THIP binding, the amino acid may 
be involved in THIP-evoked conformational changes.  
 
5. 2. 4   GABA and THIP-evoked Currents at α4100Hβ2γ2l and α4Y208Cβ2γ2l Receptors 
To determine whether α4R100H and α4Y208C affected THIP’s partial agonism at α4β2γ2L, 
these mutants were co-expressed with β2+γ2L subunit. Unlike the αβ and αβδ receptors, γ-
containing receptors are known to be insensitive to Zn2+ inhibition [32, 33]. Thus, to confirm 
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the presence of γ subunit into the receptors, 10 µM of Zn2+ was co-applied with 30 µM GABA. 
The co-application of 10 µM Zn2+ did not inhibit current traces evoked by 30 µM GABA (Fig. 
5.5). In accordance with previous studies, the EC50 of GABA at α4β2γ2L had a value of 41.45 
µM (Fig. 5.2A), which is much less potent (~20-fold) than at α4β2δ receptors [13].  
  
 
Fig. 5.5 Representative current traces of an oocyte expressing α4β2γ2l GABAARs. Example of 
traces from single experiments demonstrating current responses to GABA, GABA + Zn2+ and THIP. 
Bars above each trace represent application period and the specific compounds concentration.     
 
Mutants of α4R100Hβ2γ2L and α4Y208Cβ2γ2L receptors had GABA EC50 values of 64.49 
µM and 42.8 µM, which were not statistically different from wild-type receptors (Fig. 5.6A, 
Table 5.2). The Hill slope at α4R100Hβ2γ2L receptors was significantly different from the 
corresponding wild-type value (Table 5.2) (P < 0.05).       
1 mM THIP evoked peak current amplitudes of approximately 34% of GABAmax at α4β2γ2L 
receptors, showing that THIP acted as a partial agonist at the γ2-containing receptors ,which is 
in line with previous studies (Fig. 5. 6B, Table 5.2) [11, 13, 15, 21]. THIP was much less potent 
than GABA at the wildtype receptors, with an EC50 value of 417.5 µM. At α4Y208Cβ2γ2L 
and α4R100Hβ2γ2L receptors, 1 mM THIP evoked peak current amplitudes of approximately 
42% and 35% of GABAmax, respectively, which were similar to the THIP-evoked maximum 
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current of the wild-type (Fig. 5.6B, Table 5.2). Meanwhile, THIP had EC50 values of 247.2 µM 
and 633 µM at α4Y208β2γ2L and α4R100Hβ2γ2L respectively (Fig. 5.6B, Table 5.2). This 
result showed that THIP was significantly more potent at α4Y208Cβ2γ2L compared to the 
wild-type receptors (Fig. 5.2B) (P < 0.05).  
 
 
Fig. 5.6 GABA and THIP concentration-response curves for wild-type α4β2γ2l and mutants of 
α4Y208β2γ2l and α4R100Hβ2γ2l expressed in Xenopus oocytes. (A) Peak current amplitudes for 
GABA activation were normalized to the maximum current fitted from individual experiments 
(IGABA_max_fit) while (B) peak current amplitudes for THIP activation were normalized to the maximum 
GABA current (IGABA_max) and fitted to a one-site Hill equation by non-linear regression. Regression 
results are presented in Table 5.2. Normalized responses were plotted as mean ± S.E. from n = 4-6        
oocytes.  
 
5. 2. 5   Double Mutation of H92A/S155T on the δ- Side did not Abolish THIP’s Super-
agonism    
At α4β2γ2 and α4β2δ receptors, the α4+ side forms interfacial binding sites with the γ2- and 
δ- side respectively. As the α4+δ- interface is absent at α4β2γ2 receptors, the δ- side may be a 
potential determinant for superagonism activity of THIP at δ-containing receptors. Our 
sequence alignments showed that histidine at position 92 and serine at position 155 of the δ- 
side is adjacent to the proposed binding pocket at α4+δ- interface. These amino acids 
correspond to alanine and threonine at γ- side respectively. To investigate whether the δ- side 
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responsible for THIP’s superagonism, we performed a double mutation of H92A/S155T on the 
δ subunit. This double mutation altered the δ- side to resemble the γ- side sequence (hence 
referred as α4β2δγ-). GABA and THIP activity was evaluated at α4β2δγ- receptors. GABA had 
an EC50 of 2.54 µM and a Hill slope value of 0.84, which was not significantly different 
compare to the wild-type receptors (Fig. 5.3B, Table 5.2). Although the double mutation 
significantly decreased THIP’s efficacy to 139%, THIP maintained its superagonist activity 
(Fig. 5.4B, Table 5.2) (P < 0.05). In addition, the Hill slope at α4β2δγ- was also significantly 
lower than the wild-type receptors (Fig. 5.4B, Table 5.2) (P < 0.05). Overall, these results 
suggested that the δ- side is not the sole determinant for THIP’s superagonism.          
 
5. 3 Discussion 
In the present study, we sought to test that THIP has an additional binding site, other than the 
classical orthosteric binding site, and that this site is responsible for THIP selectivity at the 
extrasynaptic δ-containing receptors. The THIP binding mode at the interface of α4+ and β2- 
was predicted with a homology model and two mutations were selected accordingly. Two 
point-mutations were made and expressed in Xenopus oocytes with wild type α4-containing 
receptors. Additionally, a double mutation on δ- side was made to investigate whether this side 
affects direct activation of THIP. No significant shift of GABA and THIP concentration-
response curves were observed at the mutant receptors, however, a significant decrease in THIP 
efficacy was observed in the α4Y208C mutant. Our result indicated that the amino acid did not 
contribute to the potency of THIP. 
Although other studies demonstrated increased GABA sensitivity with δ subunit incorporation 
[14], our result showed otherwise. GABA potency at α4βδ was not differed from the binary 
α4β i.e., at low micromolar range. The binary αβ are sensitive to low GABA concentration and 
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thus suited to the characteristic of GABAARs found in peri- or extrasynaptic sites. This result 
supports the notion that αβ receptors are expressed in the brain and contribute to the tonic 
currents [34, 35]. Further, the presence of α4β receptors in the brain has been previously 
reported [36].    
Consistent with other findings, THIP elicited maximal currents that were larger than GABA-
evoked currents at α4βδ and α4β2-3 receptors and as such, THIP is considered as a superagonist 
relative to GABA [13, 21, 24, 25, 37]. Mortensen et al. (2010) proposed that the superagonism 
of THIP derived from differences in the intrinsic activation properties between δ- and γ-
containing receptors where THIP was able to prolong channel mean opening times and also 
increases channel’s open probability at α4β3δ receptors. In addition, single-channel recordings 
demonstrated that application of THIP at high concentration resulted in higher channel 
conductance than GABA, leading to higher efficacy [20]. In contrast to GABA partial agonism 
at α4β and α4βδ receptors, GABA is an efficacious agonist at α4β2γ2 and thus, THIP acts as a 
partial agonist at these receptors. Although single-channel recordings partly explained distinct 
activity of THIP at different receptors, others have suggested that THIP may have an additional 
binding site [20, 21, 38].    
THIP binds to the orthosteric binding site and we reasoned that differences in THIP activity 
resulted from binding to another site(s). Indeed, distinct GABAARs receptors exhibit different 
pharmacological properties since the presence of different subunits can change not only the 
intrinsic properties of the receptors but also ligand-recognition site. GABA concentration-
response curves at the mutants of α4R100H and α4Y208C only showed minor but significant 
changes to the EC50 of α4Y208Cβ2 and Hill slopes of α4R100Hβ2, α4R100Hβ2δ and 
α4R100Hβ2γ2l. Since the mutated amino acids lies on the α4+ site, only very small changes to 
GABA concentration-response curve were observed. Meanwhile, the mutations resulted in a 
decrease in THIP efficacy at α4β2 and α4β2δ receptors, albeit significance was only observed 
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at α4Y208C mutants. THIP’s efficacy reduction was not accompanied by a shift in potency, 
indicating that the amino acids tested do not contribute to the potency of THIP. The decrease 
in THIP’s efficacy was more profound at the α4Y208C mutants because the amino acid is 
located at loop C that plays a pivotal role in both binding and the initial conformational changes 
that activate the receptors [39, 40]. Replacing the tyrosine with cysteine results in eliminating 
the π stacking effect that is mediated by the tyrosine, and thus THIP may not be able to bind in 
its best conformation to induce channel gating. At α4Y208Cβ2γ2l, THIP potency increased 
approximately ~1.7-fold compared to wild-type receptors. Since there was no significant 
change in THIP activity at receptors where THIP acts as a superagonist, there is little chance 
to see a significant change at α4β2γ2L receptors, considering that GABA evokes bigger 
amplitudes at α4β2γ2L receptors.  
α4β2δγ- exhibited similar GABA potency and Hill slope compared to the wild-type receptors 
while small but significant changes were evident at THIP concentration-response curves for 
the Hill slope and efficacy. Interestingly, the double mutation at α4β2δγ- receptors did not 
change THIP activity into a more partial agonist as observed in γ-containing receptors. This 
indicates that the amino acids mutated are unlikely to be the determinant of THIP’s 
superagonism at δ-containing receptors.      
α4R100 and α4Y208C lies at the α4+ and these amino acids may form interfaces with other 
subunit, including α4+β- and α4+δ- at α4βδ, α4+β- at α4β, and α4+β- and α4+γ- at α4β2γ2l 
receptors. The absence of significant changes in the potency of THIP in this study does not 
necessarily lead to a conclusion that THIP does not bind at the α4+ interface. Other amino acids 
at this interface may form additional binding site for THIP. Moreover, the additional binding 
site may be voided at the α4+, but may be located on different interfaces. A previous study 
using β3δ, α4β3 and α4β3δ receptors strongly suggest that the α subunit contribute to THIP’s 
potency but that other interfaces, including β-β, β-α, and β-δ [22] could also bind THIP as THIP 
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has effects at receptors lacking the α subunit. Indeed, there is a profound challenge in 
elucidating additional binding site for THIP, considering that THIP always occupies the 
dominant binding site, that is the interface of β+ and α-. Therefore, it is difficult to observe 
significant changes using mutational studies.   
  
5. 4 Conclusion 
In conclusion, the amino acids that we tested are unlikely to contribute to the THIP binding 
site. The possibility of THIP having an additional binding site could not be ruled out completely 
since our evaluation is limited to two amino acids at α4+ and at δ- side. It is plausible that other 
amino acids on the same interface and/or other interface(s) contribute to THIP binding site and 
a rigorous evaluation is required to solve this.  
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Chapter 6 
General Discussion 
 
There has been growing interest in the α4βδ receptors in the past decades as studies have 
identified them as an important drug targets in various neurological and psychiatric disorders, 
including stroke. Despite their potential as therapeutic targets for CNS drug development, the 
drug discovery process is hindered by the fact that pharmacological studies on these receptors 
in recombinant heterologous systems often result in contradictory results between different 
laboratories. Variations in the pharmacological properties of α4β2δ receptors may arise from 
the expression of different stoichiometries or subunit arrangements. Our results in chapter 3 
successfully addressed the underlying cause of this variability. By creating a matrix of different 
mRNA injection ratios of α, β and δ subunits injected into Xenopus oocytes, we acquired two 
distinct receptor populations exhibiting different sensitivity towards GABA and the δ-selective 
positive allosteric modulator, delta selective 2 (DS2) compound. The existence of these receptor 
populations were further verified using two other compounds, namely AA29504, a positive 
allosteric modulator, and THIP, a GABAA agonist, known to have preference for δ-containing 
receptors.  
The first receptor population, arises from a high α4:β2 ratio, has an EC50 value of ~1 μM, a Hill 
slope close to 1 and minute DS2 direct activation. This receptor population is modulated by 
DS2, indicating that the δ subunit is incorporated into the receptor. The pharmacological 
properties of this population is similar to previous studies of α4β2δ receptors expressed in 
oocytes [1, 2] which are most likely to have a stoichiometry of (α4)2(β2)2(δ)1. The second 
receptor population, derived from a low α4:β2 ratio, has higher GABA sensitivity of sub-
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micromolar concentrations, a shallow Hill slope of ~0.3 and substantial DS2 direct activation. 
In section 3. 2. 2, we demonstrated that the injection of β2+δ barely resulted in functional 
receptors as GABA-evoked currents were observed only in 8 out of 17 oocytes. This result 
suggests that the presence of α4 in the receptor is important to mediate GABA-evoked currents 
and thus at least one α4 subunit must be present in the second population of α4β2δ receptors. 
The δ subunit is also expressed within the receptor because this population is sensitive to DS2, 
but as changing the ratio of δ subunit does not affect the pharmacological properties of the 
resultant receptors, it appears likely that only one δ subunit is incorporated. Consequently, it is 
proposed that three β2 subunits fill the remaining positions, forming a stoichiometry of 
(α4)1(β2)3(δ)1.  
The expression of distinct receptor populations displaying different pharmacological properties 
that vary in their stoichiometry has also been reported in other GABAARs subtypes, such as 
α1β3 and β3γ2L and in other ligand-gated ion channels, including the nicotinic acetylcholine 
receptors [3-6]. Thus our results demonstrate that altering molar ratios of cRNAs of GABA α 
and β subunits affects the receptor populations expressed in the heterologous systems, which 
is in line with previous reports [4, 6, 7]. Given the importance of subunit cRNA ratios, the 
quality of individual subunit cRNA batches can cause variations in the types of receptor 
ultimately expressed. To minimize this problem, subunit ratios need to be optimized, preferably 
using the same batches of cRNA and standardized to avoid a potentially misleading 
interpretation of electrophysiology data in recombinant systems. Other factors that affect the 
expression of GABAARs are differences in the translational efficacy, protein stability and 
turnover of each subunit.    
Our conclusion on the proposed stoichiometry is limited as it is taken from functional 
approaches without direct structural approaches. Nevertheless, our findings showed clear 
evidence of pharmacological differences between α4β2δ receptors expressed with different 
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injection ratios, which was further established by the application of THIP and AA29504. Given 
that various stoichiometries are expressed in the recombinant system, it is imperative to 
determine which stoichiometry or group of stoichiometries exist in native brain tissue. As one 
of the proposed stoichiometries has an additional β subunit, compounds that are selective for 
β-β interface can be utilized to determine the stoichiometry expressed in vivo.     
In chapter 4, the pharmacological role of δ-containing receptors was investigated in stroke. The 
typical exstrasynaptic receptors, containing either the δ or α5 subunits, mediate tonic inhibition 
that is implicated in this disease. The use of subtype-selective GABAARs compounds 
circumvents the failed translation of the neuroprotection effect of GABAergic compounds in 
clinical trials because these compounds target GABAARs subtypes involved in stroke and have 
fewer side effects. Reducing tonic current 3 days after stroke using an inverse agonist of α5-
containing receptors, L655,708, enhances functional recovery in a mouse model of 
photothrombotic stroke [8]. However, acute treatment of L655,708 early after stroke onset 
resulted in a significant increase in infarct size, indicating that dampening tonic currents too 
early exacerbate stroke [8]. We found that enhancing tonic current 1 hour post-stroke using 1 
mg/kg of THIP favours stroke recovery as evident by reduced infarct size and improved motor 
functions in mice with photothrombotic stroke. THIP has preference for δ- over γ-containing 
receptors where THIP directly activates δ-containing receptors with higher efficacy and 
potency than at γ-containing receptors [9, 10]. Interestingly, the recovery effect of THIP was 
observed in the KO group, demonstrating that the effect of THIP was not exclusively mediated 
by δ-containing receptors. This raises the possibility that the binary αβ receptors also contribute 
to THIP’s action as THIP directly activates these receptors with similar potency compared to 
α4β2δ receptors.  
Timing of GABAARs selective compounds intervention is one of the key factors that 
determines the outcome of stroke. Although the use of a δ-preferring agonist resulted in 
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enhanced stroke recovery in our study, the compounds need to be administered within 1 hour 
after stroke, making it difficult for patient use. The development of compounds that decrease 
tonic currents, i.e. δ or α5 antagonists are more favourable because the use of these compounds 
offers a prolonged therapeutic window (within 3-14 days) [8]. It is also worthwhile to evaluate 
the use of δ or α5 antagonists beyond 14 days to determine whether these compounds are still 
effective at the extended therapeutic window.     
Stroke is a complex disease that involves a series of molecular and cellular cascades in its 
development and therefore it is highly likely that subtype-selective GABAAR compounds have 
mechanisms of actions other than dampening the glutamate-mediated excitotoxicity and 
enhancing neuronal plasticity. One of the possible mechanisms is through anti-inflammatory 
pathways. GABAARs have been detected in immune cells [11-13]. Treatment with 
clomethiazole, a GABAARs agonist, in rats-induced hypoxia-ischaemia reduced the release of 
pro-inflammatory cytokines and promoted the release of anti-inflammatory cytokines [14].   
In the current study, we did not measure tonic current following THIP treatment in the peri-
infact cortex using brain slice electrophysiology to verify that 1 mg/kg of THIP is sufficient to 
increase tonic currents. Subcutaneous (s.c) injection of THIP at 2.5 mg/kg resulted in brain 
concentrations of approximately 0.7 µM in rats [15]. Given that intraperitoneal injection 
technique was used, and the blood brain barrier is impaired in stroke, it is likely that 1 mg/kg 
of THIP results in sufficient brain concentrations of THIP to increase tonic currents. In 
addition, a very low concentrations of THIP, 30 nM, has been shown to evoke tonic currents 
in cerebellar granule cells [16]. 
The protective effect of THIP early in stroke is postulated from selectively increasing the tonic 
current. The selectivity, in part, arises from THIP’s preference for δ-containing receptors where 
THIP acts as a superagonist at δ-containing with higher efficacy and potency than at γ-
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containing receptors. This has led us to evaluate the binding sites of THIP. By investigating 
the basis of the selectivity of THIP, it will facilitate the development of subtype selective 
GABAARs compounds. We hypothesized that the distinct activity of THIP at δ- and γ-
containing receptors derived from additional binding site at α4+ and δ- side. Two separate point 
mutations on the α4+ side and a double mutation on δ- side were generated and co-injected 
with wild-type β2, β2+δ, β2+γ or α4+β2 in Xenopus oocytes. The Y208C and H92A/S155T 
mutants only exhibited changes that were small in magnitude while the R100H had no effect 
on the THIP concentration-response curves, suggesting that the amino acids tested appeared 
unlikely to contribute to THIP’s binding site.  
So far, distinct intrinsic activation properties between δ- and γ-containing receptors is regarded 
as the probable cause of relative superagonism of THIP at δ-containing receptors. High 
concentrations of THIP resulted in higher channel conductance than GABA which led to higher 
efficacy in single-channel recordings [17]. In line with this, at α4β3δ receptors THIP prolonged 
the channel mean opening times and increased channel’s open probability [18]. Although 
single-channel recordings partly explained distinct activity of THIP at δ- and γ-containing 
receptors, others could not rule out the possibility that THIP has an additional binding site [17-
19], aside from the canonical binding of β+α- interface. Our mutational studies is confined to 
two amino acids at α4+ and δ- side and thus it is plausible that other amino acids on the same 
interface and/or other interface(s) contribute to the THIP binding site.  
Taken together, this thesis provides an insight in the pharmacological properties of δ-
containing receptors using electrophysiology and a mouse model of photothrombotic 
ischaemia. Our findings demonstrate that discrepancy in the pharmacological properties of 
α4β2δ is caused by the expression of distinct receptor populations with different stoichiometry. 
We further provided evidence that extrasynaptic GABAARs are a novel target of stroke as 
demonstrated by neuroprotection following acute treatment of THIP in early phase of stroke. 
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Lastly, we eliminate R100 and Y208 of α4 subunit and H92 and S155 of δ subunit as the 
potential binding sites of THIP.        
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GABAA receptors that contain the a4 and d subunits are thought to be located extrasynaptically,
mediating tonic currents elicited by low concentrations of GABA. These a4bd receptors are modulated
by neurosteroids and certain anesthetics, identifying them as important drug targets in research.
However, pharmacological studies on these receptors have often yielded variable results, possibly due
to the expression of receptors in different stoichiometries or arrangements.
In this study, we injected different ratios of a4, b2 and d cRNA into Xenopus oocytes and measured the
sensitivity to GABA and DS2 activation of the resulting receptor populations. By creating a matrix of RNA
injection ratios from stock RNA concentrations, we were able to compare the changes in pharmacology
between injection ratios where the ratio of only one subunit was altered.
We identified two distinct populations of receptors, the first with an EC50 value of approximately
100 nM to GABA, a low Hill slope of approximately 0.3 and substantial direct activation by DS2. The
second population had an EC50 value of approximately 1 lM to GABA, a steeper Hill slope of 1 and little
direct activation, but substantial potentiation, by DS2. The second population was formed with high a4
ratios and low b2 ratios, but altering the ratio of d subunit injected had little effect. We propose that
receptors with high sensitivity to GABA and direct activation by DS2 are the result of a greater number
of b2 subunits being incorporated into the receptor.
Crown Copyright  2016 Published by Elsevier Inc. All rights reserved.1. Introduction
Activation of GABAA receptors (GABAARs) in the brain generally
leads to cellular inhibition by allowing influx of Cl ions. These
receptors can be located at both the synapse, where they con-
tribute to phasic inhibition controlled by presynaptic GABA
release, and at extrasynaptic and perisynaptic sites where they
generate tonic inhibition in response to low concentrations of
GABA to fine-tune the inhibitory response of neurons (reviewed
in [1]). To perform these different cellular roles, different GABAARs
subtypes are formed from the large number of distinct receptor
subunits. In recent years there has been a growing interest in
understanding how GABAAR subtypes, especially receptors
containing a4, b and d subunits, are activated at low GABA
concentrations to mediate tonic inhibition [2]. The pharmacologyof a4bd receptors has also been of considerable interest in
research, with these receptors identified as important targets for
neurosteroids, alcohol, and certain anesthetics [1,3–5]. A deeper
understanding of the pharmacology of these receptors is required
to fulfill their potential as drug targets for various neurological
and psychiatric disorders, including pain, epilepsy, sleep disorders,
depression, and schizophrenia [2,6,7].
Despite considerable research efforts in the field, it is striking
how the functional and pharmacological studies of d-containing
receptors have yielded variable results. The sensitivity of
a4bd receptors to ethanol is a classic example whereby some
researchers report that low concentrations of ethanol potentiate
GABA on d-containing receptors [8–11], while others do not
observe this potentiation [12]. Additionally, there are a number
of reports that describe a4b3d receptors forming two distinct
receptor populations: one receptor population that is sensitive to
nanomolar concentrations of GABA and THIP (gaboxadol) and
another population that is sensitive to micromolar concentrations
of both compounds. A similar difference in GABA potency was also
observed at a4b2d receptors in one study [13]. While most reports
describe micromolar effects of GABA at a4b2d receptors [14–17],
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using concatenated constructs [13].
The subunit composition of GABAARs and their pentameric
arrangement around a central, ion-conducting pore are crucial
determinants of the pharmacological properties of the receptor,
determining the putative ligand-binding interfaces and intrinsic
activation properties [18]. To date, the exact stoichiometry of
a4bd receptors expressed both natively, and in heterologous sys-
tems, remains equivocal. While a number of studies attempt to
address this question [19–22], firm conclusions have been difficult
to draw over what stoichiometrie(s) or arrangement(s) are formed,
and under what conditions these occur. In the abundant a1b2c2
receptor, the c2 subunit take the position as a fifth ‘‘auxiliary” sub-
unit that does not participate in GABA binding, and it is generally
assumed that the d subunit substitutes for the c2 subunit in
a4bd receptors. This has been questioned by reports that the level
of d subunit incorporation varies by varying the ratio of cRNA or
cDNA in recombinant systems [20], while the expression of con-
catenated constructs suggest that the d subunit can occupy various
positions within the receptor complex [18,21]. Differences in func-
tional and pharmacological properties of these receptors are
thought to accompany these differences in both subunit stoichiom-
etry and arrangement [10,22]. However, a caveat of some of these
studies is that while measuring the responses of concatenated con-
structs can potentially yield information about a specific arrange-
ment and stoichiometry of a single receptor, the technique itself
may alter intrinsic receptor properties and force the assembly of
receptors that would not occur otherwise. Along this, the use of
concatenated constructs was recently shown to significantly alter
the sensitivity to GABA and etomidate [23].
The pharmacological tool described as the Delta Selective agent
(4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridin-3-yl]benzamide
(DS2)) has proven useful at identifying d-containing GABAARs in
native systems where it enhances tonic currents. At the molecular
level, DS2 can either positively modulate GABA-elicited currents,
or directly activate a4b3d receptors. Similarly, there are reports
of various levels of direct activation of a4b2d receptors by DS2
but it is not well understood what conditions favor direct activa-
tion as opposed to positive modulation [13–15,24].
We hypothesized that variations in the pharmacology of a4b2d
receptors arise from the expression of receptors with either differ-
ent stoichiometries or different subunit arrangements. In this
study, we tested this hypothesis by injecting a matrix of different
cRNA injection ratios that varied the subunit ratio of a4, b2, and
d cRNA in Xenopus laevis oocytes. The pharmacology of the recep-
tors expressed was evaluated with GABA and DS2 to determine
functional changes between the receptors expressed under differ-
ent injection ratios. Our results demonstrate that GABA and DS2
activity were markedly changed depending on the subunit ratio
of a4:b2, clearly indicating that receptors with different stoi-
chiometries are expressed. There are at least two discrete receptor
populations: one containing high GABA sensitivity and high effica-
cious DS2 direct activation and another with lower GABA sensitiv-
ity and relatively low-efficacy DS2 activation. At the latter
receptors, DS2 positively modulated the GABA-elicited current.
These data suggest that variability of the pharmacological proper-
ties of a4b2d receptors are likely to be the result of the expression
of receptors with different stoichiometries.2. Materials and methods
2.1. Compounds
GABA, DMSO and all the ingredients for buffers used in this
study were purchased from Sigma–Aldrich (St. Louis, MO, USA)while DS2 was purchased from Tocris Bioscience (Bristol, UK). THIP
(4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridine-3(-ol) (gaboxadol))
was generously provided by Dr. Bjarke Ebert (H. Lundbeck A/S,
Valby, Denmark).
2.2. GABA receptor subunit construct
Human cDNA a4 and d subunits were subcloned into
pcDNA1/Amp and the b2 was subcloned into pcDM8. The plasmids
containing the a4 and d subunits were linearized with the
restriction enzymes HpaI (Life Technologies) and b2 plasmids were
linearized with NotI (Life Technologies). cRNAs were transcribed
using mMESSAGE mMACHINE T7 Transcription Kit (Life Tech-
nologies). DNAse was added to the cRNA and then polyadenylated
using the Poly-A-tailing kit (Life Technologies) and purified
using lithium chloride precipitation. The concentrations of cRNAs
were measured with a Nanodrop ND-1000-UV–Vis spectropho-
tometer and the quality was determined using 1% agarose gel
electrophoresis.
2.3. X. laevis surgery and oocyte injection
Surgery procedures on X. laeviswere approved by Animal Ethics
Committee of the University of Sydney (reference number:
2013/5915). Female X. laevis was anesthetized by submerging the
X. laevis in 0.17% tricaine. A small incision on the abdomen was
made to obtain several ovarian lobes. The ovarian lobes were cut
into smaller lobes and stored in oocytes Ringer’s buffer 2 (OR2)
(82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES hemisodium
salt; pH 7.4). The lobes were then treated with collagenase A
(Boehringer Mannheim, Indianapolis, IN, USA) diluted in OR2 solu-
tion for 1–2 h at 18 C to separate oocytes from follicle cell layer
and connective tissues. After the digestion was completed, the
oocytes were rinsed thoroughly with OR2 and ND96 solution
(96 mM NaCl, 2 mM KCl, 1 mMMgCl2, 1.8 mM CaCl2, 5 mM HEPES;
pH 7.4) supplemented with 2.5 mM sodium pyruvate and 0.5
theophylline. Stages V–VI oocytes were collected and injected
(Nanoject, Drummond Scientific Co.) with 5–8 ng of cRNA in a final
volume of 50.6 ll in the ratios stated in the text. The injected
oocytes were incubated in ND96 augmented with 50 lg/ml gen-
tamycin and tetracycline at 18 C for 4–7 days prior to recording.
2.4. Injection ratio matrix
All cRNA was derived from a single RNA stock of each subunit to
allow for a comparison between relative cRNA ratios. An initial
ratio of 1:1:1 (a4:b2:d) RNA was made and injected into Xenopus
oocytes. As the aimwas not to study potential receptor populations
arising from extreme cRNA ratios, changes were kept modest, and
the lowest and highest percentages a given subunit represented in
the cRNA mixture was within the range of approximately 10–70%.
A matrix of injection ratios were developed such that the relative
a4 ratio was altered by creating a 5:1:1 and 1:5:5 ratio, while
the b2 ratio was altered by creating a 1:5:1 and 5:1:5 ratio, and
the d ratio was altered by creating a 1:1:5 and 5:5:1 ratio.
2.5. Electrophysiological recording
Whole-cell current was recorded using the two-electrode
voltage clamp technique with a Geneclamp 500B amplifier and
digitized with a Powerlab/200 analogue to digital conversion with
the Chart version 3.5 software as previously described [25]. The
recording microelectrodes were filled with 3 M KCl and had resis-
tance between 0.2 and 1.2 MX. Oocytes were impaled and clamped
at 60 mV and superfused with ND96 during recording. DS2 was
Table 1
Fitted GABA concentration–response relationships from a4b2d receptors using X.
laevis oocyte electrophysiology.
a4 + b2 + d ratio EC50 (95% CI) (lM) nH Imax (nA) n
1:1:1 0.14 (0.072–0.26) 0.3 ± 0.03 160 ± 10 11
5:1:1 1.6 (1.3–2.0)⁄ 0.9 ± 0.1⁄⁄ 60 ± 8 6
1:5:5 0.46 (0.1–2.0) 0.3 ± 0.1 70 ± 14 9
1:5:1 0.57 (0.16–2.03) 0.3 ± 0.04 75 ± 9 5
5:1:5 1.6 (1.3–1.9)⁄ 0.9 ± 0.1⁄⁄ 55 ± 7 7
1:1:5 0.72 (0.18–2.8) 0.4 ± 0.1 70 ± 10 8
5:5:1 0.23 (0.12–0.42) 0.4 ± 0.03 85 ± 11 8
*P < 0.05 and **P < 0.01, Dunn’s multiple comparison post hoc test compared to
a4 + b2 + d (1:1:1).
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was applied to oocytes.
2.6. Data analysis
The currents evoked by GABA (I) were normalized to the fitted
maximum currents evoked by GABA (IGABA_max_fit) and the currents
evoked directly by DS2 or THIP were normalized to the maximum
GABA-evoked currents (IGABA_100lM).
Meanwhile, the modulation of DS2 was measured in the pres-
ence of increasing concentration of GABA on a fixed concentration
of DS2. The modulation was calculated as follows:
%Modulation ¼ ðIGABAþDS2Þ=IGABA 100lMÞ  100%
Normalized concentration–response relationships were gener-
ated and analyzed using GraphPad Prism version 6.04 according
to the following equation:
I ¼ Imax ð½AnH=ð½AnH þ ECnH50 ÞÞ
where [A] is the agonist concentration, nH is Hill slope, and the EC50
value is the concentration of agonist that produces a response that
is 50% of the maximum current. Mean parameters of each curve
were obtained from at least five oocytes. EC50 values are expressed
as mean with 95% confidence interval while nH and percentage of
activation by DS2 are expressed as mean ± SEM.
The estimated logEC50 values, Hill slopes and DS2 activation on
different ratios of a4 + b2 + d were compared using the non-
parametric Kruskal–Wallis test followed by a Dunn’s post hoc test.
Meanwhile, the estimated logEC50 values and Hill slopes between
two different ratios were compared with Student’s t-test.
3. Results
There has been considerable variation in the reports describing
the pharmacological properties of d-containing GABAARs. We
hypothesized that these variations in the pharmacology of a4b2d
receptors arise from the expression of receptors with either differ-
ent stoichiometries or different subunit arrangements in heterolo-
gous systems. To investigate whether the expression of different
receptor populations can be manipulated to preferentially express
one receptor population in preference to another, we varied the
molar ratios of a4, b2, and d cRNA injected in X. laevis oocytes. This
method has previously been shown to give a reasonable degree ofFig. 1. Electrophysiological recordings of GABA- and DS2-evoked a4b2d currents using
injected with a cRNA mixture containing a4 + b2 + d subunits in a 1:1:1 ratio as described
panel) or DS2 activation (bottom panel). Bars above each trace represent application pe
omitted. (B) Peak current amplitudes for GABA activation were normalized to the m
(IGABA_max_fit). Normalized responses were plotted as mean ± S.E. from n = 11 oocytes and
intervals: 0.072–0.26 lM) with a Hill slope of 0.3 ± 0.03. (C) Peak current amplitudes fo
concentration (IGABA_100lM) in the same oocytes and plotted as mean ± S.E. from n = 15 o
0.97 lM (95% confidence intervals: 0.47–2.0 lM) with a Hill slope of 0.99 ± 0.15.control over subunit assembly of resulting receptors [22,26–28].
All cRNA was derived from a single RNA stock of each subunit to
allow for a comparison between relative cRNA ratios. We then cre-
ated a matrix of injection ratios allowing us to alter the relative
ratio of one subunit while keeping the ratio of the other two
constant.3.1. a4b2d receptors expressed from the injection of a 1:1:1 cRNA ratio
in oocytes
Equimolar or close to equimolar (e.g. 1:1:2) cRNA ratios have
commonly been used to express GABAA a4b2d receptors in oocytes
[14]. a4b2d receptors were therefore initially expressed by inject-
ing a cRNA mixture with a 1:1:1 ratio of the three subunits. As
expected, receptors responded to applications of GABA in a
concentration-dependent manner (Fig. 1A top panel). When stim-
ulated with a maximally efficacious GABA concentration
(100 lM, henceforth termed GABA100lM), the average evoked peak
current amplitude from n = 11 oocytes were 160 nA (Table 1), a
finding that was in good agreement with previous reports of
d-containing receptors [14,15]. Plotting average GABA-evoked peak
current amplitudes as a function of the concentration of GABA
revealed a concentration–response relationship (CRR) that when
fitted with a one-site Hill equation had an EC50 value (half maximal
efficacious GABA concentration) of 140 nM and a Hill slope of 0.3
(Fig. 1B, Table 1).
This low Hill slope is atypical for a GABAA receptor and may
instead be the result of two receptor populations with distinct
GABA potencies. However, fitting the CRR to a higher-orderX. laevis oocytes injected with cRNA containing a 1:1:1 subunit ratio. Oocytes were
in the methods. (A) Example of traces from single experiments showing GABA (top
riod and the specific GABA or DS2 concentration. Applied bulk washout periods are
aximum current fitted from individual experiments fitted to the Hill equation
fitting data to the Hill equation yielded an EC50 value of 0.14 lM (95% confidence
r DS2 activation were normalized to that of a maximal efficacious GABA (100 lM)
ocytes. Data points were fitted to the Hill equation, which yielded an EC50 value of
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one-site Hill equation (t-test, P = 0.24), suggesting this was not a
biphasic curve. When GABA CRRs were plotted and fitted for each
oocyte, the EC50 values had a wide range from 6.4 to 610 nM and
the Hill slopes ranged from 0.28 to 0.42. This suggests that the
low Hill slope is likely to be an inherent feature of the receptor
population(s) expressed in all oocytes (Fig. 1B), as opposed to be
a result of averaging data from oocytes expressing receptors with
either high or low affinity for GABA.
A defining feature of d containing receptors has been their sen-
sitivity to high modulatory efficacy of DS2. This potentiation of
GABA-elicited currents has been described by several groups and,
although results vary between studies, it is widely accepted that
d incorporation into a GABAAR increases the modulatory efficacy
of GABA by DS2 [29]. Therefore, we attempted to describe the
DS2 modulation by performing a full GABA CRR in presence
of DS2. However, this proved difficult to perform as applications
of DS2 (1 lM) alone elicited current amplitudes that were approx-
imately 4-fold larger than that of GABA100lM (Fig. 1A bottom
panel). This effect where DS2 directly activated the receptor
confounded the measurement of the efficacy of modulation.
To determine the potency and efficacy of DS2 agonism relative
to GABA, we performed CRRs of DS2 and a4b2d receptors
responded to DS2 application in a concentration-dependent
manner. The average DS2-evoked peak current amplitudes plotted
as a function of the DS2 concentration were well approximated by
the Hill equation (Fig. 1C), with derived fitting parameters of an
EC50 value of 0.97 lM and a Hill slope of 0.98, indicating the
presence of a saturable DS2 binding site(s).
Although these features of a4b2d receptors, including the cur-
rent amplitude levels and sensitivity to DS2, are in good agreement
with previous data, the EC50 value of GABA and the Hill slope value
appear to be different (Table 2) [14,30]. GABA was approximately
10-fold more potent than the bulk of previous descriptions, and
this was accompanied with a low Hill slope of the CRR. High
GABA-sensitivity receptors have been described for the a4b3d sub-
type and this has been accompanied with biphasic fitting of the
CRR [30]. Further, while there is consensus in the literature that
DS2 is a modulator with some selectivity for d-containing recep-
tors, there remains controversy regarding the direct activating
effects of the compound. Jensen et al. reported strong activation
by DS2 on human recombinant a4b3d receptors expressed in
Xenopus oocytes whereas other studies using either concatenated
constructs or free subunits of a4b2d in oocytes or HEK 239 cells
did not reveal any direct DS2 activation [13,15,24] (Table 2). It is
generally accepted that GABAARs can form promiscuously whenTable 2
Properties of a4b2/3d expressed in Xenopus oocytes from selected publications.
Receptor (ratio) GABA
EC50 (lM) nH
a4 + b2 + d (high sensitivity) 0.14–0.72 0.3–0.4
a4 + b2 + d (low sensitivity) 1.6 0.9 ± 0.1
a4 + b2 + d (1:1:2) 1.5 ± 0.1 NAa
a4 + b3 + d (1:1:2) NAa NAa
a4 + b2 + d (1:1:5) 1 1.3 ± 0.2
a4 + b3 + d (1)b = 0.012 (1)b = 1.2 ± 0.5
(5:1:5) (2)b = 1.3 (2)b = 1.1 ± 0.3
a4 + b2 + d (5:1:5) 0.8 ± 0.1 0.8 ± 0.1
d–b2–a4 + b2–a4c 1.4 ± 0.3 1.2 ± 0.1
a4 + b2 + d (5:1:5) 0.010 ± 0.001 0.8 ± 0.1
b2–d + a4c 0.17 ± 0.02 1 ± 0.1
a NA: Not available.
b Fitted to biphasic curve.
c Concatenated receptor.expressed in heterologous expression systems such as oocytes
[31]. Accordingly, injection of a4 + b2 + d subunits using a 1:1:1
cRNA ratio could potentially form more than one receptor
population that varies either in composition, stoichiometry and/
or subunit arrangement.
3.2. a4d, b2d and a4b2 binary receptors
The formation of binary receptors constitutes one possible rea-
son for receptor populations with distinct pharmacological proper-
ties to be formed. For example, binary a1b2 receptors express well
in a variety of expression systems [26,32]. Therefore, to determine
the functional properties of potential binary receptors, cRNA mix-
tures of a4 + d, b2 + d or a4 + b2 were injected into oocytes using
subunit ratios of 5:1 or 1:5 (e.g. a4 + d (5:1) or a4 + d (1:5)).
Oocytes injected with a4 + d (5:1), a4 + d (1:5) or b2 + d (5:1)
ratio did not elicit any response to GABA or GABA + DS2 applica-
tions. b2 + d (1:5) injection resulted in minute GABA-evoked cur-
rents in 8 out of 17 oocytes with a mean peak current amplitude
of 6.5 ± 1.5 nA from the n = 8 expressing oocytes (Fig. 2A). These
currents were not modulated by DS2 (0.3 lM). Somewhat larger
currents were observed from injecting a4 + b2 (5:1), where
GABA100lM evoked currents with a mean peak amplitude of
25 ± 7 nA from n = 6 oocytes (Fig. 2B). This is significantly less than
that observed with a4 + b2 + d (1:1:1) above (t-test, P < 0.001).
Further, a low concentration of GABA (1 lM) barely evoked any
current and co-applications of DS2 (1 lM) had no effect. Finally,
injecting a4 + b2 (1:5) resulted in GABA100lM-evoked currents
with a mean peak amplitude of 95 ± 10 nA for n = 7 oocytes. Upon
visual inspection, currents from these a4b2 receptors appeared to
have a faster current decay in presence of GABA compared with the
a4b2d receptors above (Fig. 2C and D, compared with 1A), but
otherwise had similar properties. A full GABA CRR fitted to a
one-site Hill equation revealed an EC50 value of 1.9 lM and a low
Hill slope of 0.5 (Fig. 2E), while a higher order biphasic fit was
not significantly better (P = 0.68, F-test). The application of DS2
(0.3–1 lM) did not modulate an EC20 concentration of GABA nor
give direct activation at these a4b2 receptors (Fig. 2C).
Out of the three possible types of binary receptors (a4d, b2d and
a4b2), only a4b2 receptors gave robust GABA-evoked currents.
Since binary receptors themselves can potentially express in differ-
ent stoichiometries, e.g. (a4)3(b2)2 or (a4)2(b2)3, expression of the
binary receptor combinations were attempted with two different
cRNA ratios (5:1 and 1:5). Interestingly, injection of a4b2 (1:5)
cRNA gave rise to substantially higher current levels than a4b2
(5:1) cRNA. This indicates that an (a4)2(b2)3 stoichiometry eitherDS2 activity References
Modulation Activation
NAa U Current study
U Current study
U U [14]
U U
NAa NAa [30]
NAa NAa
U [15]
U
U [13]
NAa NAa
Fig. 2. GABA activation and DS2 modulation of binary b2d or a4b2 receptors recorded using X. laevis oocytes electrophysiology. Oocytes were injected with a b2 + d or a4 + b2
cRNAmixtures in subunit ratios of 5:1 or 1:5. Representative current traces evoked by applications of GABA, GABA + DS2 or DS2 alone for (A) b2 + d (1:5), (B) a4 + b2 (5:1) and
(C) a4 + b2 (1:5). (D) Representative GABA-evoked current traces in an oocyte injected with a4 + b2 (1:5). (E) Peak current amplitudes from GABA concentration–response
relationships at a4 + b2 (1:5) injected oocytes were fitted as described in the Fig. 1 legend and plotted as averaged values ± S.E. from n = 7 oocytes. Data points were fitted to
the Hill equation, which resulted in an EC50 value of 1.9 (0.9–4.2) lM and a Hill slope of 0.5 ± 0.1.
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vation upon GABA applications. This is consistent with previous
studies showing that a1b2 GABAARs yield best current levels in
the 2a:3b arrangement [33]. Several studies have suggested that
ab receptors are fully functional and often constitute a contami-
nant when expressing ternary receptors [4,32]. However, in the
context of the current study, a4b2 receptors were insensitive to
modulation and direct activation by DS2. This is in sharp contrast
to observations with the a4 + b2 + d (1:1:1) ratio above and this
limits the likelihood that a4b2 binary receptors constitute a major
fraction of the receptor pool in these experiments.3.3. a4b2d ternary receptors from variant cRNA ratios
As binary receptors do not appear to constitute a major receptor
population expressed from injecting a4 + b2 + d (1:1:1), we next
determined how altering the molar subunit ratio of a4 + b2 + d in
the cRNA mixture might influence ternary receptor formation.
The receptors formed by different injection ratios were compared
by performing full GABA CRRs and evaluating the direct activation
properties of DS2 (300 nM) (DS2300nM). The 300 nM concentration
was chosen as it elicited large currents at receptors with high
sensitivity to DS2, without compromising the potential selectivity
by activating receptors with lower sensitivity to DS2.3.3.1. Varying the a4 cRNA ratio
Initially, the effects of increasing the ratio of the a4 subunit,
while maintaining a constant b2:d ratio were evaluated. Oocytes
injected with a4 + b2 + d (5:1:1) responded to GABA100lM applica-
tions with an average peak current amplitude of 60 nA (Table 1).
The full GABA CRR was well approximated with a one-site Hill
equation giving an EC50 value of 1.6 lM and Hill slope of 0.9
(Fig. 3A, Table 1). Further, the direct DS2300nM activation levelwas low (Fig. 3C) and the DS2300nM activation, EC50 value and Hill
slope to GABA were all significantly different from that of the
a4 + b2 + d (1:1:1) ratio (P < 0.05 DS2 and EC50, P < 0.01 Hill slope)
(Fig. 3B).
Decreasing the relative amount of a4 by injecting a4 + b2 + d
(1:5:5) resulted in an average GABA100lM-elicited peak current
amplitude of 70 nA (Table 1). When fitted to a one-site Hill equa-
tion, the full GABA CRR had an EC50 value of 720 nM and a low Hill
slope of 0.4 (Fig. 3A, Table 1). Similar to oocytes injected with
a4 + b2 + d (1:1:1), oocytes injected with a4 + b2 + d (1:5:5) were
efficiently activated by DS2300nM (Fig. 3B and D). The EC50 value,
Hill slope and DS2 activation were not significantly different to
that obtained with the a4 + b2 + d (1:1:1) (P > 0.05).3.3.2. Varying the b2 cRNA ratio
Next, we altered the relative amounts of b2, initially increasing
the amount of b2 and injecting a ratio of a4 + b2 + d (1:5:1).
Oocytes injected with this ratio responded to GABA100lM applica-
tions with an average peak current amplitude of 75 nA (Table 1).
The fitted GABA CRR displayed an EC50 value of 570 nM and a Hill
slope of 0.3 (Fig. 4A, Table 1). DS2300nM evoked currents with
amplitudes similar to that of GABA100lM (Fig. 4C), with no signifi-
cant differences between the a4 + b2 + d (1:5:1) and (1:1:1) ratios
for the GABA EC50 value, Hill slope or DS2300nM activation
(P > 0.05). Hence, the data obtained from increasing the relative
amount of the b2 subunit resembled those obtained with the a4
+ b2 + d (1:1:1) ratio (Fig. 4B).
Decreasing the amount of b2 by injecting a4 + b2 + d (5:1:5)
resulted in an average GABA100lM-evoked peak current amplitude
of 55 nA (Table 1). The GABA CRR was well approximated by a one-
site Hill equation with an EC50 value of 1.6 lM and Hill slope of 0.9
(Fig. 4A, Table 1). There was limited direct activation with
DS2300nM (Fig. 4D) and the DS2300nM activation, EC50 value and Hill
Fig. 3. Electrophysiological recordings of GABA- and DS2-evoked a4b2d receptor currents using cRNA with variant relative amounts of a4. Oocytes were injected with cRNA
mixtures of a4 + b2 + d subunits, where the relative amount of the a4 subunit in comparison with a 1:1:1 ratio was either increased or decreased (5:1:1 or 1:5:5).
Observations for the a4 + b2 + d (1:1:1) ratio from Fig. 1 are depicted in gray to allow comparison. (A) a4b2d (5:1:1) and a4b2d (1:5:5) GABA concentration–response
relationships plotted as (A) averaged values ± S.E. from n = 6–9 oocytes. Regression results are presented in Table 1. (B) Peak current activation by DS2 (300 nM) (IDS2_300nM)
was normalized to maximal efficacious GABA (100 lM) control applications (IGABA_100lM) in the same oocytes and depicted as mean ± S.E. from n = 7–10 oocytes for the
indicated cRNA ratios. (C, D) Representative current traces evoked by applications of a maximally efficacious GABA concentration (GABA100lM) or DS2 (300 nM) for (C) a4
+ b2 + d (5:1:1) and (D) a4 + b2 + d (1:5:5). * Indicate statistical significant difference (P < 0.05, Kruskal–Wallis, Dunn’s post hoc).
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a4 + b2 + d (1:1:1) ratio (P < 0.05 DS2 and EC50, P < 0.01 Hill slope)
(Fig. 4B). However, the EC50 value, Hill slope and DS2300nM were not
significantly different to the a4 + b2 + d (5:1:1) ratio (compare
Fig. 4A with 3A). Hence, the data obtained from decreasing the
relative amount of the b2 subunit resembled those obtained with
the a4 + b2 + d (5:1:1) ratio (Fig. 4A and B).
3.3.3. Varying the d cRNA ratio
We then altered the relative amount of the d subunit that was
injected, initially increasing the amount of d subunit by injecting
a4 + b2 + d (1:1:5). Oocytes responded to GABA100lM applications
with an average peak current amplitude of 70 nA, and the GABA
CRR was well approximated by a one-site Hill equation with an
EC50 value of 720 nM and a Hill slope of 0.4 (Fig. 5A, Table 1).
Robust direct activation was observed with DS2300nM (Fig. 5C), sim-
ilar to the EC50 value, Hill slope and DS2300nM activation obtained
by the a4 + b2 + d (1:1:1) ratio.
Decreasing the relative amount of the d subunit by injecting
a4 + b2 + d (5:5:1) gave an average GABA100lM-evoked peak cur-
rent amplitude of 85 nA and the GABA CRR was well approximated
by a one-site Hill equation, with an EC50 value of 230 nM and a Hill
slope of 0.4 (Fig. 5A, Table 1). DS2300nM-evoked current amplitudes
were on par with those of GABA100lM (Fig. 5D). There were no sig-
nificant differences in any of the GABA CRRs or DS2300nM-activation
measured between the three ratios where only the ratio of the
d subunit was altered (Fig. 5A and B).
3.3.4. Overall observations from the variant cRNA ratios
All a4 + b2 + d cRNA ratios yielded GABA100lM-evoked peak
current amplitudes that were of similar magnitude, indicating that
none of the ratios used were approaching a limit hinderingreceptor expression levels. Further, the results from the variant
a4 + b2 + d cRNA ratios show that expressed receptors fall into
two classes. Two cRNA ratios, 5:1:1 and 5:1:5, yielded receptors,
which had single-digit micromolar GABA sensitivity, Hill slopes
close to 1 and limited direct DS2 activation. The remaining ratios
yielded receptors that had sub-micromolar GABA sensitivities with
accompanying low CRR Hill slopes and efficacious direct activation
by DS2 applications, features that resemble those obtained with
the 1:1:1 ratio. While data for 5:1:1 and 5:1:5 ratios were signifi-
cantly different from all other ratios, no further significant differ-
ences were noted even for a4 + b2 (1:5). This indicates that a
high a4 to b2 ratio favors formation of a receptor population with
low GABA sensitivity and little DS2 activation, whereas the reverse
leads to receptors with higher sensitivity to GABA and much
greater levels of direct DS2 activation. Interestingly, the pharmaco-
logical properties of the low-sensitivity a4b2d receptors appear to
correspond to previously published data [14,30].
3.4. DS2 potentiated the GABA-elicited currents at a4b2d receptors
injected with 5:1:1 and 5:1:5 cRNA ratios
As a4b2d receptors from the 5:1:1 or 5:1:5 cRNA ratios only
displayed limited activation upon DS2300nM application it was
necessary to both verify that the d subunit was still incorporated
in the receptor complexes, and determine the pharmacology of
DS2 at these receptors. To do this, full CRRs of GABA were obtained
in absence and presence of DS2. DS2 (1 lM) increased the GABA
sensitivity approximately 2-fold with EC50 values of 0.8 and
0.7 lM, respectively (Fig. 6A and B). However, more pronounced
effects were observed for the average maximum current
amplitudes, which were increased at all concentrations. At the
maximum GABA concentrations, the mean peak current
Fig. 4. Electrophysiological recordings of GABA- and DS2-evoked a4b2d receptor currents using cRNA with variant relative amounts of b2. Oocytes were injected with cRNA
mixtures of a4 + b2 + d subunits, where the relative amount of the b2 subunit in comparison with a 1:1:1 ratio was either increased or decreased (1:5:1 or 5:1:5).
Observations for the a4 + b2 + d (1:1:1) ratio from Fig. 1 are depicted in gray to allow comparison. (A) a4b2d (1:5:1) and a4b2d (5:1:5) GABA concentration–response
relationships plotted as averaged values ± S.E. from n = 5–7 oocytes. Regression results are presented in Table 1. (B) Peak current activation by DS2 (300 nM) (IDS2_300nM) was
normalized to maximal efficacious GABA (100 lM) control applications (IGABA_100lM) in the same oocytes and depicted as mean ± S.E. from n = 5–7 oocytes for the indicated
cRNA ratios. (C, D) Representative current traces evoked by applications of a maximally efficacious GABA concentration (GABA100lM) or DS2 (300 nM) for (C) a4 + b2 + d
(1:5:1) and (D) a4 + b2 + d (5:1:5). * Indicate statistical significant difference (P < 0.05, Kruskal–Wallis, Dunn’s post hoc).
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agreement with previous observations [14].3.5. THIP activation on different receptor populations
THIP is a widely used pharmacological tool that activates d-
containing receptors with high sensitivity [34]. To determine if
the different stoichiometries of a4b2d receptors were activated dif-
ferently by THIP, we injected two ratios that represented the two
distinct receptor populations; an a4 + b2 + d (1:1:1) ratio for high
sensitivity receptors and an a4 + b2 + d (5:1:1) ratio for low sensi-
tivity receptors populations. The application of 1 mM THIP evoked
peak current amplitudes approximately 1.8-fold greater than
GABA100lM at both ratios. When fitted to a one-site Hill equation,
the THIP CRR at the 1:1:1 ratio had an EC50 value of 1.69 lM, which
was approximately 6-fold lower than at the 5:1:1 ratio. Further,
the Hill slope of the THIP CRR was significantly lower at 1:1:1 com-
pare to 5:1:1 ratio (t-test, P < 0.0005) (Fig. 7). Differences in the
EC50 values and Hill slopes indicate that the injection of a4b2d in
1:1:1 and 5:1:1 ratios resulted in the expression of different recep-
tor populations that had different THIP-activation properties.4. Discussion
d-containing GABAARs have in general been challenging to
study due their inherent low GABA-evoked current responses
and the limited range of available selective compounds [10,15].
To further complicate matters, there is considerable variability in
the functional and pharmacological properties of a4b(x)d GABAARs,most likely due to the expression of receptor populations with dif-
ferent subunit stoichiometries. To investigate this, we evaluated
the effect of varying the cRNA ratio of a4 + b2 + d receptor subunits
on resulting receptor populations using X. laevis oocyte electro-
physiology and discovered that cRNA ratios indeed have large
effects on the pharmacological characteristics of the resultant
receptor populations.4.1. The ‘‘reference” a4b2d receptor
Mixed receptor populations are a common phenomenon when
expressing GABAARs in recombinant expression systems [30,35].
Further, studies with nicotinic acetylcholine receptors have shown
that differences in receptor stoichiometry of the same two sub-
units can have a significant impact on receptor properties, includ-
ing the sensitivity to the endogenous ligand (acetylcholine) and the
pharmacological modulation by exogenous compounds [27,36].
Hence, different receptor populations need not necessarily be the
result of receptors formed by different subunits, but may be the
result of an alternative subunit stoichiometry or arrangement of
the same subunits in case of ternary receptors.
To investigate whether different stoichiometries or arrange-
ments influenced receptor function, this study evaluated the influ-
ence of varying cRNA ratios on fundamental a4b2d receptor
characteristics including the GABA-evoked current levels, GABA
concentration–response relationships and DS2 sensitivity. These
characteristics were initially defined for a ‘‘reference” a4b2d recep-
tor population, formed by the injection of a4 + b2 + d cRNA in a
1:1:1 ratio, which other receptor populations could be compared
Fig. 5. Electrophysiological recordings of GABA- and DS2-evoked a4b2d receptor currents using cRNA with variant relative amounts of d. Oocytes were injected with cRNA
mixtures of a4 + b2 + d subunits, where the relative amount of the d subunit in comparison with a 1:1:1 ratio was either increased or decreased (1:1:5 or 5:5:1). Observations
for the a4 + b2 + d (1:1:1) ratio from Fig. 1 are depicted in gray to allow comparison. (A) a4b2d (1:1:5) and a4b2d (5:5:1) GABA concentration–response relationships plotted
as averaged values ± S.E. of n = 8 oocytes. Regression results are presented in Table 1. (B) Peak current activation by DS2 (300 nM) (IDS2_300nM) was normalized to maximal
efficacious GABA (100 lM) control applications (IGABA_100lM) in the same oocytes and depicted as mean ± S.E. from n = 6–7 oocytes for the indicated cRNA ratios.
(C, D) Representative current traces evoked by applications of a maximally efficacious GABA concentration (GABA100lM) or DS2 (300 nM) for (C) a4 + b2 + d (1:1:5) and
(D) a4 + b2 + d (5:5:1).
Fig. 6. Electrophysiological recordings of DS2 modulated GABA-evoked currents from a4b2d receptors using X. laevis oocytes. Oocytes were injected with cRNA mixtures
of a4 + b2 + d subunits in ratios of 5:1:1 or 5:1:5. Peak current amplitudes were normalized to prior maximally efficacious GABA (100 lM) applications (IGABA_100lM) and
fitted to a one-site Hill equation by non-linear regression. (A) a4b2d (5:1:1) GABA concentration–response relationships plotted as averaged values ± S.E. of n = 6 oocytes.
In the absence of DS2 the fitted EC50 value was 1.47 (1.01–1.98) lM and the Hill slope 0.95 ± 0.1 whereas presence of DS2 (1 lM) resulted in a fitted EC50 value of
0.76 (0.60–0.96) lM and Hill slope of 0.96 ± 0.1. (B) a4b2d (5:1:5) GABA concentration–response relationships plotted as averaged values ± S.E. of n = 8 oocytes. In the
absence of DS2 the fitted EC50 value was 1.6 (1.29–2.03) lM and the Hill slope 0.88 ± 0.1 whereas presence of DS2 (1 lM) resulted in a fitted EC50 value of 0.69 (0.52–0.91) lM
and Hill slope of 1.16 ± 0.2.
L.Y. Hartiadi et al. / Biochemical Pharmacology 103 (2016) 98–108 105to. Notably, these receptors had high sensitivity to GABA with an
EC50 value of 140 nM, a very low fitted Hill slope of 0.3 and were
directly activated by DS2.
The pharmacological properties of this ‘‘reference” receptor is
different to most previous reports of a4b2d receptors, where a typ-
ical EC50 value of 1–2 lM, a Hill slope in the vicinity of 1 and no
DS2 direct activation has been observed [14,29]. Where the exis-
tence of d-containing receptors with GABA sensitivity in the nMrange that were directly activated by DS2 has been found, this
has usually been reported for a4b3d receptors [14,29]. It is possible
that our ‘‘reference” receptor population contained a mixture of
different stoichiometries or arrangements, which would be consis-
tent with the low Hill slope that we observe. Alternatively, as the
low Hill slope is observed within all individual oocytes, this could
suggest that a uniform receptor population with ‘‘unusual”
properties is also plausible.
Fig. 7. Electrophysiological recordings of THIP-evoked current from a4b2d recep-
tors using X. laevis oocytes. Oocytes were injected with cRNAmixtures of a4 + b2 + d
subunits in ratios of 1:1:1 or 5:1:1 to represent high sensitivity receptors and low
sensitivity receptors, respectively. Peak current amplitudes were normalized to
maximal efficacious GABA (100 lM) applications (IGABA_100lM) and fitted to a one-
site Hill equation by non-linear regression. THIP concentration–response relation-
ships plotted as averaged value ± S.E. of n = 5–6 oocytes. The fitted EC50 value was
1.7 (0.42–6.8) lM and the Hill slope 0.3 ± 0.04 for 1:1:1 ratio. While at 5:1:1 ratio,
the fitted EC50 value was 10.9 (7.7–15.6) lM and the Hill slope 0.87 ± 0.1.
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In addition to the ‘‘reference” ratio, a matrix of six different
cRNA ratios of ternary receptors were expressed where each sub-
unit in turn constituted of a high (70) or low (10) percentage
of the total cRNA mixture. Across all the variations of these ratios
that were tested, the overall current amplitude levels remained
similar. This indicates that altering the ratio of subunit cRNA is
not having a large effect on the overall expression levels of
a4b2d receptors.
Four out of the six cRNA ratios that were analyzed resulted in
receptors with characteristics resembling the ‘‘reference” receptor,
including high GABA sensitivity, shallow Hill slopes and direct acti-
vation by applications of a low concentration of DS2. A common
denominator of these ratios was that they contained either
equimolar or 5-times surplus of b2 subunits compared with a4
subunits. Only two ratios yielded receptors with different charac-
teristics. These had lower GABA sensitivity, Hill slopes close to 1
and displayed no direct activation by DS2 applications; however,
they were still efficiently modulated by DS2, which demonstrates
the incorporation of the d subunit. A 5-fold surplus of a4 compared
with b2 subunits represented the common denominator for these
two ratios. Therefore, the receptor populations could reasonably
be grouped into two categories: a population with higher sensitiv-
ity to GABA and efficacious DS2 activation and a population with
lower sensitivity to GABA and minimal DS2 activation. As men-
tioned, it is the latter of these two receptor categories that resem-
bles the pharmacological properties of the bulk of previous studies
on a4b2d receptors expressed in oocytes [14,16].
Given the substantial influence of the d subunit on the intrinsic
characteristics of a4b2d receptors, it might be anticipated that
large differences would result when changing the molar ratios of
the d subunit vs. a4 and b2 subunits. Instead, a d subunit compo-
nent in the range of 10–70% of the total cRNA mixtures ensured
incorporation into all assembled receptors. This finding is in
contrast to a study in HEK293 cells showing that increasing the d
subunit cDNA component in transfected HEK293 cells increased
incorporation of d in surface expressed receptors on behalf of b2
subunits [20,22]. However, these data are consistent with a recent
report, concluding that the stoichiometry of a4b3d receptors in
HEK293 cells remains (a4)2(b3)2(d)1 despite variations in the
transfected d subunit cDNA [10,17]. Hence, it appears plausible
that the d subunit incorporates consistently into a4bd receptorsprovided the relative molar ratios in the cRNA or cDNA are not
too extreme.
4.3. DS2 pharmacology at a4b2d receptors
The pharmacology of DS2 is considerably more complicated
than a selective positive modulator at d-containing GABAARs.
While it has significantly higher efficacies at a4b2d than a4b2c
receptors, this is strongly influenced by the intrinsic properties of
the a4b2d receptors. Here, we report that at certain populations
of a4b2d receptors, DS2 is an efficient agonist. This has also been
reported at a4b3d receptors [14].
An important consideration is how DS2 can have such different
pharmacological properties at receptors with different stoichiome-
tries or arrangements. The positive modulator of a4b2 nicotinic
acetylcholine receptors, NS9283, becomes an agonist at receptors
when additional binding sites are introduced [37]. It is possible
that when we shift subunit ratios, we are increasing the number
of DS2 binding sites and thus converting a positive modulator into
an agonist. Alternatively, we may have altered the intrinsic proper-
ties of the receptor such that it is far more likely to open when DS2
is bound, regardless of whether a GABA molecule is also bound.
This question is likely to require future sophisticated electrophys-
iological experiments to answer.
4.4. Ternary receptor stoichiometries and subunit assembly order
The different categories that we identify raise the question of
what receptor populations can be expressed in oocytes. One recep-
tor population arises from a high a4:b2 ratio, and our data are con-
sistent with a receptor that most likely consists of (a4)2(b2)2(d)1
stoichiometry. This conclusion is fully consistent with a receptor
having two b2–a4 interface GABA-activation sites with equal bind-
ing affinity, which would result in a Hill slope close to 1, and the
incorporation of the d subunit is demonstrated by the DS2 potenti-
ation of GABA-elicited currents. From the large body of literature
data, including those for the archetypical c-containing receptors
[19,33], the subunit arrangement of such a receptor would likely
be b2–a4–b2–a4–dwith a counterclockwise rotation when viewed
from the extracellular side (Fig. 8A).
For the low a4:b2 ratio ternary receptors, the situation is more
complex. There must be at least one a4 subunit present, since min-
imal currents are recorded from the injection of b2 and d alone. It is
thus likely that a low a4:b2 ratio would result in receptors with
only one a4 subunit present. Further, we can infer that the receptor
complex must have at least one d subunit present given the high
sensitivity to DS2 applications, however since altering the ratio
of the d subunit gives identical results, it is more likely that only
one d subunit is incorporated. This leaves three b2 subunits to take
up the remaining positions and a likely stoichiometry of
(a4)1(b2)3(d)1, a hypothesis consistent with data for binary
(a4)2(b2)3 receptor (a4b2 (1:5) injection) where the presence of
three b2 subunits yield a similar low Hill slope.
To further complicate matters, a receptor stoichiometry
composed of (a4)1(b2)3(d)1 could potentially have four different
subunit arrangements: b2–a4–b2–b2–d, b2–b2–a4–b2–d, b2–b2–
b2–a4–d, a4–b2–b2–b2–d and (Fig. 8B–E). As it was previously
shown that the additive effects of activation via three sites in the
nicotinic acetylcholine receptor a7 require binding in non-
consecutive sites [38], the four possible arrangements can then
be separated into those that have consecutive sites
(Fig. 8D and E) and those that do not (Fig. 8B and C). Furthermore,
the coupling of ligand binding to channel gating may also be
altered by different arrangements of subunits. This would lead to
different intrinsic activation properties, and possibly different rates
of channel opening in the presence of none, or one, molecule of
Fig. 8. Proposed stoichiometries of a4b2d receptors arising from high or low a4:b2 ratios. Receptors are viewed from the extracellular side. Given that changing the total
cRNAmixture content of the d subunit from approximately 10–70% made no difference, all proposed stoichiometries are assumed to have one d subunit. (A) A high a4:b2 ratio
likely results in a ‘‘classical” (a4)2(b2)2(d)1 stoichiometry arrangement where the receptor has two b2–a4 interface GABA binding sites (arrows). (B–E) A low a4:b2 ratio likely
results in receptors with one a4 and three b2 subunits. Four potential stoichiometry arrangements are possible in this scenario. These receptor combinations can additionally
harbor b2–b2 and b2–d interface GABA binding sites (arrows). While GABA binding has so far not been demonstrated in b2–b2 interfaces, b3 homomeric receptors can be
activated by GABA. That the b2–d interface can bind GABA is supported by the (low) activity at b2d binary receptors in Fig. 2. Since it has been shown that optimal additive
effects on activation requires three non-consecutive interfaces, some of the potential b2–b2 GABA binding interfaces are less likely to be involved in receptor activation (open
arrows).
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slope. At this point, it cannot be concluded which of these combi-
nations arise from expressing receptors with a low a4:b2 ratio and
in fact it is likely that some, or all of them express simultaneously
to some degree, at a given injection ratio.
Translating these results of the receptor populations that are
expressed in oocytes to the receptors found in the mammalian
brain is not straightforward. The concentrations of THIP that acti-
vate extrasynaptic GABAARs in the brain have been proposed to
be too low for the low sensitivity receptor, suggesting the possibil-
ity that more b2 subunits may be incorporated into the native
receptor [39]. It is also possible that the regulation of subunit order
and stoichiometry is not as strict in native brain tissue, or that it is
more variable under certain conditions and during development.
This may be resolved by compounds that selectively enhance,
modulate or inhibit one of the receptor populations.
5. Conclusion
This study demonstrates that given sufficient amounts of a4, b2
and d subunits in a cRNA mixture, the molar ratio of a4:b2 deter-
mines whether resulting receptor populations display low or high
sensitivity for GABA. Whereas the receptor with low sensitivity to
GABA most likely has a stoichiometry of (a4)2(b2)2(d)1, the recep-
tor with a high sensitivity to GABA appears to have an additional
b2 subunit and hence a stoichiometry of (a4)1(b2)3(d)1. An impor-
tant point in this regard, is that the subunit ratios in cRNAmixtures
are not an exact science and the outcome of any given mixture will
vary depending on the quality of the individual cRNA batches. Con-
sequently, despite using similar conditions different researchers
can perform experiments on different receptor populations and
report seemingly contradictory pharmacological properties. Inter-
estingly, most literature data on a4b2d receptors expressed in
mammalian cell lines such as HEK293 appear to observe only
receptors with a low sensitivity to GABA. This raises the thought-
provoking question for future studies of whether receptors with
high sensitivity to GABA exist in native brain tissue and under
which conditions.
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